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A B S T R A C T
Background
Chest physiotherapy is widely prescribed to assist the clearance of airway secretions in people with cystic fibrosis (CF). Positive expiratory
pressure (PEP) devices provide back pressure to the airways during expiration. This may improve clearance by building up gas behind mu-
cus via collateral ventilation and by temporarily increasing functional residual capacity. The developers of the PEP technique recommend
using PEP with a mask in order to avoid air leaks via the upper airways and mouth. In addition, increasing forced residual capacity (FRC)
has not been demonstrated using mouthpiece PEP. Given the widespread use of PEP devices, there is a need to determine the evidence
for their effect. This is an update of a previously published review.
Objectives
To determine the effectiveness and acceptability of PEP devices compared to other forms of physiotherapy as a means of improving mucus
clearance and other outcomes in people with CF.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising of references identified from compre-
hensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. The electronic
database CINAHL was also searched from 1982 to 2017.
Most recent search of the Group's CF Trials Register: 20 February 2019.
Selection criteria
Randomised controlled studies in which PEP was compared with any other form of physiotherapy in people with CF. This included, postural
drainage and percussion (PDPV), active cycle of breathing techniques (ACBT), oscillating PEP devices, thoracic oscillating devices, bilevel
positive airway pressure (BiPaP) and exercise.
Data collection and analysis
Three authors independently applied the inclusion and exclusion criteria to publications, assessed the risk of bias of the included studies
and assessed the quality of the evidence using the GRADE recommendations.
Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (Review)
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Main results
A total of 28 studies (involving 788 children and adults) were included in the review; 18 studies involving 296 participants were cross-over
in design. Data were not published in sufficient detail in most of these studies to perform any meta-analysis. In 22 of the 28 studies the PEP
technique was performed using a mask, in three of the studies a mouthpiece was used with nose clips and in three studies it was unclear
whether a mask or mouthpiece was used. These studies compared PEP to ACBT, autogenic drainage (AD), oral oscillating PEP devices,
high-frequency chest wall oscillation (HFCWO) and BiPaP and exercise.
Forced expiratory volume in one second was the review's primary outcome and the most frequently reported outcome in the studies (24
studies, 716 participants). Single interventions or series of treatments that continued for up to three months demonstrated little or no
difference in effect between PEP and other methods of airway clearance on this outcome (low- to moderate-quality evidence). However,
long-term studies had equivocal or conflicting results regarding the effect on this outcome (low- to moderate-quality evidence).
A second primary outcome was the number of respiratory exacerbations. There was a lower exacerbation rate in participants using PEP
compared to other techniques when used with a mask for at least one year (five studies, 232 participants; moderate- to high-quality evi-
dence). In one of the included studies which used PEP with a mouthpiece, it was reported (personal communication) that there was no
difference in the number of respiratory exacerbations (66 participants, low-quality evidence).
Participant preference was reported in 10 studies; and in all studies with an intervention period of at least one month, this was in favour
of PEP. The results for the remaining outcome measures (including our third primary outcome of mucus clearance) were not examined
or reported in sufficient detail to provide any high-quality evidence; only very low- to moderate-quality evidence was available for other
outcomes. There was limited evidence reported on adverse events; these were measured in five studies, two of which found no events. In a
study where infants performing either PEP or PDPV experienced some gastro-oesophageal reflux , this was more severe in the PDPV group
(26 infants, low-quality evidence). In PEP versus oscillating PEP, adverse events were only reported in the flutter group (five participants
complained of dizziness, which improved after further instructions on device use was provided) (22 participants, low-quality evidence).
In PEP versus HFCWO, from one long-term high-quality study (107 participants) there was little or no difference in terms of number of
adverse events; however, those in the PEP group had fewer adverse events related to the lower airways when compared to HFCWO (high-
certainty evidence).
Many studies had a risk of bias as they did not report how the randomisation sequence was either generated or concealed. Most studies
reported the number of dropouts and also reported on all planned outcome measures.
Authors' conclusions
The evidence provided by this review is of variable quality, but suggests that all techniques and devices described may have a place in
the clinical treatment of people with CF.
Following meta-analyses of the effects of PEP versus other airway clearance techniques on lung function and patient preference, this
Cochrane Review demonstrated that there was high-quality evidence that showed a significant reduction in pulmonary exacerbations
when PEP using a mask was compared with HFCWO. It is important to note that airway clearance techniques should be individualised
throughout life according to developmental stages, patient preferences, pulmonary symptoms and lung function. This also applies as
conditions vary between baseline function and pulmonary exacerbations.
P L A I N   L A N G U A G E   S U M M A R Y
Using positive expiratory pressure physiotherapy to clear the airways of people with cystic fibrosis
Review question
We reviewed the evidence on the effect of positive expiratory pressure (PEP) physiotherapy to clear the airways of people with cystic
fibrosis (CF).
Background
CF affects approximately one in 3000 live births in white populations and causes frequent lung infection, due to mucus blocking the air-
ways. Chest physiotherapy is often used to try to clear the mucus from the lungs. We wanted to discover whether using a PEP device (a
form of chest physiotherapy) was better or worse than other other forms of chest physiotherapy for clearing the mucus from the lungs in
people with CF. A PEP device provides positive pressure behind the mucus to try to push it out of the lungs. This is an update of a previously
published review.
Search date
The evidence is current to 20 February 2019.
Study characteristics
Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (Review)
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The review includes 28 studies with 788 people (from infants to adults) with CF with mild to severe lung disease. The studies compared
PEP to other methods of chest physiotherapy; the length of treatment ranged from a single session to two years of treatment.
Key results
Generally, the efficacy of PEP is similar to other methods of chest physiotherapy such as postural drainage with percussion, active cycle of
breathing techniques, autogenic drainage, oscillatory PEP devices such as the flutter and acapella, thoracic oscillating devices such as the
'Vest', and bilevel positive airway pressure (BiPaP) (typically used for ventilatory support, but by changing the inspiratory and expiratory
pressures on the device and combining it with huffing, BiPaP has been used for airway clearance). We found no difference between PEP
and other forms of chest physiotherapy in lung function, the amount of mucus cleared from the airways or its related effects on the health
of people with CF. However, the rate of flare ups of respiratory symptoms decreased in people using PEP compared to other forms of
physiotherapy such as a vibrating PEP device or a vibrating vest. There was some evidence that people with CF may prefer PEP to other
chest physiotherapy methods. There was no evidence of PEP causing harm, except in one study where infants performing either PEP or
percussion in various positions which use gravity to help drain secretions, experienced some gastro-oesophageal reflux (regurgitation of
food) in head-down positions; this was more severe in the group using postural drainage with percussion. In all the other trials PEP was
performed in a sitting position.
In 10 of the 28 studies studied single PEP treatment sessions. The results from these studies are very limited as they could not report on the
number of respiratory infections and lung function did not change with just one treatment. Two one-year studies compared PEP to postural
drainage and percussion; in the study with children, PEP improved their lung function, while in the adult study, lung function declined
slightly with both PEP and postural drainage and percussion. Also, the method of performing PEP was different in the two age groups.
Although PEP seems to have an advantage in reducing flare ups (based on the combined results of a few studies), different physiotherapy
techniques and devices may be more or less effective at varying times and in different individuals during baseline function and chest flare
ups. Each person should talk to their clinician to help choose which method of airway clearance is best for them and which they will adhere
to, so as to provide the best quality of life and long-term outcomes.
Quality of the evidence
Some studies were of low quality. These studies highlight the difficulty in comparing studies using PEP compared to other forms of chest
physiotherapy. Factors such as age and severity of lung disease in the participants may affect the results as well as the method of perform-
ing each treatment. Overall, the evidence provided by this review for whether PEP reduces flare ups compared to other forms of chest
physiotherapy was moderate to high quality, but evidence for other outcomes was of very low to moderate quality, as results were limited.
Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (Review)



























































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Summary of findings - PEP compared with PDPV for cystic fibrosis
PEP compared with PDPV for CF




Illustrative comparative risks* (95% CI)













FEV1: change from baseline (%
predicted)
Follow-up: 2 days to 2 years
There was significant advantage to the PEP group compared to the
PDPV group in the change in FEV1 from baseline in 1 study (1 year
duration)










Number of respiratory exac-
erbations
Follow-up: NA
1 study which used PEP with a mouthpiece, it was reported (per-





















1 study conducted exercise testing using cycle ergometry, but re-






Well being: QWB scale
Follow-up: 2 years
Neither group demonstrated a significant change in QWB scores,




























































































































































Outcome not reported. NA  
Adverse events
Follow-up: 1 year
No adverse events were reported in 1 study.
In the other study, gastro-oesophageal reflux was reported more
commonly in the PEP group than the PDPV group, but more par-
ticipants withdrew due to severe gastro-oesophageal reflux in the






*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CF: cystic fibrosis; FEV1: forced expiratory volume at 1 second; LCI: lung clearance index; NA: not applicable; PDPV: postural drainage, percussion and ventilation; PEP: posi-
tive expiratory pressure; quality of well-being; QWB: quality of well-being.
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
a. Downgraded twice due to serious risk of bias: cross-over studies did not have washout periods so were at high risk of bias due to carryover effects. Methodological details of
the studies relating to randomisation and allocation concealment were unclear and some studies were at high risk of selective reporting bias.
b. Downgraded once due to risk of bias: Methodological details of the study relating to randomisation and allocation concealment were unclear and the cross-over study did not
have washout periods so were at high risk of bias due to carryover effects.
c. Downgraded once due to imprecision: no numerical data available to enter into analysis.
d. Downgraded once due to risk of bias: Methodological details of the studies relating to randomisation and allocation concealment were unclear and some of the studies were
at high risk of selective reporting bias.
e. Downgraded once due to applicability: the two studies recruited children only, so results are not applicable to adults
 
 
Summary of findings 2.   Summary of findings - PEP compared to oscillating PEP for cystic fibrosis
PEP compared with oscillating PEP for CF
Patient or population: adults and children with CF
Settings: outpatients
Intervention: PEP





















































































































































Illustrative comparative risks* (95% CI)













FEV1: change from baseline (% predict-
ed)
Follow-up: single treatment to 13
months
There was no significant difference in the change from










Number of respiratory exacerbations:
requiring either IV antibiotics or hospi-
talisation
Follow-up: 1 year to 13 months
One study of 1 year duration showed that significantly
fewer hospitalisations occurred in the PEP group com-
pared to the oscillating PEP group.
The other two studies showed no significant differences in






Direct measures of mucus clearance
Follow-up: NA
Outcome not reported. NA  
Exercise tolerance: modified shuttle
test
Follow up: 10 days to 1 year
There was no significant difference in exercise tolerance






Well being: QWB scale. CF Short Form
-36 and Chronic Respiratory Question-
naire
Follow up: 1 year
There was no significant change from baseline between
groups in the QWB scale, Short Form -36 domains or







Follow up: 12 months
The mean (SD) LCI in the
oscillating PEP group was
0.2 (2.47).
The mean LCI in the PEP
group was













Five participants complained of dizziness when using the
Flutter device which improved after further instructions




























































































































































No adverse events were reported in the PEP group.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CF: cystic fibrosis; IV: intravenous; LCI: lung clearance index; NA: not applicable; PEP: positive expiratory pressure; QWB: quality of well-being; SD: standard deviation.
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
a.Downgraded once due to risk of bias: Methodological details of the studies relating to randomisation and allocation concealment were unclear and some of the studies were
at high risk of bias due to incomplete outcome data.
b. Downgraded once due to imprecision: no numerical data available to enter into analysis.
c. Downgraded once due to applicability: the study recruited children only, so results are not applicable to adults
d. Downgraded once due to potential risk of bias: six out of seven studies did not clearly state whether any adverse events occurred or not during the study
 
 
Summary of findings 3.   Summary of findings - PEP compared to HFCWO for cystic fibrosis
PEP compared with HFCWO for CF




Illustrative comparative risks* (95% CI)

















There was no significant difference in the change from baseline









Number of respiratory ex-
acerbations























































































































































Follow-up: 1 year (458 to 791 per 1000). (0.55 to 0.95) (1 study)
Direct measures of mucus
clearance
Follow-up: NA
Outcome not reported. NA  
Exercise tolerance
Follow-up: NA
Outcome not reported. NA  
Well being
Follow-up: NA
Outcome not reported. NA  
LCI
Follow-up: single treatment
1 study showed an improvement in ventilation distribution and
gas mixing with both treatments which was not significantly dif-














200 adverse events were re-
ported.
A mean of 2.46 events related
to the lower airway were re-
ported.
163 adverse events were re-
ported.
A mean of 1.72 events related to




















pain) in the HFCWO
group compared to
the PEP group (P =
0.023).
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CF: cystic fibrosis; CI: confidence interval; FEV1: forced expiratory volume at 1 second; HFCWO: high frequency chest wall oscillation; LCI: lung clearance index; NA: not ap-





















































































































































GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
a. Downgraded twice due to serious risk of bias: cross-over studies did not have washout periods so were at high risk of bias due to carryover effects. Methodological details of
the studies relating to randomisation and allocation concealment were unclear and some studies were at high risk of selective reporting bias.
b. Downgraded once due to imprecision: no numerical data available to enter into analysis.
 
 
Summary of findings 4.   Summary of findings - PEP compared to BiPAP for cystic fibrosis
PEP compared with BiPAP for CF




Illustrative comparative risks* (95% CI)















gle treatment to 3
months
There was no significance difference in FEV1 between treatment







One study reported FEV1
in litres and % predicted.
In the other study, it was






































































































































































There was no significant difference between treatment groups in












One study reported a significant improvement in the distribution




















*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CF: cystic fibrosis; BiPAP: bilevel positive airway pressure; CI: Confidence interval;LCI: lung clearance index; NA: Not applicable; PEP: positive expiratory pressure.
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
a.Downgraded once due to risk of bias: Methodological details of the studies relating to randomisation and allocation concealment were unclear and some of the studies
b. Downgraded once due to imprecision: no numerical data available to enter into analysis.
c. Downgraded once due to potential risk of bias: one of the studies did not clearly state whether any adverse events occurred or not during the study
 
 
Summary of findings 5.   Summary of findings - PEP compared to airway clearance techniques for cystic fibrosis
PEP compared with airway clearance techniques for CF
























































































































































Comparison: airway clearance techniquesa
Illustrative comparative risks* (95% CI)
















FEV1: change from baseline (%
predicted)
Follow-up: single treatment to
3 months
One study found that FEV1 (% predicted) was significantly lower af-
ter a treatment of AD followed by Hi-PEP, compared to AD alone.
All other studies found no significant difference between treat-







Number of respiratory exac-
erbations
Follow-up: single treatment to
1 month
The two studies reported participants being withdrawn due to ex-
acerbations, although these are not well-defined and it is unclear
which treatments the participants were randomised to at the time







Direct measures of mucus
clearance: radioisotope reten-
tion
Follow-up: single treatment to
2 weeks
One study showed that radioisotope retention 2 hours after a 20-
minute treatment of PEP and FET was significantly less than for
FET alone.
No significant difference in clearance was identified between PEP









Follow up: 1 year







Well being: Short Form -36
Follow up: 1 year
There was no significant change from baseline between groups in








One study reported worsening of the distribution of ventilation fol-
lowing PEP and high pressure PEP compared to control. However,
in this study gas mixing improved suggesting that PEP opened up






































































































































































Outcome not reported. NA  
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
ACBT: Active cycle of breathing techniques; AD: autogenic drainage; CF: cystic fibrosis; CI: confidence interval;FET: forced expiration technique; FEV1: forced expiratory vol-
ume at 1 second; Hi-PEP: high-pressure positive expiratory pressure; LCI: lung clearance index; NA: not applicable; PD: postural drainage; PDP: percussion and drainage
therapy; PEP: positive expiratory pressure.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
a. Three studies compared PEP to ACBT, one study Darbee compared two types of PEP, one study compared PEP and autogenic drainage (AD), one study compared PEP alone,
PDPV and FET, or five minutes of PEP followed by PDPV and FET, one study compared PEP, PDP and AD and one study compared PEP, PD and physical exercise.
b. Downgraded twice due to serious risk of bias: cross-over studies did not have washout periods so were at high risk of bias due to carryover effects. Methodological details of
the studies relating to randomisation and allocation concealment were unclear and some studies were at high risk of selective reporting bias.
c. Downgraded once due to imprecision: no numerical data available to enter into analysis and unclear results.
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B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is a relatively common, inherited, life-limiting
disorder. The genetic defect causes abnormal mucus secretion in
the airways, potentially leading to airway obstruction and mucus
plugging (Zach 1990). This predisposes the airways to infection and
inflammation, which in turn promote further mucus secretion. Per-
sistent infection and inflammation within the lungs are the major
contributory factors to airway damage and the progressive loss of
respiratory function (Cantin 1995; Konstan 1997).
Description of the intervention
Treatment methods which improve mucus clearance are consid-
ered essential in optimising respiratory status and reducing the
progression of lung disease. A variety of methods are used, some
physical, e.g. airway clearance techniques, and some chemical, e.g.
inhaled medications.
Airway clearance techniques (also referred to as chest physiother-
apy) are widely prescribed to assist the clearance of airway mucus
and usually commenced as soon as the diagnosis of CF is made. Tra-
ditionally, airway clearance consisted of postural drainage (gravi-
ty-assisted drainage positions) combined with percussion and vi-
bration (performed by an assistant such as a physiotherapist or rel-
ative), and forced expirations (huffing and coughing). Some proto-
cols included deep breathing exercises. This form of airway clear-
ance is time-consuming and sometimes uncomfortable. It also re-
quires assistance, which may have an adverse effect on adherence.
Recently, several self-administered alternatives that are able to
be used in upright sitting positions have been developed. Among
these are a range of positive expiratory pressure (PEP) devices,
which provide a back pressure to the airways during expiration.The
most common method of using PEP was defined by the Danes and
is known as the, 'PEP technique' (Falk 1984). It consists of breathing
through a flow-dependant PEP device attached to a face mask with
a closed system creating a PEP of between 10 to 20 cm H20 for 12
to 15 breaths. The PEP mask is then removed from the individual's
face and he or she then performs two to three huffing manoeuvres
(also known as a forced expiration). For the purposes of this paper
we have included studies using pressures between 8 to 20 cm H2O.
Usually the PEP device is attached to a mask, but occasionally a
mouthpiece with nose clips are used instead. However, there have
only been a few studies performed using PEP with a mouthpiece.
Another method of using PEP devices is defined by Oberwaldner
in Austria and is known as, 'high-pressure PEP' (Hi-PEP). In Hi-PEP,
the expiratory pressure may be reach 40 to 100 cm H20. Hi-PEP al-
so incorporates forced expiratory manoeuvres through the PEP de-
vice, which generates higher pressures and may stimulate cough-
ing through the mask (Oberwaldner 1986).
How the intervention might work
A theory is that PEP devices are able to improve clearance by in-
creasing gas pressure behind mucus via collateral ventilation and a
temporary increase in functional residual capacity (FRC). The FRC
level is gradually increased over the 12 to 15 breaths. The forced
expiratory manoeuvres then assist the movement of mucus from
the peripheral airways centrally to where they can be expectorat-
ed (Andersen 1979; Groth 1985). It has also been hypothesised that
Hi-PEP may stabilise airways by splinting them open during expira-
tion, which may facilitate airway clearance (Oberwaldner 1986).
Why it is important to do this review
A Cochrane Review comparing any form of chest physiotherapy
with no chest physiotherapy found evidence to demonstrate the
benefit of chest physiotherapy for increasing mucus transport, but
did not find evidence for any long-term outcomes (Warnock 2013).
Several narrative reviews have compared different types of chest
physiotherapy, including PEP, with conflicting conclusions (McIl-
waine 1996; Prasad 1993; Prasad 2000; Williams 1994; Zach 1987).
This review will examine the effect and acceptability of PEP com-
pared to other techniques used for secretion clearance.
The most effective technique for secretion clearance during an in-
fective exacerbation of CF may differ from that which is most ef-
fective for maintenance therapy. The PEP technique is also used in
combination with various other interventions, e.g. pharmacologi-
cal therapies, other physical therapy techniques, or a modification
to the PEP technique. It is therefore important to establish the ef-
fect of PEP in each stage of CF lung disease with and without co-
interventions. This review is an update of previously published ver-
sions of the Cochrane Review (Elkins 2004; Elkins 2006; McIlwaine
2015).
O B J E C T I V E S
To determine the effect of PEP on the clearance of airway secretions
compared to other airway clearance techniques in people with CF
and test the following hypotheses:
1. PEP improves outcomes for people with CF more than other air-
way clearance techniques;
2. PEP is more acceptable to people with CF than other airway
clearance techniques.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled studies.This included both parallel and
cross-over designs. Blinding was not a determinate for inclusion
since participants could not be blinded as to which technique they
were performing. Eligible studies included both individual and clus-
ter randomised designs.
Types of participants
People with CF, of any age, diagnosed on the basis of clinical criteria
and sweat testing or genotype analysis, with any degree of disease
severity. People with CF, post-lung transplant, were excluded.
Types of interventions
In the existing literature, variation occurs in the application of
each individual airway clearance technique. For example; when
using PEP as an airway clearance technique, some people per-
form 12 breaths through the device, whereas others perform 15
breaths. This may be followed by two or three forced expiratory ma-
noeuvres. As separate analyses of variations within each technique
would render this review unmanageable, it has been necessary to
group these variations within broad definitions of the established
treatment modalities.
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One of the interventions used in the studies will be required to meet
one of the two following descriptions.
1. PEP mask, or mouthpiece as described by the authors, with or
without additional techniques. Originally, PEP was defined as
breathing with a positive expiratory pressure of 10 to 20 cm H2O
(Falk 1984).
2. High-pressure PEP (Hi-PEP) mask therapy as described by the
authors, with or without additional techniques. Hi-PEP includes
a full forced expiration against a fixed mechanical resistance
which usually generates pressures ranging from 40 to 100 cm
H2O (Oberwaldner 1986).
At least one comparator intervention used in the studies will be re-
quired to meet one of the following descriptions.
1. Postural drainage with percussion and vibration (PDPV) - in oth-
er reviews this has been described as conventional chest phys-
iotherapy (CCPT).
2. Active cycle of breathing techniques (ACBT) - this comprises re-
laxation or breathing control, forced expiration technique (FET),
thoracic expansion exercises and may include postural drainage
or percussion.
3. Autogenic drainage (AD) - this breathing technique uses high ex-
piratory flow rates at varying lung volumes to enhance mucous
clearance while avoiding airway closure.
4. Oral oscillatory devices - include flutter, cornet, acapella and
intrapulmonary percussive ventilation. The flutter, cornet and
acapella devices produce an oral oscillatory PEP effect with-
in the airways. Intrapulmonary percussive ventilation provides
continuous oscillation of the air pressure in the airways via the
mouth.
5. Thoracic oscillating devices - these include Thairapy Vest®, In-
Courage system, Smart vest, and the Hiyak Oscillator which pro-
vide external chest wall oscillation.
6. BiPaP - a bilevel PEP system which delivers both inspiratory and
expiratory positive pressure.
7. Exercise - prescribed for the purpose of airway clearance either
independently or as an adjunct to other techniques.
Types of outcome measures
Primary outcomes
1. Forced expiratory volume at one second (FEV1) (change in FEV1
between baseline and post-intervention; L and per cent (%) pre-
dicted values are both stated wherever possible)
2. Number of respiratory exacerbations between baseline and
post-intervention (respiratory exacerbations must have been
defined either by symptoms or by initiation of antibiotics for res-
piratory symptoms after medical assessment)
3. Direct measures of mucus clearance (mucus transport rate or
mucociliary clearance rate as assessed by radioactive tracer)
Secondary outcomes
1. Expectorated secretions, dry or wet weight, or volume (an in-
crease in the amount of expectorated secretions as a short-term
(less than seven days) effect of the intervention is considered as
beneficial; in long-term studies this outcome variable will not be
included)
2. Other pulmonary parameters (post-intervention change from
baseline)
a. forced vital capacity (FVC)
b. forced expiratory flow 25% - 75% (FEF25-75)
c. total lung capacity (TLC)
d. residual volume (RV)
e. functional residual capacity (FRC)
3. Exercise tolerance (subjective exercise tolerance, or objective
measures such as six-minute walk test)
4. Well-being (quality of life scales such as the CF Quality of Life
scale, or ability to participate in activities of daily living using in-
struments such as the HAES (Habitual Activity Estimation Scale)
5. Blood oxygen levels (measured by arterial blood gas, pulse
oximetry or transcutaneous oximetry)
6. Lung clearance index (LCI)
7. Ventilation scanning (radiological or nuclear medicine imaging)
8. Cost of intervention (equipment and duration)
9. Adherence to treatment or participant preference (may be de-
termined either as the nominated technique of choice by the
participant at the conclusion of the study, or by a comparison of
technique acceptability (e.g. visual analogue scales))
10.Adverse effects (such as pneumothorax, haemoptysis, deaths or
other adverse changes in condition from baseline)
Search methods for identification of studies
We searched for all relevant published and unpublished trials with-
out restrictions on language, year or publication status.
Electronic searches
The Cochrane Cystic Fibrosis and Genetic Disorders Group's Infor-
mation Specialist conducted a search of the Group's Cystic Fibrosis
Trials Register for relevant trials using the term: positive expiratory
pressure*.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials (CEN-
TRAL) (updated each new issue of the Cochrane Library), weekly
searches of MEDLINE, a search of Embase to 1995 and the prospec-
tive handsearching of two journals - Pediatric Pulmonology and the
Journal of Cystic Fibrosis. Unpublished work is identified by search-
ing the abstract books of three major cystic fibrosis conferences:
the International Cystic Fibrosis Conference; the European Cystic
Fibrosis Conference and the North American Cystic Fibrosis Con-
ference. For full details of all searching activities for the register,
please see the relevant section of the Cochrane Cystic Fibrosis and
Genetic Disorders Group's website.
Date of the most recent search of the Cochrane Cystic Fibrosis and
Genetic Disorders Group's Cystic Fibrosis Trials Register: 20 Febru-
ary 2019.
We also searched the following trials registries:
• US National Institutes of Health Ongoing Trials Register Clinical-
trials.gov (www.clinicaltrials.gov; searched 20 February 2019);
• World Health Organization International Clinical Trials Registry
Platform (WHO ICTRP) (apps.who.int/trialsearch; searched 20
February 2019).
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For details of our search strategies, please see Appendix 1.
Searching other resources
We checked the bibliographies of included studies and any relevant
systematic reviews identified for further references to relevant tri-
als.
The review authors contacted manufacturers of PEP devices re-
garding any additional studies. The authors contacted other cen-
tres where studies on PEP were being undertaken. Authors of in-
cluded studies were contacted to see if they knew of any unpub-
lished studies.
The review authors also handsearched the proceedings of the
North American Cystic Fibrosis Conference (2008 to 2018) and the
European Cystic Fibrosis Conference (2008 to 2019).
Data collection and analysis
Selection of studies
Three authors independently reviewed all citations and abstracts
identified by the search to determine which papers should be in-
cluded. The authors resolved disagreements by discussion and
consensus.
Data extraction and management
Three authors independently extracted data for each of the out-
come measures listed above. Where studies were published in in-
sufficient detail, the review authors contacted the study authors
with a request to provide the required data. The authors used the
Cochrane software (Review Manager) to compile and analyse the
data (Review Manager 2014).
For all included studies, the authors recorded the following details
where possible: criteria for diagnosis of CF; methods of participant
selection; and baseline characteristics of the active and placebo
groups including age, sex, genotype and lung function.
Assessment of risk of bias in included studies
Three authors independently assessed the risk of bias using text
from study reports to make judgements of high, low or unclear
risk for six features of a study (Higgins 2003). These include: ran-
dom sequence generation; allocation concealment; blinding; in-
complete outcome data; selective outcome reporting; and other
types of bias. The authors resolved any disagreements through dis-
cussion. The review authors used both published data and addi-
tional data obtained from study authors in determining whether
criteria were met.
Measures of treatment e@ect
For continuous outcomes, the review authors recorded either the
mean change from baseline for each group or mean post-treatment
or intervention values and the standard deviation (SD) for each
group. The authors combined data using the mean difference (MD)
and 95% confidence intervals (CIs).
In the case of binary outcomes, the authors combined the data from
the studies using risk ratios (RR) and 95% CIs.
Unit of analysis issues
None of the included studies were cluster randomised.
Elbourne discusses methods for meta-analysing cross-over studies
(Elbourne 2002). These methods rely on the data that are report-
ed within the primary paper. The authors have adopted a method
within this review which uses the data from the first period only, ig-
noring any data from the second period that was available if a car-
ryover effect was identified. If the authors did not identify a carry-
over effect and the papers reported data sufficiently, then the re-
view authors planned to use the methods stated by Elbourne (El-
bourne 2002).
When a study included multiple interventions, the review authors
included each in the relevant comparison, as specified in the data
synthesis section below.
Dealing with missing data
In order to allow an intention-to-treat analysis, the authors collect-
ed data on the number of participants with each outcome event by
allocated treated group irrespective of compliance and whether or
not the participant was later thought to be ineligible or otherwise
excluded for treatment or follow-up.
The authors contacted the primary investigators of the included
studies for any additional data they thought were missing. Unpub-
lished data were provided and reported on in the review for four
studies (Darbee 1990; Gaskin 1998; Tyrrell 1986; van Asperen 1987).
Assessment of heterogeneity
If the authors had been able to include adequate numbers of stud-
ies, they would have looked for heterogeneity between studies. The
authors planned to assess this visually in the forest plots and us-
ing the I2 statistic which describes the percentage of total varia-
tion across studies that are due to heterogeneity rather than chance
(Higgins 2003). The values of I2 lie between 0% and 100%, and a sim-
plified categorization of heterogeneity that the authors planned to
use is of low (I2 value of 25%), moderate (I2 value of 50%), and high
(I2 value of 75%) (Higgins 2003). They will also consider the Chi2 test
with a P value less than 0.10 indicating significant heterogeneity,
although the authors will be cautious with interpretation due to the
low power of this test.
Assessment of reporting biases
The authors planned to construct a funnel plot if there were suffi-
cient studies (i.e. 10) to assess publication bias. If the funnel plot is
asymmetrical then they will consider other reasons as well as publi-
cation bias, i.e. heterogeneity, small study effects and outcome re-
porting bias.
The authors planned to assess outcome reporting bias in the risk
of bias section, by comparing protocols, if available, to the study
reports, or comparing the methods section to the results section
with knowledge of the clinical area.
Data synthesis
The authors have analysed the data using a fixed-effect model. If, in
the future, they are able to include more studies and they identify a
moderate or high degree of heterogeneity, as defined above, they
will use a random-effects model in the data analysis.
Different interventions were analysed separately. In this update,
the comparisons include:
• PEP compared with PDPV;
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• PEP compared with oscillating PEP;
• PEP compared with HFCWO.
The authors analysed studies in which the intervention consists of
a single treatment separately from those studies in which a course
of treatments is used. Within the latter group, the authors analysed
studies of up to seven days treatment separately from studies of
longer duration. The authors grouped outcome data from longer-
term studies (more than seven days) into those measured at one,
three, six, 12 months, and annually thereafter. If studies recorded
outcome data at other time periods, then the authors considered
examining these as well.
Subgroup analysis and investigation of heterogeneity
To investigate any heterogeneity identified, the authors planned to
perform separate subgroup analyses based on the following fac-
tors: a PEP level of 8 to 20 cm H2O; a PEP level of over 20 cm H2O
as used in Hi-PEP; disease state (exacerbation versus stable); use of
co-interventions (positioning, other airway clearance techniques);
age (paediatric, adolescent, adult); gender; and disease severity
(FEV1% predicted > 90%, 70% to 90%, 40% to 69%, < 40%).
Sensitivity analysis
The authors planned to test the robustness of their results by per-
forming sensitivity analyses such as excluding studies that were at
high risk of bias for blinding and using the random-effects model if
they detected a moderate or high degree of heterogeneity.
Summary of findings tables and quality of the evidence (GRADE)
In a post hoc change in line with current Cochrane guidance, at the
2017 update we added a summary of findings table for each com-
parison presented in the review (Summary of findings for the main
comparison; Summary of findings 2; Summary of findings 3; Sum-
mary of findings 4; Summary of findings 5). We selected the follow-
ing seven outcomes to report (chosen based on relevance to clini-
cians and consumers):
1. FEV1
2. Number of respiratory exacerbations





We determined the quality of the evidence using the GRADE ap-
proach; and downgraded evidence in the presence of a high risk of
bias in at least one study, indirectness of the evidence, unexplained
heterogeneity or inconsistency, imprecision of results, high prob-
ability of publication bias. We downgraded evidence by one level
if they considered the limitation to be serious and by two levels if
very serious.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of exclud-
ed studies; Studies awaiting classification.
Results of the search
The search retrieved 116 citations which represented 70 studies.
No extra studies were identified with the CINAHL search or through
contacting manufacturers of PEP devices.
A total of 28 studies involving 788 participants met the inclusion
criteria; 21 were published as full articles (Braggion 1995; Dar-
bee 2004; Darbee 2005; Fainardi 2011; Falk 1984; Hofmeyr 1986;
Lagerkvist 2006; Lannefors 1992; McIlwaine 1997; McIlwaine 2001;
McIlwaine 2013; Mortensen 1991; Newbold 2005; Pfleger 1992; Pry-
or 2010; Rodriguez 2016; Steen 1991; Tyrrell 1986; van Asperen
1987; van Winden 1998; West 2010). Seven studies were published
in abstract form only (Costantini 2001; Darbee 1990; Falk 1993;
Gaskin 1998; Kofler 1998; McIlwaine 1991; Tannenbaum 2005).
A total of 33 studies are listed as excluded.
Six studies are awaiting assessment as they have been published
in abstract form only; the study design or outcome data have been
reported in insufficient detail to determine whether the inclusion
criteria have been met (Elkins 2005; Grzincich 2008; Parreira 2008;
Kofler 1994; Parreira 2008; Wong 2000).
Included studies
Additional data were obtained from the authors of nine of the stud-
ies (Costantini 2001; Darbee 1990; Gaskin 1998; Kofler 1998; McIl-
waine 1991; McIlwaine 1997; McIlwaine 2001; Tyrrell 1986; van As-
peren 1987).
Trial design
The 28 included studies (788 participants) had sample sizes in in-
dividual studies ranging from six (Darbee 2004) to 107 participants
(McIlwaine 2013). 10 studies had more than two treatment arms
(i.e. more than one comparator to PEP).
With regards to duration, 10 studies examined single treatments
(Darbee 2005; Darbee 2004; Fainardi 2011; Falk 1984; Falk 1993;
Kofler 1998; Lagerkvist 2006; Lannefors 1992; Mortensen 1991;
Pfleger 1992). In two studies the duration of each treatment arm
was less than seven days (Braggion 1995; Hofmeyr 1986). In the
remaining 16 studies, the duration of each treatment arm ranged
from 10 days to two years (Costantini 2001; Darbee 1990; Gaskin
1998; McIlwaine 1997; McIlwaine 1991; McIlwaine 2001; McIlwaine
2013; Newbold 2005; Pryor 2010; Rodriguez 2016; Tannenbaum
2005; Steen 1991; Tyrrell 1986; van Asperen 1987; van Winden 1998;
West 2010).
There were 18 cross-over studies, involving 296 participants. The
four studies conducted in participants experiencing a respiratory
exacerbation all used a cross-over design with a duration of one or
two days in each arm (Braggion 1995; Darbee 2005; Fainardi 2011;
Hofmeyr 1986). Data from the end of the first period were obtained
for three of the 18 cross-over studies (Darbee 1990; Tyrrell 1986;
van Asperen 1987), but could not be obtained for the remaining
15 studies, although analysis was undertaken on all available da-
ta (Braggion 1995; Darbee 2004; Darbee 2005; Fainardi 2011; Falk
1984; Falk 1993; Hofmeyr 1986; Kofler 1998; Lagerkvist 2006; Lan-
nefors 1992; McIlwaine 1991; Mortensen 1991; Pfleger 1992; Steen
1991; van Winden 1998). Six studies had a washout period between
techniques which ranged from two days to eight weeks (Darbee
2004; Lagerkvist 2006; Lannefors 1992; McIlwaine 1991; Mortensen
1991; van Winden 1998).
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One study was a multicentre study involving 12 CF centres in Cana-
da (McIlwaine 2013).
Participants
One study was conducted exclusively with infants under four
months of age (Costantini 2001). Nine studies were conducted
exclusively with children between the ages of six years and 18
years of age (Lagerkvist 2006; McIlwaine 1991; McIlwaine 1997; McIl-
waine 2001; Tannenbaum 2005; Tyrrell 1986; van Asperen 1987; van
Winden 1998; West 2010). Five studies were conducted exclusively
in adults (Darbee 1990; Fainardi 2011; Newbold 2005; Pryor 2010;
Rodriguez 2016). Both paediatric and adult participants were re-
cruited to 12 studies; only one of these provided data for any age
subgroup independently (Gaskin 1998). One study did not report
the age of the participants (Falk 1993).
The gender of the participants was reported in 22 of the includ-
ed studies involving 692 participants (Braggion 1995; Costantini
2001; Darbee 1990; Darbee 2004; Fainardi 2011; Falk 1984; Gaskin
1998; Hofmeyr 1986; Kofler 1998; Lagerkvist 2006; Lannefors 1992;
McIlwaine 1997; McIlwaine 2001; McIlwaine 2013; Mortensen 1991;
Newbold 2005; Pfleger 1992; Rodriguez 2016; Tannenbaum 2005;
Tyrrell 1986; Pryor 2010; van Winden 1998). Two had an even gen-
der ratio (Braggion 1995; Rodriguez 2016), but most had more male
than female participants, resulting in an overall male: female ratio
of 3:2.
Four cross-over studies were conducted in participants experienc-
ing a respiratory exacerbation with a duration of one or two days
in each arm; hence they provide limited evidence for the effect
of PEP for treatment of an exacerbation (Braggion 1995; Darbee
2005; Fainardi 2011; Hofmeyr 1986). Three studies did not report
any measure of disease severity of the included participants. A total
of 25 studies reported the FEV1% predicted values of participants
at baseline. In three of these studies, FEV1 values were only in the
moderate to severe range (less than 70% predicted) (Darbee 2004;
Falk 1984; Rodriguez 2016). The remaining 21 studies included par-
ticipants with a wide range of lung function impairment, most com-
monly from severe to normal (less than 40% to greater than 90%
predicted). Those studies reporting Shwachman scores as a mea-
sure of disease severity also included participants with a wide range
of scores.
Interventions
In two of the included studies, the intervention included a full
forced expiration against a fixed mechanical resistance at pressures
greater than 20 cm H2O and thus met the definition of Hi-PEP (Dar-
bee 2004; Pfleger 1992).
Eight studies (207 participants) compared PEP with PDPV (Braggion
1995; Costantini 2001; Darbee 1990; Falk 1984; Gaskin 1998; McIl-
waine 1997; Tyrrell 1986; van Asperen 1987). Seven studies (247 par-
ticipants) compared PEP with oscillating PEP (acapella, flutter and
cornet) ( Darbee 2005; Lagerkvist 2006; McIlwaine 2001; Newbold
2005; Pryor 2010; van Winden 1998; West 2010). Four studies (174
participants) compared PEP with HFCWO (Braggion 1995; Darbee
2005; Fainardi 2011; McIlwaine 2013). Two studies compared PEP
with BiPAP (Kofler 1998; Rodriguez 2016). In eight cross-over stud-
ies, PEP was compared to a variety of different airway clearance
techniques.
In 22 of the 28 included studies the PEP technique was performed
using a mask (Costantini 2001; Darbee 1990; Darbee 2004; Darbee
2005; Fainardi 2011; Falk 1984; Falk 1993; Kofler 1998; Lannefors
1992; McIlwaine 1991; McIlwaine 1997; McIlwaine 2001; McIlwaine
2013; Mortensen 1991; Newbold 2005; Pfleger 1992; Rodriguez
2016; Steen 1991; Tyrrell 1986; van Asperen 1987; van Winden 1998;
West 2010). Three studies reported using a mouthpiece (Gaskin
1998; Hofmeyr 1986; Lagerkvist 2006) and in three studies it was un-
clear whether the PEP technique was performed using a mask or a
mouthpiece (Braggion 1995; Pryor 2010; Tannenbaum 2005).
Outcome measures
Individual outcomes are reported for each PEP comparison, with
FEV1 being reported in 26 studies. One of the two studies who did
not report FEV1 used FEV0.75 (Tyrrell 1986) and the second study
was in infants (Costantini 2001). LCI was used in three studies (Dar-
bee 2005; Rodriguez 2016; Tannenbaum 2005). More details on the
reported outcomes can be found in the characteristics tables (Char-
acteristics of included studies).
Excluded studies
A total of 33 studies were excluded from the review.
Eight studies did not compare PEP to a physical airway clearance
technique (Aquino 2006; Aubriot 2016; Falk 1988; Laube 2000; Or-
lik 2015; Reychler 2015; Wettstein 2014; Wilson 2015) and in a fur-
ther six studies, neither of the interventions was PEP (Aquino 2012;
Kraemer 1996; Liedtke 1996; Oermann 2001; Patel 2013; Roos 1987).
Eight studies were excluded as the PEP technique used did not
meet the definition of PEP for this review; two used underwater
tubing (Balestri 2004; Battistini 2001), two used a flow-independant
PEP device (Padman 1999; van der Schans 1991), three did not in-
clude huffing (McCarren 2006; Placidi 2001; Sanchez Riera 1999)
and one was positive end-expiratory pressure and not PEP (Dos-
man 2003). In six studies, PEP versus other airway clearance tech-
niques was not the randomised intervention (Bishop 2011; Borka
2012; Fitzgerald 2001; Marks 1998; Orlik 2000; Znotina 2000). Two
studies did not report any data in their published papers for out-
comes of interest in this review (Castle 1994; Gotz 1995). Two stud-
ies recruited participants not eligible for this review; one study was
performed on post-transplant individuals (Munro 2007) and one on
people with chronic bronchitis (van Hengstum 1987). Another study
compared reported adherence against objectively measured ad-
herence (Richmond 2016).
Studies awaiting classification
Nine studies are currently awaiting classification and will be fully
assessed at the next update of the review (Elkins 2005; Grzincich
2008; Kofler 1994; Parreira 2008; Radtke 2018; Tonnesen 1982; Ven-
drusculo 2019; Ward 2018; Wong 2000).
Risk of bias in included studies
Allocation
Sequence generation
Five studies described the randomisation procedure (Fainardi
2011; McIlwaine 2013; Pryor 2010; Rodriguez 2016; West 2010) and
were considered to have a low risk of bias. In the remaining 23 stud-
ies, the participants were described as being randomly allocated to
groups (in those that were cross-over in design, to treatment order),
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but no further details were provided; these studies were therefore
at an unclear risk of bias.
Allocation concealment
In five studies the allocation was concealed (i.e., the person who de-
termined if a participant was eligible for inclusion in the study was
unaware, when this decision was made, to which group the par-
ticipant would be allocated) and these five studies were therefore
deemed at low risk of bias (McIlwaine 2001; McIlwaine 2013; New-
bold 2005; Rodriguez 2016; West 2010). None of the remaining 23
studies discussed the method of allocation concealment and thus
were deemed to have an unclear risk of bias.
Blinding
Due to the nature of the therapy, the participants in each of the
studies were aware of which group they had been allocated to. All
studies were therefore at a high risk of bias. Also, after randomisa-
tion occurred, the person applying the therapy knew which group
the participants were allocated to.
In 10 of the studies the person assessing at least one outcome mea-
sure did not know which group the participants had been allocat-
ed to and they were therefore deemed to be at a low risk of bias
(Fainardi 2011; Falk 1984; McIlwaine 1997; McIlwaine 2001; McIl-
waine 2013; Mortensen 1991; Newbold 2005; Pryor 2010; Rodriguez
2016; West 2010). For self-reported outcomes (e.g. visual analogue
scale, pain diary), the assessor is only considered to be blinded if
the participant was blinded. No other study reported on who was
blinded and are judged to have an unclear risk of bias.
Incomplete outcome data
In 21 studies, the measures of at least one key outcome at one time
point were obtained from more than 85% of the participants initial-
ly allocated to groups (Darbee 1990; Darbee 2005; Fainardi 2011;
Falk 1984; Gaskin 1998; Hofmeyr 1986; Kofler 1998; Lagerkvist 2006;
Lannefors 1992; McIlwaine 1991; McIlwaine 1997; McIlwaine 2013;
Mortensen 1991; Newbold 2005; Pfleger 1992; Steen 1991; Pryor
2010; Rodriguez 2016; Tannenbaum 2005; van Winden 1998; West
2010).
In seven studies, all participants, for whom outcome measures
were available, received the treatment or control condition as allo-
cated or, where this was not the case, data for at least one key out-
come was analysed by 'intention-to-treat' (Falk 1984; Gaskin 1998;
Lagerkvist 2006; McIlwaine 2013; Pryor 2010; Rodriguez 2016; West
2010). This criterion is satisfied (even if there is no mention of analy-
sis by intention-to-treat) if the report explicitly states that all partic-
ipants received treatment or control conditions as allocated. Inten-
tion-to-treat analysis was explicitly mentioned in two studies (McIl-
waine 2013; Pryor 2010); however, 13 participants in the Pryor study
withdrew as they did not like the intervention they had been ran-
domised to; it is unclear if these participants were included in the
intention-to-treat group (Pryor 2010). In the 2013 McIlwaine study,
16 participants withdrew after randomisation but prior to initiation
of study therapy regimens, these participants were not included in
the intention-to-treat analysis (McIlwaine 2013). In the 2001 McIl-
waine study, three participants dropped out from the PEP group
due to non-compliance while five participants dropped out from
the flutter group as they believed that the flutter was ineffective
in clearing their secretions (McIlwaine 2001). It is unclear whether
these participants were included in the analysis. In the Tyrrell study,
three out of 19 participants were excluded due to non-adherence
(Tyrrell 1986). The risk of bias is low in the first two studies (McIl-
waine 2013; Pryor 2010) and unclear in the last two studies (McIl-
waine 2001; Tyrrell 1986).
Selective reporting
The results of between-group statistical comparisons are reported
for all outcomes in 13 studies (Darbee 2004; Darbee 2005; Fainardi
2011; Falk 1984; Falk 1993; Lagerkvist 2006; McIlwaine 2001; McIl-
waine 2013; Mortensen 1991; Newbold 2005; Rodriguez 2016; van
Winden 1998; West 2010). The results of between-group statistical
comparisons are reported for at least one key outcome in 13 studies
(Darbee 1990; Gaskin 1998; Hofmeyr 1986; Kofler 1998; Lannefors
1992; McIlwaine 1991; McIlwaine 1997; Pfleger 1992; Pryor 2010;
Tannenbaum 2005; Steen 1991; Tyrrell 1986; van Asperen 1987).
Two studies did not report any between group statistical compar-
isons (Braggion 1995; Costantini 2001).
In 27 studies the following are provided, either:
(a) point measures and measures of variability for at least one con-
tinuous outcome; or
(b) the number of participants in each category for at least one cat-
egorical outcome; or
both (a) and (b) (Costantini 2001; Darbee 1990; Darbee 2004; Dar-
bee 2005; Fainardi 2011; Falk 1984; Falk 1993; Gaskin 1998; Hofmeyr
1986; Kofler 1998; Lagerkvist 2006; Lannefors 1992; McIlwaine
1991; McIlwaine 1997; McIlwaine 2001; McIlwaine 2013; Mortensen
1991; Newbold 2005; Pfleger 1992; Pryor 2010; Rodriguez 2016;
Steen 1991; Tannenbaum 2005; Tyrrell 1986; van Asperen 1987;van
Winden 1998; West 2010). The risk of bias for these studies is low. In
one study neither (a) or (b) were provided (Braggion 1995). In this
study the risk of bias was assessed as high.
Other potential sources of bias
In one study, no information was provided regarding similarities at
baseline (unclear risk of bias) (Costantini 2001). In the remaining 27
studies, the groups were similar at baseline regarding the most im-
portant prognostic indicators (i.e. based on at least one measure
of the severity of CF and one outcome measure at baseline, the
groups' outcomes would not be expected to differ by a clinically
significant amount), which indicates a low risk of bias.
There were 18 studies of cross-over design which has the potential
to increase the risk of bias. Eight studies were of one or two days in
duration, with no washout period, which may be a potential source
of bias (Braggion 1995; Darbee 2005; Fainardi 2011; Falk 1984; Falk
1993; Hofmeyr 1986; Kofler 1998; Pfleger 1992). Cross-over studies
of longer duration have a higher risk of bias and in these 10 stud-
ies, there were three which lasted one month and had no washout
period between techniques (Steen 1991; Tyrrell 1986; van Asperen
1987).
There are relatively few meetings for reporting research about CF;
however, it is possible that some studies may have been published
or presented as abstracts at physiotherapy conferences that do not
appear on online searches.
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E@ects of interventions
See: Summary of findings for the main comparison Summary of
findings - PEP compared with PDPV for cystic fibrosis; Summary of
findings 2 Summary of findings - PEP compared to oscillating PEP
for cystic fibrosis; Summary of findings 3 Summary of findings -
PEP compared to HFCWO for cystic fibrosis; Summary of findings
4 Summary of findings - PEP compared to BiPAP for cystic fibrosis;
Summary of findings 5 Summary of findings - PEP compared to
airway clearance techniques for cystic fibrosis
1. PEP compared with PDPV
Eight studies included in this review (207 participants) make com-
parisons of PEP versus conventional physiotherapy (PDPV) for CF
(Braggion 1995; Costantini 2001; Darbee 1990; Falk 1984; Gaskin
1998; McIlwaine 1997; Tyrrell 1986; van Asperen 1987). These com-
parisons are also made by the Cochrane Review 'Conventional
chest physiotherapy compared to other airway clearance tech-
niques for cystic fibrosis' (Main 2005).
Primary outcomes
1. FEV1
Five studies (148 participants) measured FEV1 (Braggion 1995; Dar-
bee 1990; Gaskin 1998; McIlwaine 1997; van Asperen 1987) (Analy-
sis 1.1). Unpublished data were provided for three studies allowing
these studies to be included in analysis (Darbee 1990; Gaskin 1998;
van Asperen 1987). First-period data only from two studies were in-
cluded in analysis due to concerns over risk of bias as these cross-
over studies did not have a washout period (Darbee 1990; van As-
peren 1987).
a. Short-term (up to seven days)
One study (16 participants) measured FEV1 after four treatments of
PEP, postural drainage with undefined chest physiotherapy tech-
niques, or flutter over two days and found no significant differences
in FEV1 (% predicted) (low-quality evidence) (Braggion 1995). This
was a cross-over study from which data from the end of the first
randomisation arm could not be obtained.
b. Long-term studies (more than seven days)
Four studies (119 participants) measured FEV1 after a series of
treatments over more than seven days (low-quality evidence) (Dar-
bee 1990; Gaskin 1998; McIlwaine 1997; van Asperen 1987) (Analysis
1.1). Results are reported as change in % predicted for FEV1.
No significant differences in FEV1 were demonstrated after one
month of PEP or PDPV, MD 0.60% predicted (95% CI -6.33 to 7.53)
(13 participants) (van Asperen 1987), or after three months of PEP or
PDPV, MD -0.50% predicted (95% CI -3.68 to 2.68) (13 participants)
(Darbee 1990).
Two studies lasted at least one year (106 participants) (Gaskin 1998;
McIlwaine 1997). In the one year study of children and adolescents,
FEV1 improved by a mean of 5.98% predicted for the PEP group,
while in the PDPV group it deteriorated by 2.28% predicted, this was
a significant difference favouring PEP, MD 8.26 (95% CI 0.76 to 15.76)
(40 participants) (McIlwaine 1997). However, in a two-year study,
predominately in adults, no significant difference in the rates of de-
cline in FEV1 were reported between the PEP group and the PDPV
group, with mean annual declines of 2.76% predicted and 2.11%
predicted, respectively, MD -0.65 (95% CI -3.25 to 1.95) (66 partici-
pants) (Gaskin 1998).
One cross-over study (13 participants) reported participants being
withdrawn due to exacerbations, although these are not well-de-
fined (van Asperen 1987). It is also unclear which treatments the
participants were randomised to at the time of departure.
2. Number of respiratory exacerbations between baseline and post-
intervention
In the Gaskin study (which used PEP with a mouthpiece), it was
reported (personal communication) that there was no difference
in the number of respiratory exacerbations (low-quality evidence)
(Gaskin 1998).
3. Direct measures of mucus clearance
One study (20 participants) measured radio-labelled aerosol clear-
ance after a single treatment of PEP and found no significant dif-
ference in clearance between PEP and PDPV (low-quality evidence)
(Darbee 1990). This was a cross-over study from which data from
the end of the first randomisation arm could not be obtained so no
data have been entered into the review.
Secondary outcomes
1. Expectorated secretions, dry or wet weight, or volume
Three cross-over studies reported measures of expectorated spu-
tum (43 participants) (Braggion 1995; Falk 1984; van Asperen 1987).
a. Single treatment
One study (14 participants) found that wet weight of sputum during
and for 50 minutes after PEP (whether in sitting or PD positions)
was greater than that induced by PDPV or pursed lip breathing (Falk
1984). These results were not available by treatment period, so are
presented in an additional table (Table 1).
b. Short-term (up to seven days)
In one study (13 participants), no significant difference in expec-
torated secretions was identified between the treatment groups,
measured by sputum volume (van Asperen 1987). In a further study
(16 participants), no significant difference in wet or dry weight of
sputum was identified between PEP and PDPV or HFCC and no fur-
ther data were available (Braggion 1995).
c. Long-term (more than seven days)
As outlined in the Types of outcome measures section, this review
does not examine this outcome where it is measured after more
than seven days of treatment.
2. Other pulmonary parameters
a. FVC
Six studies (165 participants) measured FVC (Darbee 1990; Falk
1984; Gaskin 1998; McIlwaine 1997; Tyrrell 1986; van Asperen 1987)
(Analysis 1.2). Unpublished data were provided for four of these, al-
lowing these studies to be included in analysis (Darbee 1990; Gaskin
1998; Tyrrell 1986; van Asperen 1987). First-period data for only
three studies were included in the analysis due to concerns over risk
of bias as these cross-over studies did not have a washout period
(Darbee 1990; Tyrrell 1986; van Asperen 1987). Results are reported
as change in % predicted for FVC.
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i. Single treatment
One study (19 participants) measured FVC after a single treatment
(Tyrrell 1986). After a single treatment with PEP or PDPV, no signif-
icant difference in FVC was demonstrated, MD 1.90 (95% CI -4.96 to
8.76) (Tyrrell 1986) (Analysis 1.2).
ii. Short term (up to seven days)
In one study (14 participants), after two days of twice-daily treat-
ment, FVC significantly increased in a group performing PEP in sit-
ting and significantly decreased in a group performing PDPV (Falk
1984). These results were not available by treatment period, so are
presented in an additional table (Table 2).
iii. Long term (more than seven days)
Five studies (151 participants) measured FVC after a series of treat-
ments over more than seven days (Darbee 1990; Gaskin 1998; McIl-
waine 1997; Tyrrell 1986; van Asperen 1987). After one month of
twice-daily treatments with PEP or PDPV, no significant difference
in FVC was found in adolescents (19 participants) (Tyrrell 1986), or
in children and adolescents (13 participants) (van Asperen 1987).
Meta-analysis of these two studies indicated a significant difference
in favour of PDPV, MD -4.18 (95% CI -12.92 to 4.56) (Tyrrell 1986; van
Asperen 1987) (Analysis 1.2). Results are reported as change in %
predicted for FVC. In a further trial (13 participants), no significant
difference in FVC was demonstrated after three months of PEP or
PDPV, MD 2.09 (95% CI -5.46 to 9.64) (Darbee 1990).
At the end of a one-year study (40 participants), mean FVC for the
PEP group increased by 6.57% predicted, and mean FVC for the
PDPV group decreased by approximately 2.17% predicted; this was
a significant difference favouring PEP, MD 8.74 (95% CI 1.44 to 16.04)
(McIlwaine 1997). In a two-year study (66 participants), no signifi-
cant difference in the rates of decline in FVC were reported between
the PEP group and the PDPV group, with mean annual declines of
2.54% predicted and 0.97% predicted, respectively, MD -1.57 (95%
CI -4.33 to 1.19) (Gaskin 1998).
b. FEF25-75
Three studies (66 participants) reported results for FEF25-75 (Dar-
bee 1990; McIlwaine 1997; van Asperen 1987). Unpublished data
were provided for the Darbee and van Asperen studies, allowing
these studies to be included in analysis (Darbee 1990; van Asperen
1987). First-period data only of two studies were included in analy-
sis due to concerns over risk of bias as these cross-over studies did
not have a washout period (Darbee 1990; van Asperen 1987). Re-
sults are reported as change in % predicted for FEF25-75.
i. Single treatment
No studies reported at this time point.
ii. Short-term (up to seven days)
No studies reported at this time point.
iii. Long-term (more than seven days)
Three (66 participants) studies measured FEF25-75 after a series of
treatments over more than seven days (Darbee 1990; McIlwaine
1997; van Asperen 1987) (Analysis 1.3).
No significant differences in FEF25-75 were demonstrated after one
month of PEP or PDPV, MD -6.20 (95% CI -14.41 to 2.01) (13 partici-
pants) (van Asperen 1987). No significant difference in FEF25-75 was
demonstrated after three months of PEP or PDPV, MD -3.08 (95% CI
-7.87 to 1.71) (13 participants) (Darbee 1990).
At the end of a one-year study (40 participants), mean FEF25-75 for
the PEP group increased by 3.32% predicted; mean FEF25-75 for
the PDPV group decreased by approximately 0.24% predicted. This
equates to a MD for this study of 3.56 (95% CI -6.18 to 13.30) (McIl-
waine 1997).
c. TLC
One study (13 participants) measured TLC (Darbee 1990), unpub-
lished data were provided for the first period. No statistically sig-
nificant difference in TLC was demonstrated after three months of
PEP or PDPV, MD -3.38 (95% CI -13.67 to 6.91) (Darbee 1990) (Analy-
sis 1.4).
d. RV
No studies reported on this outcome.
3. Exercise tolerance
One study (66 participants) conducted exercise testing using cycle
ergometry, but reported no data for this outcome measure (low-
quality evidence) (Gaskin 1998).
4. Well-being
One study (66 participants) reported well-being as an outcome
measure and used the quality of well-being (QWB) scale (Gaskin
1998). In the two-year, parallel study of PEP versus PDPV, neither
group demonstrated a significant change in QWB scores, which was
similar at baseline and no further data were available (low-quality
evidence) (Gaskin 1998).
5. Blood oxygen levels
Two studies (40 participants) measured blood oxygen levels
(Costantini 2001; Falk 1984).
a. Single treatment
No studies reported at this time point.
b. Short term (up to seven days)
In a study (14 participants) comparing four treatments once each
over two days, the mean gain in SpO2 35 minutes after treatment
was significantly higher for PEP in sitting than for PEP in postural
drainage (PD) positions, for pursed lip breathing, or for PDPV (Falk
1984). These results were not available by treatment period, so are
presented in an additional table (Table 3). It should be noted that
the treatment durations were unequal in this study.
c. Long-term (more than seven days)
One study (26 participants) measured SpO2 after a series of treat-
ments over more than seven days (Costantini 2001). In a one-year
study of infants, oxygen saturation values in the PEP group are de-
scribed as "higher than the PDPV group in every evaluation (98.1%
versus 96.7%, P = 0.049)". Participants were evaluated at 0, 6 and 12
months in this study, so it is unclear to which evaluation the data
refer. The data have not been entered in Data and analyses as no
measures of variability were available (Costantini 2001).
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6. LCI
No studies reported on this outcome.
7. Ventilation scanning
Three studies (132 participants) reported on this outcome (Costan-
tini 2001; Gaskin 1998; McIlwaine 1997) (Analysis 1.5; Analysis 1.6)
In a year-long study of 26 infants, an increase in radiologic bronchial
markings was less common in the PEP group than the PDPV group,
RR 0.88 (95% CI 0.69 to 1.12) (Costantini 2001) (Analysis 1.5). In
the same study, hyperinflation was assessed, but only data for the
PDPV group are reported for this outcome.
A one-year study of PEP versus PDPV (40 participants) measured
Brasfield chest radiograph score, and reported identical results for
the two groups, MD 0.00 (95% CI -1.20 to 1.20) (McIlwaine 1997)
(Analysis 1.6). A two-year study of PEP versus PDPV (66 participants)
also measured Brasfield chest radiograph score, but reported no
data for this outcome measure (Gaskin 1998).
8. Cost of intervention
No studies reported on this outcome.
9. Adherence to treatment and participant preference
One study (40 participants) monitored adherence with PEP versus
PDPV over one year (McIlwaine 1997). Levels of compliance were
recorded as 96% in the PEP group and 92% in the PDPV group (McIl-
waine 1997), this is presented in an additional table and no SDs
were reported (Table 4).
Five studies (109 participants) reported on technique acceptability
or participant preference (Braggion 1995; Costantini 2001; Darbee
1990; Falk 1984; McIlwaine 1997).
a. Single treatment
One study (14 participants) measured participant preference after
a single treatment (Falk 1984). The preferred treatment for 11 of 14
participants was PEP in sitting when compared to PEP in PD po-
sitions, PDPV, or pursed lip breathing. It was reported that "even
though all participants had received postural drainage and percus-
sion as an integral part of treatment, they did not hesitate to accept
(PEP in sitting), which was easier, less time-consuming and could
be used when needed" (Falk 1984).
b. Short-term (up to seven days)
One study involving 16 participants measured participant prefer-
ence after a short-term treatment course. A two-day course of four
treatments with PEP was compared with the same regimen of PD
with undefined chest physiotherapy techniques, or flutter. Three-
point rating scales (criteria unspecified) of effectiveness and toler-
ance were recorded after each arm, with no significant differences
between interventions and no further data were available (Brag-
gion 1995).
c. Long-term (more than seven days)
Three studies (79 participants) measured participant preference af-
ter a treatment course of greater than seven days duration (Costan-
tini 2001; Darbee 1990; McIlwaine 1997). In the long-term, cross-
over study (13 participants), PEP was the treatment of choice when
compared to PDPV, "patients... preferred PEP mask for conve-
nience, independence and ease of use, as determined by a stan-
dardized written questionnaire" (not described) (Darbee 1990).
Participant preference also favoured PEP in two one-year parallel
studies (66 participants) (Costantini 2001; McIlwaine 1997). In the
study of PEP versus PDPV (40 participants), participant preference
was only recorded in the PEP group, as all participants were PEP-
naive prior to starting the study; and all 18 participants in the PEP
group nominated the PEP intervention as their preferred airway
clearance modality (McIlwaine 1997). Although it was not stated
how participant preference was determined, the conclusion from
the study of PEP versus PDPV in 26 infants was that the parents and
infants 'greatly' preferred PEP (Costantini 2001). Data from these
studies could not be obtained in sufficient detail for inclusion in
analysis.
10. Adverse effects
Two studies with 66 participants reported adverse events as an out-
come measure (low-quality evidence) (Costantini 2001; McIlwaine
1997). In a year-long study of PEP versus conventional PDPV in 40
children and adolescents, no adverse events were reported by ei-
ther group (McIlwaine 1997).
In a one-year study of 26 infants, side effects were described as rare.
Although gastro-oesophageal reflux was reported more commonly
in the PEP group than the PDPV group, risk ratio (RR) 1.25 (95% CI
0.43 to 3.63), those in the PEP group described their reflux as mild.
Reflux severe enough to cause withdrawal from the study was also
examined, with all three cases occurring in the PDPV group, RR 0.14
(95% CI 0.01 to 2.52) (Costantini 2001) (Analysis 1.7).
2. PEP compared with oscillating PEP (acapella, flutter and
cornet)
This comparison was made in seven studies (247 participants)
(Lagerkvist 2006; McIlwaine 2001; Newbold 2005; Pryor 2010; Tan-
nenbaum 2005; van Winden 1998; West 2010). However, the Pry-
or study (75 participants) had five treatment arms and three treat-
ment arms with 15 participants randomised to each arm (i.e. 45
participants in total) are included in this comparison (PEP, and two
types of oscillating PEP (flutter and cornet)) (Pryor 2010).
Primary outcomes
1. FEV1
All seven studies measured FEV1 (moderate-quality evidence)
(Lagerkvist 2006; McIlwaine 2001; Pryor 2010; Newbold 2005; Tan-
nenbaum 2005; van Winden 1998; West 2010) (Analysis 2.1).
a. Single treatment
Two studies (37 participants) found no significant difference in FEV1
(% predicted) after PEP compared to the flutter after a single treat-
ment (Lagerkvist 2006; van Winden 1998). The two studies were
cross-over studies from which data from the end of the first ran-
domisation arm could not be obtained.
b. Short term (up to seven days)
No studies considered this outcome in the short term.
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c. Long term (more than seven days)
Six studies (202 participants) measured FEV1 after a series of treat-
ments over more than seven days (McIlwaine 2001; Newbold 2005;
Pryor 2010; Tannenbaum 2005; van Winden 1998; West 2010). All
data entered into analysis is reported as the change from baseline
in FEV1 (% predicted) (Analysis 2.1).
In one study (22 participants), no significant differences in FEV1 (%
predicted) were demonstrated after two weeks of treatment with
either PEP or flutter (van Winden 1998). This was a cross-over study
from which data from the end of the first randomisation arm could
not be obtained.
In a further study (23 participants), no significant differences in
FEV1 were demonstrated after 10 days of treatment with either PEP
or acapella, MD -9.37 (95% CI -24.90 to 6.16) (Analysis 2.1) (West
2010). However, enrolment did not meet the necessary threshold
to detect a difference in FEV1.
Four studies lasted at least one year. In a one-year study in 40 chil-
dren and adolescents, FEV1 declined by a mean of 1.24% predict-
ed in the PEP group, while in the flutter group it deteriorated by
10.95%, MD 9.71 (95% CI -2.12 to 21.54) (McIlwaine 2001) (Analysis
2.1). However, in a 13-month study in 42 adults, the annual decline
in FEV1 was 4.2% predicted in the PEP group and 2% predicted in
the flutter group, MD -2.20 (95% CI -7.07 to 2.67) (Newbold 2005)
(Analysis 2.1). Another one-year study (30 participants) reported a
decrease in FEV1 of 1.9% in the PEP group and an increase of 1.3%
in the cornet group, MD -3.20 (95% CI -15.29 to 8.89) (Tannenbaum
2005). There was no significant difference between groups when
the two studies were combined, MD -2.34 (95% CI -6.86 to 2.18)
(Analysis 2.1).
In the Pryor study (45 participants), no reported significant differ-
ence was found in FEV1 between PEP, cornet and flutter with a de-
cline over a one-year period of 0.15 L with PEP, 0.03 L with cornet
and 0.03 L with flutter (between-group change data were not re-
ported) (Pryor 2010).
2. Number of respiratory exacerbations between baseline and post-
intervention
Two parallel studies (82 participants) reported the number of
respiratory exacerbations severe enough to require either intra-
venous (IV) antibiotics or hospitalisation (moderate-quality evi-
dence) (McIlwaine 2001; Newbold 2005). In a one-year study with
20 participants per group, respiratory exacerbations severe enough
to require hospitalisation occurred five times in the PEP group and
18 times in the flutter group. A Wilcoxon rank sum test indicated
this difference was statistically significant favouring PEP (P = 0.03)
but the number of hospitalisations per individual is not reported,
so these data do not appear in our analysis (McIlwaine 2001). Simi-
larly, a 13-month study with 21 participants per group found respi-
ratory exacerbations severe enough to require hospitalisation oc-
curred six times in the PEP group and 14 times in the flutter group
(moderate-quality evidence) (Newbold 2005). This represented a
mean of 0.3 hospitalisations per participant in the PEP group and
0.7 hospitalisations per participant in the flutter group, MD -0.40
(95% CI -0.92 to 0.12) (Analysis 2.2).
A further parallel study of one year (30 participants), reported the
number of respiratory exacerbations requiring either oral or IV an-
tibiotics as the primary outcome (Tannenbaum 2005) but no stan-
dard deviations were reported so this data could not be entered in-
to analysis. This study reported that there were eight respiratory
exacerbations reported in 14 participants in the PEP group (mean
0.57) and six respiratory exacerbations in 10 participants in the cor-
net group (mean 0.6) which was not significantly different (moder-
ate-quality evidence). It is unclear if these participants required IV
only or IV or oral antibiotics.
3. Direct measures of mucus clearance
No studies reported on this outcome.
Secondary outcomes
1. Expectorated secretions, dry or wet weight, or volume
No studies reported this outcome.
2. Other pulmonary parameters
a. FVC
Six studies (217 participants) measured FVC (Lagerkvist 2006; McIl-
waine 2001; Newbold 2005; Pryor 2010; van Winden 1998; West
2010) (Analysis 2.3)
i. Single treatment
Two cross-over studies (37 participants) measured FVC after a sin-
gle treatment, but data from the end of the first randomisation
arm could not be obtained (Lagerkvist 2006; van Winden 1998). No
significant difference in FVC (% predicted) was demonstrated af-
ter one treatment with either PEP or flutter (Lagerkvist 2006; van
Winden 1998).
ii. Short term (up to seven days)
No studies reported at this time point.
iii. Long term (more than seven days)
Five studies (172 participants) measured FVC after a series of treat-
ments over more than seven days (McIlwaine 2001; Newbold 2005;
Pryor 2010; van Winden 1998; West 2010). All data entered into
analysis is reported as the change from baseline in FVC (% predict-
ed) (Analysis 2.3).
In one study (22 participants), no significant difference in FVC (%
predicted) was demonstrated after two weeks of treatment with
PEP or flutter (as above, no data available from first arm) (van
Winden 1998). In a further study (23 participants), no significant dif-
ference in FVC was demonstrated after 10 days of treatment with
PEP compared to acapella, MD -5.40 (95% CI -20.01 to 9.21) (West
2010) (Analysis 2.3).
In a one-year study (40 participants), a decrease in mean FVC was
reported with flutter of 8.62% predicted, while in the PEP group
mean FVC increased 0.06% predicted, but this was not significant,
MD 8.68 (95% CI -0.54 to 17.90) (McIlwaine 2001). In a 13-month
study (42 participants), the annual decline in FVC was 4.7% predict-
ed in the PEP group and 3% predicted in the flutter group, MD -1.70
(95% CI -6.27 to 2.87) (Newbold 2005) (Analysis 2.3).
In another one-year study (45 participants) comparing PEP to flut-
ter and cornet, no significant difference between techniques were
found although the study did not report the actual data (Pryor
2010).
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b. FEF25-75
Four studies (127 participants) reported results for FEF25-75 (McIl-
waine 2001; Newbold 2005; van Winden 1998; West 2010) (Analysis
2.4).
i. Single treatment
In one study (22 participants), no significant difference in FEF25-75
(% predicted) was noted after one treatment with PEP or flutter
(van Winden 1998). This study was a cross-over study from which
data from the first randomisation arm could not be obtained.
ii. Short term (up to seven days)
No studies reported at this time point.
iii. Long term (more than seven days)
Four studies (127 participants) measured FEF25-75 after a series of
treatments over more than seven days (McIlwaine 2001; Newbold
2005; van Winden 1998; West 2010). All data entered into analysis
is reported as the change from baseline in FEF25-75 (% predicted)
(Analysis 2.4).
In one study (22 participants), no significant differences in FEF25-75
were demonstrated after two weeks of treatment with either PEP
or flutter (as above, no data available from first arm) (van Winden
1998). In a further study (23 participants), no significant differences
in FEF25-75 were demonstrated after 10 days of treatment with PEP
compared to acapella, MD -15.26 (95% CI -40.64 to 10.12) (West
2010) (Analysis 2.4).
In a one-year study in 40 children and adolescents, FEF25-75 de-
clined by a mean of 3.58% predicted in the PEP group, while in the
flutter group it deteriorated by 8.87% predicted; however, the dif-
ference was not significant, MD 5.29 (95% CI -7.84 to 18.42) (McIl-
waine 2001). In a 13-month study (42 participants), annual decline
in FEF25-75 was 3.1% predicted in the PEP group and 2% predicted
in the flutter group, MD -1.10 (95% CI -6.50 to 4.30) (Newbold 2005)
(Analysis 2.4).
c. TLC
One cross-over study (22 participants) measured TLC (as above,
no data available from first arm) (van Winden 1998). No significant
changes in TLC occurred both after one treatment and after two
weeks of treatment with PEP and flutter (van Winden 1998).
d. RV
No studies reported this.
3. Exercise tolerance
Two studies (68 participants) conducted exercise testing using the
modified shuttle test and reported no significant difference in out-
come between PEP, AD, ACBT, cornet and flutter over a one-year pe-
riod (Pryor 2010) or between PEP and acapella over 10 day treat-
ment, MD 6.32 (95% CI -15.46 to 28.10) (West 2010) (Analysis 2.5).
4. Well-being
Two studies (75 participants) reported well-being as an outcome
measure (low-quality evidence) (Pryor 2010; Tannenbaum 2005). In
the Tannenbaum study (30 participants), there was no significant
change from baseline in either group on the QWB scale; no data are
available as this study were only published in abstract form (Tan-
nenbaum 2005).
Pryor (45 participants) found no significant differences between
the five groups (PEP, cornet and flutter as well as AD and ACBT) in
the physical domain (P = 0.99) or the mental domain (P = 0.27) us-
ing Short Form -36; and no significant differences among the five
groups in the dyspnoea domain (P = 0.7), fatigue (P = 0.85), emotion
(P = 0.39) or mastery (P = 0.82) using the Chronic Respiratory Ques-
tionnaire (Pryor 2010). No data were reported that could be entered
into analysis.
5. Blood oxygen levels
Two studies (37 participants) measured blood oxygen levels
(Lagerkvist 2006; van Winden 1998).
a. Single treatment
In one cross-over study (15 participants), with no data available for
the first arm, both transcutaneous oxygen levels (Pto2) and carbon
dioxide levels (Ptco2) were measured. The immediate results after a
single treatment of flutter showed higher Pto2 (P = 0.05) and lower
Ptco2 (P < 0.0001) compared to PEP, but at steady state after treat-
ment all differences had disappeared (Lagerkvist 2006).
b. Short term (up to seven days)
No studies reported at this time point.
c. Long term (more than seven days)
One cross-over study (22 participants), with no data available for
the first arm, measured SpO2 after a series of treatments over more
than seven days (van Winden 1998). In this two-week study, there
was no difference in SPO2 between flutter and PEP measured be-
fore, during and after treatment.
6. LCI
One study (30 participants) used multiple, breath inert gas washout
to examine lung clearance (Tannenbaum 2005). They reported no
significant difference in LCI between PEP and cornet over a one-
year period, MD 0.80 (95% CI -1.36 to 2.96) (low-quality evidence)
(Analysis 2.6).
7. Ventilation scanning
In a one-year study of PEP versus flutter (40 participants), a blind-
ed radiologist evaluated changes in chest radiographs. The groups
were not significantly different, although no data were published
to support this (McIlwaine 2001).
8. Cost of intervention
No studies reported on this outcome.
9. Adherence to treatment and participant preference
Three studies monitored adherence or patient satisfaction (McIl-
waine 2001; Tannenbaum 2005; West 2010).
a. Single treatment
No studies reported at this time point.
b. Short term (up to seven days)
No studies reported at this time point.
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c. Long term (more than seven days)
The West study used a patient satisfaction survey and found no
significant difference between PEP and acapella after 10 days, MD
-0.36 (95% CI -0.85 to 0.13) (West 2010) (Analysis 2.7).
In the one-year study of PEP versus flutter (40 participants), two
participants were withdrawn from the PEP group due to non-com-
pliance, RR 5.00 (95% CI 0.26 to 98.00) (McIlwaine 2001) (Analysis
2.8). While no participants were withdrawn from the flutter group
for non-compliance, five dropped out due to a perceived lack of
treatment efficacy with flutter, and a further two were withdrawn
due to clinical deterioration. Overall, adherence was reported as
95.6% for the PEP group and 93.8% for the flutter group (McIlwaine
2001). This is presented in an additional table (Table 5).
Participants preferred PEP in the one-year parallel study of PEP ver-
sus flutter which reported "discontinuation due to lack of perceived
effectiveness in clearing their secretions" (McIlwaine 2001). Of 40
participants, five discontinued for this reason, all from the flutter
group; however, there was no significant difference between treat-
ment groups, RR 0.09 (95% CI 0.01 to 1.54) (McIlwaine 2001) (Analy-
sis 2.9).
A one-year study of PEP versus cornet (30 participants) reported
that one child in each group stopped using the device as they found
it 'ineffective and fiddly to clean' (Cornet group) or they preferred
a previously used device (PEP group) (Tannenbaum 2005). No data
were available to enter into analysis.
10. Adverse effects
One cross-over study (22 participants) reported that five partici-
pants complained of dizziness when using the Flutter device which
improved after further instructions on breathing techniques when
using the device was provided (low-quality evidence) (van Winden
1998).
No other studies reported than any adverse events occurred
3. PEP compared with HFCWO
This comparison was made in four studies (174 participants) (Brag-
gion 1995; Darbee 2005; Fainardi 2011; McIlwaine 2013).
Primary outcomes
1. FEV1
Four studies measured FEV1 (Braggion 1995; Darbee 2005; Fainardi
2011; McIlwaine 2013) (Analysis 3.1; Analysis 3.2).
a. Single treatment
Two studies (51 participants) measured FEV1 after a single treat-
ment (Darbee 2005; Fainardi 2011). There was no significant differ-
ence in FEV1 (% predicted) after PEP compared to HFCWO (low-
quality evidence) (Darbee 2005; Fainardi 2011). Both were cross-
over studies from which data from the end of the first randomisa-
tion arm could not be obtained.
b. Short term (up to seven days)
One cross-over study (16 participants), with no data available for
the first arm, measured FEV1 after four treatments of PEP, postur-
al drainage with undefined airway clearance techniques, or flutter
over two days and found no significant differences in FEV1 (% pre-
dicted) (low-quality evidence) (Braggion 1995).
c. Long term (more than seven days)
One study (107 participants) measured FEV1 after a series of treat-
ments over more than seven days (McIlwaine 2013). In the only one-
year study comparing PEP to HFCWO, FEV1 increased by a mean
of 0.22 L with PEP and 0.23 L with HFCWO (McIlwaine 2013). Data
were provided at each study visit and the change in FEV1 (% pre-
dicted) over one year was not significantly different between the
two groups, MD -3.59 (95% CI -9.29 to 2.11) (low-quality evidence)
(Analysis 3.1).
2. Number of respiratory exacerbations between baseline and post-
intervention
One parallel study with 107 participants which ran for one year,
reported the number of respiratory exacerbations requiring either
oral or IV antibiotics as the primary outcome (McIlwaine 2013). In 43
participants performing PEP, 26 had 49 respiratory exacerbations
compared with 96 respiratory exacerbations in 40 of the 48 partici-
pants performing HFCWO, which showed a significant difference in
favour of PEP, RR 0.73 (95% CI 0.55 to 0.95) (high-quality evidence)
(Analysis 3.2). This study by McIlwaine also reported that respirato-
ry exacerbations, which were severe enough to require either IV an-
tibiotics or hospitalisation, occurred six times in the PEP group (six
participants) and 19 times in the HFCWO group (13 participants).
This represented a mean of 0.12 respiratory exacerbations requir-
ing IV antibiotics per participant in the PEP group and a mean of 0.4
respiratory exacerbations requiring IV antibiotics per participant in
the HFCWO group (McIlwaine 2013).
3. Direct measures of mucus clearance
No study reported on this outcome.
Secondary outcomes
1. Expectorated secretions, dry or wet weight, or volume
Two cross-over studies (52 participants), with no data available for
the first arms, reported measures of expectorated sputum (Brag-
gion 1995; Fainardi 2011).
a. Single treatment
One study (36 participants) measured expectorated secretions af-
ter a single treatment (Fainardi 2011). Wet weight of sputum was
not significantly different after single treatments of PEP and HFC-
WO (Fainardi 2011).
b. Short term (up to seven days)
In one study (16 participants), no significant difference in wet or dry
weight of sputum was identified between PEP and PDPV or HFCWO
(Braggion 1995).
c. Long term (more than seven days)
As outlined in the Data extraction and management section, this
review does not examine this outcome where it is measured after
more than seven days of treatment.
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2. Other pulmonary parameters
a. FVC
Three studies measured FVC (158 participants) (Darbee 2005;
Fainardi 2011; McIlwaine 2013) (Analysis 3.3).
i. Single treatment
Two cross-over studies (51 participants), with no data available for
the first arms, measured FVC (% predicted) after a single treatment
(Darbee 2005; Fainardi 2011). In one study (15 participants), both
PEP and HFCWO significantly improved FVC during an acute exacer-
bation, but there was no significant difference between either treat-
ment (Darbee 2005). A second study (36 participants) comparing
PEP to HFCWO over a single treatment also showed no significant
difference (Fainardi 2011).
ii. Short term (up to seven days)
No study reported at this time point.
iii. Long term (more than seven days)
One study (107 participants) measured FVC after a series of treat-
ments over more than seven days (McIlwaine 2013). No significant
difference in FVC was demonstrated at the end of a one-year study
comparing PEP to HFCWO (McIlwaine 2013). The PEP group in-
creased by mean 0.3 L and HFCWO by mean 0.35 L. Data were pro-
vided at each study visit and the change in FVC (% predicted) over
one year was not significantly different between the two groups, MD
-5.00 (95% CI -10.30 to 0.30) (Analysis 3.3).
b. Forced expiratory flow 25-75%
Three studies measured FEF25-75 (158 participants) (Darbee 2005;
Fainardi 2011; McIlwaine 2013) (Analysis 3.4).
i. Single treatment
Two cross-over studies (41 participants), with no data available for
the first arms, measured FEF25-75 (% predicted) after a single treat-
ment (Darbee 2005; Fainardi 2011). In one study (15 participants),
there was no significant difference between treatments (Darbee
2005). A second study (36 participants) comparing PEP to HFC-
WO over a single treatment also showed no significant difference
(Fainardi 2011).
ii. Short term (up to seven days)
No study reported at this time point.
iii. Long term (more than seven days)
One study (107 participants) measured FEF25-75 after a series of
treatments over more than seven days (McIlwaine 2013). No signif-
icant difference in FEF25-75 was demonstrated at the end of a one
year study comparing PEP to HFCWO (McIlwaine 2013). The PEP
group increased by mean 0.27 L and HFCWO by mean 0.19 L. Da-
ta were provided at each study visit and the change in FEF25-75 (%
predicted) over one year was not significantly different between the
two groups, MD -0.34 (95% CI -12.54 to 11.86) (Analysis 3.4).
c. TLC
No study reported this outcome.
d. RV
No study reported this outcome.
3. Exercise tolerance
No study reported this outcome.
4. Well-being
No study reported this outcome.
5. Blood oxygen levels
Two studies (51 participants) measured blood oxygen levels (Dar-
bee 2005; Fainardi 2011). HFCWO was associated with a significant
decrease in SpO2 during treatment whereas the PEP technique pro-
duced significant increases in SpO2 during treatment and is pre-
sented as a figure in the trial report.
a. Single treatment
One cross-over study (36 participants), for which data were not
available for the first arm, reported that during a single treatment
of HFCC compared to HFCC, there was a small but significant de-
crease in SpO2 values after PEP treatment (98% ± 1% versus 97% ±
1.2%; P < 0.001), but not after HFCC (97% ± 1.6% versus 97% ± 1.2%)
(Fainardi 2011).
b. Short term (up to seven days)
No study reported at this time point.
c. Long term (more than seven days)
No study reported at this time point.
6. LCI
One cross-over study (15 participants), for which data were not
available for the first arm, reported the results of lung clearance
using a single-breath inert gas test which examines distribution of
ventilation (Darbee 2005). This study compared PEP to HFCWO and
showed an improvement in ventilation distribution and gas mixing
with both treatments which was not significantly different between
both techniques (very low-quality evidence) (Darbee 2005).
7. Ventilation scanning
No study reported this outcome.
8. Cost of intervention
One study (107 participants) discussed costs of devices (PEP device
at GBP 50 versus a HFCWO device at GBP 7000), but no further in-
formation was provided (McIlwaine 2013).
9. Adherence to treatment and participant preference
In a one-year study (107 participants) comparing PEP to HFCWO,
adherence was measured by participants keeping a daily diary and
reported on monthly phone calls, adherence was recorded at 96%
in both groups (McIlwaine 2013).
Two studies (52 participants) reported on technique acceptabili-
ty or participant preference (Braggion 1995; Fainardi 2011).Due to
the cross-over design of these studies, data cannot be entered into
analysis.
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a. Single treatment
One study measured participant preference after a single treat-
ment (Fainardi 2011). In this group of 36 participants comparing
PEP to HFCWO,18 preferred PEP, three preferred HFCWO and 13 had
no preference.
b. Short term (up to seven days)
One study involving 16 participants measured participant prefer-
ence after a short-term treatment course. A two-day course of four
treatments with PEP was compared with the same regimen of PD
with undefined chest physiotherapy techniques, or flutter. Three-
point rating scales (criteria unspecified) of effectiveness and toler-
ance were recorded after each arm, with no significant differences
between interventions (Braggion 1995) and no further data were
available.
c. Long term (more than seven days)
No studies reported at this time point.
10. Adverse events
One parallel study with 107 participants which ran for one year, re-
ported the number of adverse events (McIlwaine 2013). In total, 163
events were reported in the PEP group and 200 in the HFCWO group;
this was not significantly different between the groups. However,
there were significantly more adverse events related to the lower
airways (increased cough, chest infection, haemoptysis, decreased
lung function and chest pain) in the HFCWO group compared to the
PEP group (mean 2.46 versus mean 1.72, P = 0.023) (high-quality ev-
idence).
4. PEP compared with BiLevel positive airway pressure (BiPAP)
Two studies compared PEP with BiPAP. BiPAP is typically used for
ventilatory support, however, by changing the inspiratory and expi-
ratory pressures on the device and combining it with huffing, it has
been used as an airway clearance device (52 participants) (Kofler
1998; Rodriguez 2016). One was a short-term cross-over study (20
participants) (Kofler 1998) while the other was a long-term compar-
ative study (32 participants) (Rodriguez 2016).
Rodriguez reported data before and after treatment, analysing
within group and between group differences with a generalised lin-
ear model (Rodriguez 2016). The data presented could not be en-
tered into analysis so is presented in an additional table (Table 6).
Primary outcomes
1. FEV1
Both studies measured FEV1 (Kofler 1998; Rodriguez 2016).
a. Single treatment
One study (20 participants) measured FEV1 after a single treatment
(Kofler 1998). There was no significant difference in FEV1 after PEP
compared to non-invasive bilevel ventilatory support (BiPAP) (low-
quality evidence) (Kofler 1998). This was a cross-over study from
which data from the end of the first randomisation arm could not
be obtained. It was unclear whether FEV1 was measured in litres or
% predicted.
b. Short term (up to seven days)
No studies reported at this time point.
c. Long term (more than seven days)
One study (32 participants) measured FEV1 after a series of treat-
ments over more than seven days (Rodriguez 2016). No significant
differences in FEV1 (litres or % predicted) were demonstrated after
three months of PEP compared to BiPAP (P = 0.98 and P = 0.52 re-
spectively) (low-quality evidence) (Rodriguez 2016) (Table 6)
2. Number of respiratory exacerbations between baseline and post-
intervention
No studies reported at this time point.
3. Direct measures of mucus clearance
No studies reported at this time point.
Secondary outcomes
1. Expectorated secretions, dry or wet weight, or volume
a. Single treatment
No studies reported at this time point.
b. Short term (up to seven days)
No short-term studies were reported.
c. Long term (more than seven days)
As outlined above in the Types of outcome measures section, this
review does not examine this outcome where it is measured after
more than seven days of treatment.
2. Other pulmonary parameters
a. FVC
FVC was measured in the two studies (52 participants) (Kofler 1998;
Rodriguez 2016).
i. Single treatment
One study (20 participants) measured FVC after a single treatment
(Kofler 1998). No significant difference in FVC was noted after one
treatment with PEP or BiPaP (Kofler 1998). This was a cross-over
study from which data from the end of the first randomisation arm
could not be obtained. It was unclear whether FVC was measured
in litres or % predicted.
ii. Short term (up to seven days)
No studies reported at this time point.
iii. Long term (more than seven days)
One study (32 participants) measured FVC over a three-month peri-
od (Rodriguez 2016). This study reported no significant differences
in FVC (litres or % predicted) with either PEP or BiPAP (P = 0.54 and
P = 0.25 respectively) (Rodriguez 2016) (Table 6).
b. FEF25-75
One study (20 participants) reported results for FEF25-75 (Kofler
1998).
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i. Single treatment
No significant difference in FEF25-75 was noted after one treatment
with PEP or BiPAP (Kofler 1998) This was a cross-over study from
which data from the end of the first randomisation arm could not
be obtained.It was unclear whether FEF25-75 was measured in litres
or % predicted.
ii. Short term (up to seven days)
No studies reported at this time point.
iii. Long term (more than seven days)
No studies reported at this time point.
c. TLC
No studies reported on this outcome.
d. RV
No studies reported on this outcome.
3. Exercise tolerance
One study (32 participants) conducted exercise testing using the
six-minute walk test and reported no significant difference in out-
come (P = 0.76) between PEP and BiPAP over a three-month period
(low-quality evidence) (Rodriguez 2016) (Table 6).
4. Well-being
No studies reported on this outcome.
5. Blood oxygen levels
Two studies (52 participants) measured blood oxygen levels (Kofler
1998; Rodriguez 2016).
a. Single treatment
One study (20 participants) was a single treatment. The improve-
ment in SpO2 during a single BiPAP treatment was statistically sig-
nificantly greater than with one treatment with PEP (Kofler 1998),
this is presented in an additional table (Table 7).
b. Short term (up to seven days)
There were no short-term studies
c. Long term (more than seven days)
One study (32 participants) measured SpO2 after a series of treat-
ments over more than seven days (Rodriguez 2016). No significant
differences in SpO2 was demonstrated after three months of PEP or
BiPaP (numerical results not presented) (Rodriguez 2016).
6. LCI
One study (32 participants) reported the results of lung clearance
using a single-breath inert gas test which examines distribution of
ventilation (Rodriguez 2016). This study reported a significant im-
provement in the distribution of ventilation following BiPAP com-
pared to PEP (P = 0.01) (low-quality evidence) (Rodriguez 2016) (Ta-
ble 6).
7. Ventilation scanning
No studies reported on this outcome.
8. Cost of intervention
No studies reported on this outcome.
9. Adherence to treatment and participant preference
One study (20 participants) measured participant preference after
a single treatment (Kofler 1998). When compared to BiPAP, 60% of
participants preferred BiPAP, 25% preferred PEP, and 15% had no
preference (Kofler 1998).
10. Adverse events
Kofler reported that no untoward effects were found in any of the
20 participants (low-quality evidence) (Kofler 1998). Rodriguez (32
participants) did not report whether any adverse events occurred
(Rodriguez 2016).
5. PEP compared with a variety of di@erent airway clearance
techniques
Eight cross-over studies compared PEP with different airway
clearance techniques (116 participants) (Darbee 2004; Falk 1993;
Hofmeyr 1986; Lannefors 1992; McIlwaine 1991; Mortensen 1991;
Pfleger 1992; Steen 1991). Darbee (six participants) compared two
types of PEP (Darbee 2004). Three studies (40 participants) com-
pared PEP to ACBT (Falk 1993; Hofmeyr 1986; Mortensen 1991);
Pfleger (15 participants) compared PEP and autogenic drainage
(AD) (Pfleger 1992); Steen (28 participants) compared PEP alone,
PDPV and FET, or five minutes of PEP followed by PDPV and FET
(Steen 1991); McIlwaine (18 participants) compared PEP, PDP and
AD (McIlwaine 1991); and Lannefors (nine participants) compared
PEP, PD and physical exercise (Lannefors 1992).
As these studies were all cross-over in design, limited data are avail-
able as data from the end of the first randomisation arm could not
be obtained so no data are entered into analysis for this compari-
son.
An additional parallel group study, the Pryor study (75 participants)
had five treatment arms and three treatment arms with 15 partici-
pants randomised to each arm (i.e. 45 participants in total) are in-
cluded in this comparison (PEP, ACBT and AD) (Pryor 2010).
Primary outcomes
1. FEV1
Six studies (95 participants) measured FEV1 (low-quality evidence)
(Darbee 2004; Hofmeyr 1986; McIlwaine 1991; Mortensen 1991;
Pfleger 1992; Steen 1991).
a. Single treatment
Two studies (21 participants) measured FEV1 after a single treat-
ment (Darbee 2004; Pfleger 1992). In the Darbee study (six partic-
ipants), there was no significant difference in FEV1 (% predicted)
after PEP compared > 20 cm H2O PEP (Darbee 2004). The Pfleger
study (15 participants) found that FEV1 (% predicted) was signifi-
cantly lower after a treatment of AD followed by Hi-PEP, compared
to AD alone (Pfleger 1992). This is presented in an additional table
(Table 8).
b. Short term (up to seven days)
One study (18 participants) measured FEV1 after four treatments of
PEP in sitting, PEP in postural drainage positions, or breathing ex-
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ercises in postural drainage positions on a single day and found no
significant differences in FEV1 (% predicted) (Hofmeyr 1986).
c. Long term (more than seven days)
Three studies (56 participants) measured FEV1 after a series of
treatments over more than seven days (McIlwaine 1991; Mortensen
1991; Steen 1991). In one study (28 participants), no significant dif-
ferences in FEV1 (% predicted) were demonstrated after one month
of PEP, PEP followed by PDPV, PDPV, or PEP + FET (Steen 1991).
Similarly, after two months of PEP, AD, or PDP (18 participants)
there were no significant differences (McIlwaine 1991), nor in a fur-
ther study (10 participants) after two months of PEP or PD plus FET
(Mortensen 1991).
In the Pryor study (45 participants), no reported significant differ-
ence was found in FEV1 between PEP, cornet and flutter with a de-
cline over a one-year period of 0.15 L with PEP, 0.07 L with ACBT
and 0.02 L with AD (between-group change data were not reported)
(Pryor 2010).
2. Number of respiratory exacerbations between baseline and post-
intervention
Two cross-over studies (43 participants) reported participants be-
ing withdrawn due to exacerbations, although these are not well-
defined (very low-quality evidence) (Pfleger 1992; Steen 1991). It is
also unclear which treatments the participants were randomised to
at the time of departure from any of these studies.
3. Direct measures of mucus clearance
Three studies (31 participants) measured radio-labelled aerosol
clearance after a single treatment of PEP (low-quality evidence)
(Falk 1993; Lannefors 1992; Mortensen 1991). All were cross-over
studies from which data from the end of the first randomisation arm
could not be obtained so no data have been entered in the Data and
analyses.
In one study (12 participants), radioisotope retention two hours af-
ter a 20-minute treatment of PEP and FET was significantly less than
for FET alone (Falk 1993), this is presented in an additional table
(Table 9). For two studies (19 participants) no significant difference
in clearance was identified between PEP plus FET and PD plus FET
(Lannefors 1992; Mortensen 1991) or exercise plus FET (nine partic-
ipants) (Lannefors 1992).
Secondary outcomes
1. Expectorated secretions, dry or wet weight, or volume
Four cross-over studies (49 participants) reported measures of ex-
pectorated sputum (Darbee 2004; Hofmeyr 1986; Mortensen 1991;
Pfleger 1992).
a. Single treatment
Four studies measured expectorated secretions after a single treat-
ment (Darbee 2004; Hofmeyr 1986; Mortensen 1991; Pfleger 1992).
One study (18 participants) found wet weight of sputum was sig-
nificantly greater during PD with FET and breathing exercises com-
pared to PEP and FET in sitting (P < 0.001) or PEP and FET in PD
positions (P < 0.025) (Hofmeyr 1986). This is presented in an ad-
ditional table (Table 10). However, in one study (10 participants),
wet weight of sputum expectorated during and for 120 minutes af-
ter treatment demonstrated no significant difference between PEP
and PD (Mortensen 1991). In one study (six participants), dry weight
of sputum was not significantly different after single treatments of
PEP and > 20 cm H2O PEP (Darbee 2004). One study (15 participants)
demonstrated Hi-PEP produced significantly more sputum than ei-
ther AD (P < 0.001) or AD then Hi-PEP (P < 0.001) (Pfleger 1992). This
is presented in an additional table (Table 11).
b. Short term (up to seven days)
When wet weight of sputum was measured during and for 30 min-
utes after treatment, breathing exercises in postural drainage po-
sitions induced significantly greater sputum expectoration than
PEP in postural drainage positions. The latter in turn produced sig-
nificantly more expectorate than PEP in sitting (18 participants)
(Hofmeyr 1986). This is presented in an additional table (Table 10).
c. Long term (more than seven days)
As outlined above in the Types of outcome measures section, this
review does not examine this outcome where it is measured after
more than seven days of treatment.
2. Other pulmonary parameters
a. FVC
FVC was measured in four studies (67 participants) (Darbee 2004;
McIlwaine 1991; Pfleger 1992; Steen 1991).
i. Single treatment
Two studies (21 participants) measured FVC after a single treat-
ment (Darbee 2004; Pfleger 1992). In one study (six participants), no
significant difference in FVC was demonstrated with a single treat-
ment of PEP versus > 20 cm H2O PEP (Darbee 2004). The second
study (15 participants) found that FVC was significantly lower af-
ter a treatment of AD followed by Hi-PEP, compared to AD alone
(Pfleger 1992). This is presented in an additional table (Table 12).
ii. Short term (up to seven days)
No studies reported at this time point.
iii. Long term (more than seven days)
Two studies (46 participants) measured FVC after a series of treat-
ments over more than seven days (McIlwaine 1991; Steen 1991).
One study (28 participants) reported no significant differences in
FVC (% predicted) were demonstrated after one month of PEP,
PEP followed by PDPV, PDPV, and PEP + FET (Steen 1991). A study
(18 participants) comparing two months of PEP, PDPV or AD also
showed no significant differences in FVC (% predicted) (McIlwaine
1991).
In another one-year study (45 participants) comparing PEP to ACBT
and AD, no significant difference between techniques were found
although the study did not report the actual data (Pryor 2010).
b. FEF25-75
Four studies (62 participants) reported results for FEF25-75 (Darbee
2004; McIlwaine 1991; Mortensen 1991; Steen 1991).
i. Single treatment
No significant difference in FEF25-75 (% predicted) was noted after
one treatment with PEP or > 20 cm H2O PEP (six participants) (Dar-
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bee 2004). This was a cross-over study from which data from the
end of the first randomisation arm could not be obtained.
ii. Short term (up to seven days)
No studies reported at this time point.
iii. Long term (more than seven days)
Two studies (46 participants) measured FEF25-75 after a series of
treatments over more than seven days (McIlwaine 1991; Steen
1991). In one study (28 participants) there were no significant dif-
ferences in FEF25-75 (% predicted) were demonstrated after one
month of PEP, PEP followed by PDPV, PDPV, and PEP + FET (Steen
1991). A study (18 participants) comparing two months of PEP, PDP
or AD also showed no significant differences in FEF25-75 (% predict-
ed) (McIlwaine 1991).
c. TLC
No studies reported on this outcome.
d. RV
In one study (six participants), it was reported that the change in
RV from baseline was not significantly different after a single treat-
ment of PEP or > 20 cm H2O PEP (Darbee 2004).
3. Exercise tolerance
One study (45 participants) conducted exercise testing using the
modified shuttle test and reported no significant difference in out-
come between the five groups (PEP, AD and ACBT, as well as cornet
and flutter) over a one-year period (Pryor 2010)
4. Well-being
The Pryor study (45 participants) found no significant differences
between the five groups (PEP, AD and ACBT, as well as cornet and
flutter) in the physical domain (P = 0.99) or the mental domain (P
= 0.27) using Short Form -36; and no significant differences among
the five groups in the dyspnoea domain (P = 0.7), fatigue (P = 0.85),
emotion (P = 0.39) or mastery (P = 0.82) using the Chronic Respira-
tory Questionnaire (Pryor 2010). No data were reported that could
be entered into analysis.
5. Blood oxygen levels
Two studies (24 participants) measured blood oxygen levels (Dar-
bee 2004; Hofmeyr 1986).
a. Single treatment
One study (six participants) was a single treatment; the change in
SpO2 was not significantly different after a single treatment of PEP
versus > 20 cm H2O PEP (Darbee 2004).
b. Short term (up to seven days)
In one study (18 participants), there were no significant mid- or
post-treatment differences between four treatments of breathing
exercises with forced expirations in postural drainage positions,
PEP in postural drainage positions, and PEP in sitting in a single day
(Hofmeyr 1986).
c. Long term (more than seven days)
No studies reported on this outcome.
6. LCI
One study (six participants) reported the results of lung clearance
using a single-breath inert gas test which examines distribution of
ventilation (Darbee 2004). This study reported worsening of the dis-
tribution of ventilation following PEP and high-pressure PEP com-
pared to control (Darbee 2004); however, in this study gas mixing
improved suggesting that PEP opened up previously closed partial-
ly obstructed airways.
7. Ventilation scanning
No studies reported on this outcome.
8. Cost of intervention
No studies reported on this outcome.
9. Adherence to treatment and participant preference
Two studies (46 participants) reported on technique acceptability
or participant preference (McIlwaine 1991; Steen 1991).
a. Single treatment
No studies reported at this time point.
b. Short term (up to seven days)
No studies reported at this time point.
c. Long term (more than seven days)
Two studies measured participant preference after a treatment
course of greater than seven days duration (McIlwaine 1991; Steen
1991).
The cross-over study (18 participants) comparing two months of
PEP, conventional PDPV, and AD recorded five subjective measures
which may influence participant preference: treatment duration;
treatment comfort; flexibility of treatment times; control in per-
forming own treatment; and how interruptive treatment was to dai-
ly living (McIlwaine 1991). It was reported that PEP had a signifi-
cantly shorter treatment time than PDPV or AD; also, PEP was rated
significantly better than PDPV and not significantly different to AD
on each of the other four measures (McIlwaine 1991). Standard de-
viations were not available for these outcomes and mean data are
presented in an additional table (Table 13).
In another long-term, cross-over study (28 participants), PEP was
the treatment of choice (Steen 1991). A total of 23 of 24 participants
chose PEP in combination with FET in preference to PEP alone,
PDPV and FET, or five minutes of PEP followed by PDPV and FET as
their long-term airway clearance physiotherapy (Steen 1991).
10. Adverse events
None of the studies reported whether adverse events occurred or
not.
Subgroup analyses
None of the intended subgroup analyses were possible due to small
numbers of studies or insufficient detail to allow the separation
of subgroup data within any study. One study provided subgroup
analysis based on age, which did not conform to the age groups for
subgroup analysis defined in the protocol for this review. The data
for the subgroup used are presented as an additional table (Table
14).
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Sensitivity analyses
None of the intended sensitivity analyses were possible due to
small numbers of studies included in each comparison.
D I S C U S S I O N
Summary of main results
A total of 28 studies involving 788 participants with CF (infants, chil-
dren, adolescents and adults) met the review's inclusion criteria.
Sample sizes in individual studies ranged from five to 107 partici-
pants; 21 studies were reported in full articles and seven were pub-
lished in abstract form only.
There was a wide range of therapies to which PEP was compared.
The duration of the intervention period varied from single treat-
ments to two years. These factors together with the frequent use
and poor reporting of cross-over design, the small number of stud-
ies, and the limited information provided by some authors restrict-
ed the number of meta-analyses that could be performed.
A one-year study in children and adolescents showed a reduced
rate of hospital admission due to respiratory exacerbations with
PEP as opposed to flutter (McIlwaine 2001). A similar study in adults
showed similar results (Newbold 2005). A large (107 participants)
well-designed one-year multicentre randomised controlled trial
comparing PEP with HFCWO found that PEP reduces the number
of pulmonary exacerbations requiring oral, inhaled or IV antibiotics
during the 12 months and results in a longer time to the first pul-
monary exacerbation compared to the HFCWO group (McIlwaine
2013).
The FEV1 measurement of lung function is important in CF because
of its correlation with survival and quality of life (Liou 2001). Six
studies did not report FEV1 as an outcome measure. Four of these
studies examined mucus clearance using a radio-labelled isotope
(Darbee 1990; Falk 1993; Lannefors 1992; Mortensen 1991). One
study measured FEV0.75 (Tyrrell 1986), and another study was on
infants where FEV1 could not be measured (Costantini 2001). Five
studies measured FEV1 and compared PEP with PDPV; one was a
study of less than seven days and four studies lasted more than
seven days. Two studies lasted at least one year. In a 12-month
study in children with CF, FEV1 improved in the PEP group; with
an increase in the PEP group and decreased in the PDPV group
(McIlwaine 1997). However, in a two-year study (predominantly in
adults) comparing PEP with PDPV, there was no difference in the
rates of decline in FEV1. Both groups experienced rates of annual
decline greater than 2% (Gaskin 1998). When PEP was compared
with oscillating PEP using the flutter or acapella there were sev-
en studies that measured FEV1. Three short-term studies (less than
seven days) found that there was probably little or no difference
between techniques. Five studies measured FEV1 after a series of
treatments over more than seven days. Again, in relation to these
techniques in a two-week study, it was shown that there is probably
little or no difference between the techniques and there were mixed
results in the four studies lasting one year. In one study of children
and adolescents, FEV1 declined more in the flutter group than the
PEP group (McIlwaine 2001); while in a 13-month study in adults
both groups declined similarly (Newbold 2005). No difference was
found in two further one-year studies comparing these and other
techniques including ACBT, AD, oscillating PEP using the cornet de-
vice and BiPAP (Tannenbaum 2005; Pryor 2010; Rodriguez 2016).
A small number of studies found significant differences in expec-
torated sputum measures when other types of chest physiothera-
py were compared to PEP in single treatment and short-term stud-
ies up to seven days (Falk 1984; Hofmeyr 1986) or Hi-PEP (Pfleger
1992). However, these measures may be confounded by expecto-
rated saliva, swallowed secretions and regurgitated contents and
are generally regarded as less useful outcomes than measurement
of mucociliary clearance. One cross-over study measured radio-la-
belled aerosol clearance after a single treatment of PEP versus
PDPV; no significant difference in clearance was found (Darbee
1990).
LCI is becoming a popular outcome measure for use in CF studies.
LCI was reported in four studies. In one low-quality study it was
shown that PEP probably makes little or no difference when com-
pared to the Cornet over a one year period (Tannenbaum 2005).
Darbee in a single treatment demonstrated an improvement in LCI
with both PEP and HFCWO, but we are uncertain whether PEP, as
compared to HFCWO, improves LCI as the certainty of the evidence
has been assessed as very low (Darbee 2005). In a three-month
study BiPAP demonstrated an improvement in LCI when compared
to PEP (Rodriguez 2016).
Many other outcomes did not show a difference between PEP as
compared to other therapies. In the year-long study in infants,
blinded examination of chest radiographs showed no difference in
the incidence of increased bronchial markings between the PEP
and PDPV groups (Costantini 2001). When compared to flutter in
children and adolescents, similar results occurred in FEF25-75 and
TLC (McIlwaine 2001).
There was limited evidence reported on adverse events; these were
measured in five studies, two of which found no events. It was
recorded that there were no adverse events in the PEP group or
in the PDPV group in the year long study of 40 children (McIlwaine
1997). Nor were adverse events recorded in the PEP or the flutter
groups in the year-long study of 40 children (McIlwaine 2001). In
a year-long study of 26 infants, which was published in abstract
form only, there was no statistically significant difference in the
incidence of reflux between the PEP and PDPV groups; gastro-oe-
sophageal reflux severe enough to cause withdrawal from the study
occurred in three participants in the PDPV group and in no partic-
ipants in the PEP group (low-quality evidence) (Costantini 2001).
In PEP versus oscillating PEP, adverse events were only reported in
the flutter group (five participants complained of dizziness, which
improved after further instructions on device use was provided)
(22 participants, low-quality evidence) (van Winden 1998). In PEP
versus HFCWO, from one long-term high-quality study (107 partic-
ipants) there was little or no difference in terms of number of ad-
verse events; however, those in the PEP group had fewer adverse
events related to the lower airways when compared to HFCWO
(high-certainty evidence) (McIlwaine 2013).
In the majority of studies included in this Cochrane Review, there
were no significant differences in outcomes when PEP was com-
pared to other techniques. However, three long-term trials under-
taken in Canada using PEP have found that there was an improve-
ment in outcomes in the PEP group as compared to PDPV in chil-
dren and adolescents (McIlwaine 1997), oscillating PEP using the
flutter (McIlwaine 2001) and HFCWO in a multicentre trial across all
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age groups (McIlwaine 2013). These studies provide evidence that
PEP may be more effective in limiting exacerbations and potential-
ly preserving lung function in the longer term. Of note, these three
studies all employed PEP via the mask set-up.
In the study comparing PEP with HFCWO, treatment time was sig-
nificantly shorter in the PEP group (McIlwaine 2013). Limited evi-
dence was identified in support of the hypothesis that PEP is more
acceptable to people with CF than other forms of airway clear-
ance therapy. In studies with an intervention period of at least one
month, any measures of participant preference were in favour of
PEP. The tools used to record patient preference were generally not
well-described or validated.
There were a large number of cross-over studies in the sample
included in the review. Elbourne discusses methods for meta-
analysing cross-over studies which rely on the data that are report-
ed within the primary papers (Elbourne 2002). The method that has
been adopted within this review uses the data from the first period
only, ignoring any data from the second period that was available if
a carryover effect was identified. In this review three studies of one
month duration were identified as having no washout period and
thus may have had a carryover effect (Steen 1991; Tyrrell 1986; van
Asperen 1987). A limitation of this study was that data from the first
period of cross-over studies was only available in three out of the
18 cross-over studies.
Overall completeness and applicability of evidence
There is a large body of evidence to support the use of PEP as a
stand-alone airway clearance technique in CF. Numerous studies
found PEP to be equal to other compared techniques, however, a
few long-term studies suggest that PEP may be superior to other
techniques. In the majority of these studies PEP was administered
using a facemask in order to obtain a seal during the cycles of PEP
which resulted in a temporary increase in FRC during the cycles;
this in turn allowed air to accumulate behind secretions and move
them proximally. Where PEP was found to be superior to other tech-
niques, the way in which it was applied may have contributed to
these superior findings. Thus the applicability of the evidence is
highly based on these studies which have demonstrated fewer ex-
acerbations and decreased need for treatment with antibiotics.
In 22 out of the 28 studies PEP was administered using a face mask
in order to obtain a seal during the cycles of PEP which resulted in
a temporary increase in FRC during the cycles; this in turn allowed
air to accumulate behind secretions and move them proximally.
Where PEP was found to be superior to other techniques, the way in
which it was applied may have contributed to these superior find-
ings. In two similar studies where PEP was compared to PD&P over
a one year period, in the one study where PEP was performed using
a mask, there was a significant increase in FEV1, while in the other
study where a mouthpiece was used, there was no significant differ-
ence in FEV1 (low-quality evidence) (Gaskin 1998; McIlwaine 1997).
Quality of the evidence
The quality of the evidence varied between studies carried out over
a few days to well-designed year-long randomised controlled tri-
als. Small sample sizes and dropouts in some studies were likely
to have impacted on the precision of the results and the quality of
the evidence. As stated below, cross-over designs are not really ap-
propriate for CF studies and results from studies of this design are
likely to be of low quality. Blinding of participants and researchers
in these studies is not possible, however, blinded assessors have
been utilised in a number of the studies increases the quality of the
evidence and reduced the risk of biased results. Some unclear in-
formation regarding methodology (randomisation sequences and
allocation concealments) increased the risk of bias.
Evidence provided for by this review for primary outcome number
of respiratory exacerbations was judged to be vary between very
low to high quality, although this outcome was not reported for all
comparisons. Evidence for other outcomes, including the primary
outcome FEV1 was more limited, inconsistent and imprecise and
ranged in quality from very low to moderate quality.
Potential biases in the review process
The search process was rigorous and undertaken according to
the Cochrane Collaboration's recommendations. It is possible that
studies have been undertaken that have not been identified with
this online review process or that omissions have inadvertently oc-
curred in the search of conference publications because they have
not emerged using the recommended search process. Three au-
thors were involved in the selection of studies to be included in the
review and disagreements were resolved by discussion and con-
sensus. When a study that included one of the authors of this report
was being considered for inclusion, the author recused themselves
from the selection process in relation to that article.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The quality of the evidence varied between studies carried out over
a few days to well-designed year-long randomised controlled tri-
als; however, the evidence from the studies described in this updat-
ed Cochrane Review suggests that all techniques and devices may
have a place in the clinical treatment of patients with cystic fibro-
sis (CF). In relation to respiratory exacerbations, high-quality evi-
dence (a long-term multicentre study across all ages) showed that,
when compared to high-frequency chest wall oscillation (HFCWO),
positive expiratory pressure (PEP) using a mask reduced respira-
tory exacerbations.. There was some evidence to recommend PEP
as a more acceptable intervention long term than other forms of
physiotherapy for people with CF. However, the evidence that PEP
was preferred over other techniques came from studies which were
generally of low quality. Airway clearance techniques should be
individualised throughout life according to developmental stages,
patient choice, pulmonary symptoms and lung function. They may
need to be varied during pulmonary exacerbations versus baseline
function. It should be noted that although PEP via a mouthpiece
system is commonly used, most of the literature pertains to PEP us-
ing a mask. The mouthpiece has not shown to increase FRC in the
manner achieved by mask PEP and there is ambiguity around op-
portunity for upper airway air leaks when using a mouthpiece.
Implications for research
Short-term interventions on stable participants may be of little val-
ue given the nature of CF lung disease which frequently follows a
chronic course with acute exacerbations. Future studies should be
planned to reflect clinical practice by focusing on short-term inter-
ventions during exacerbations or long term studies on initially sta-
ble patients.
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Blinding of researchers and participants in studies comparing dif-
ferent airway clearance techniques is not possible. However, blind-
ed assessors have been utilised in a number of the reviewed stud-
ies which increases the quality of the evidence and reduces the risk
of bias. Blinded assessors should be involved in all future studies
which may have resource and cost implications which should be
considered when planning studies.
Cross-over studies are not the best design for clinical studies in
CF due to the unstable nature of the disease (Southern 2003).
They may be influenced by carry-over effects. Future parallel, ran-
domised clinical studies comparing PEP with other airway clear-
ance modalities are needed. These studies should be adequately
powered and a multicentre approach may facilitate this. Such stud-
ies should in particular, examine the influence of PEP and other
therapies on lung function parameters, quality of life, exercise tol-
erance, cost and survival.
The abstract format often prevents evaluation of the scientific
methodology of the study. Abstracts should be structured to con-
tain essential information about method and results. The large pro-
portion of studies which were published only as abstracts high-
lights the need for full publication in peer reviewed journals.
The studies in this review frequently found no significant difference
in efficacy between treatments. Expectorated sputum measures
may be confounded by expectorated saliva, swallowed secretions
and regurgitated contents and are generally regarded as less use-
ful outcomes than measurement of mucociliary clearance. Sputum
rheology differs between individuals with CF and between different
organisms. Research to determine the best technique for situations
where sputum is thin and liquid versus thick and viscous may be
a new area for more targeted research and application of different
techniques in different patients.
Exacerbation rate and time to first exacerbation in longer term tri-
als (at least 12 months) between compared airway clearance tech-
niques may be of greater use and relevance in CF, a long-term dis-
ease. Future studies should include validated measures of patient
preference including treatment time (a potential barrier to adher-
ence) as this may assist in determining a suitable treatment when
measures of efficacy are equivocal. Similarly, cost and adverse ef-
fect outcome data would assist consumers in decision-making.
Studies that broaden the knowledge of the effects of different
techniques on different aspects of the pathophysiology of CF will
progress the aspiration for evidence based physiotherapy in CF.
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Each treatment given twice daily for 2 days.
Participants CF confirmed by sweat test.
16 participants (8 male); mean age 20.3 years, range 15 - 27 years; mean FEV1 52.5, range 32% - 98%
predicted; mean Schwachman score 65.1, range 45 - 87 points.
Entry to study at time of hospital treatment of an acute pulmonary exacerbation.
Braggion 1995 
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Interventions 4 interventions: No washout period between interventions
1. PEP treatment - participants breathed through a Medipep, (Nuova Tecnomedica) mask with a steady
PEP of 10 - 20 cm H2O;
2. PDPV - 6 positions based on recent chest radiography for each participant;
3. HFCC - using ThAIRapy Bronchial Drainage System, chest compression in sitting at frequencies of 6, 8,
14, 15, 18 and 19 Hz were performed for 6 treatment sessions;
4. Control - resting in sitting, spontaneous coughing allowed.
Each treatment lasted 50 minutes: six 5-minute periods of the specific treatment, each followed by a 3-
minute period of the FET.
Outcomes FEV1, FVC, and FEF25-75 were measured before and 30 minutes after each treatment. Expectorated spu-
tum wet and dry weights during and for 30 minutes after each treatment were also measured. Tech-
nique acceptability was assessed using a 3-point rating of effectiveness completed by the participant,
and a 3-point rating of tolerance, completed by the participant and also by the physiotherapist.
Notes No statement on withdrawals or dropouts.
Participants were familiar with PDPV and PEP interventions. All were introduced to HFCC on the day be-
fore their first use. The participant's usual airway clearance regimen was used for 2 days between the
2nd and 3rd treatment periods.
This was a published paper
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, no further details provided.
Allocation concealment
(selection bias)
Unclear risk No information provided.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Participant and the physiotherapist providing the therapy were not blinded,




Unclear risk No statement on withdrawals or dropouts. Outcome data were recorded.
Selective reporting (re-
porting bias)
High risk All outcome data were only reported as no significant difference.






Treatment for 1 year.
Participants CF identified by newborn screening within the 2nd month of life and confirmed on sweat test and geno-
typing
26 participants (14 male); aged under 4 months.
Costantini 2001 
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Interventions 2 interventions: 13 participants each group
1. PEP treatment - applied via a mask;
2. PDPV.
Each treatment was performed for 30 minutes, twice daily.
The airway clearance intervention was applied by the carer(s), who received a 2-week training period in
either PEP or PDPV.
Participants were followed as outpatients for 1 year.
Outcomes The number of courses of total and intravenous antibiotic treatment were recorded, although it is not
stated whether these were prescribed in response to a respiratory exacerbation.
Possible adverse effects were monitored.
Oxygen saturation, chest radiographs, and growth were assessed. No method of radiograph assess-
ment is mentioned. Measurements were conducted at 0, 6 and 12 months.
Notes 3 participants in the PDPV group withdrew from the study. These were among 4 participants in this
group who developed gastro-oesophageal reflux. The 3 who withdrew did so "for the severity of their
symptoms and were not evaluated".
Published as abstract only, no further information obtained.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, no further information provided.
Allocation concealment
(selection bias)
Unclear risk No information provided.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Participant and the person providing the therapy were not blinded, no infor-




Low risk 3 participants in the PDPV group withdrew from the study. These were among
4 participants in this group who developed gastro-oesophageal reflux. The 3
who withdrew did so "for the severity of their symptoms and were not evaluat-
ed". All outcome measures were reported.
Selective reporting (re-
porting bias)
High risk Not all outcome measures were reported in full. No statistics were provided for
any outcomes, only percentages and mean measurements were reported.






Each treatment given 2 - 3 times daily for 3 months.
Participants CF confirmed by sweat test.
13 participants (7 male); mean age 25.7 years, range 18 - 34 years are reported in the abstract. Results
from 20 participants were presented at conference. Data on 20 participants was shared with authors.
Outcome data for 20 participants were used in the outcome analysis.
Darbee 1990 
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Interventions 2 interventions: No washout period between interventions
1. PEP treatment - participants exhaled through a mask for 8 - 10 breaths, then exhaled to a low lung
volume through the mask which usually stimulated a cough; this was repeated 5 - 6 times;
2. PDPV - percussion was applied for 3 minutes over all segments, participants breathed deeply several
times at each minute, 3 vibrations followed with exhalation through an open mouth, without force, un-
til productive coughing occurred.
Participants were instructed to treat until clear, 2 - 3 times per day.
Outcomes 2 measures of mucociliary clearance were repeated after each 3-month treatment arm: the time taken
for half the radiolabeled sputum in the whole lung to clear (T1/2-W) and the same in the peripheral re-
gion (T1/2-P). Convenience, independence and ease of use was determined with a standardised written
questionnaire (not described).
Notes No statement on withdrawals or dropouts.
Participants reported that they got clearer faster with PEP.
Published as an abstract only, further information obtained from authors.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, no further details provided.
Allocation concealment
(selection bias)
Unclear risk No information provided.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Participant and the person providing the therapy were not blinded, no infor-








Low risk All outcome measures were reported in full.
Other bias High risk No washout period between each 3 month period of interventions, potential







Each treatment given once.
Participants CFconfirmed by sweat test; stable (not defined) and not hospitalised during the previous month for
management of an exacerbation.
6 participants (3 female), mean age 18 years, range 13 years to 22 years; mean FEV1 52, range 35 - 68%
predicted.
Interventions 2 interventions: each interventions was separated by a 5 day washout period
Darbee 2004 
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1. PEP treatment - pressure 10 - 20 cm H2O, participants breathed through a mask with an expiratory
resistor between 10 - 20 cm H2O for 8 - 10 breaths, followed by coughing; this was repeated 6 times;
2. High-pressure PEP using a resistor at which FVC with PEP exceeded FVC with no PEP - participants
were instructed to perform 8 - 10 slightly lager tidal volume breaths through the PEP device followed by
an inspiration to TLC and a forced expiration into the mask; 6 cycles were performed.
Each intervention was applied on a different day (order randomised).
A 3rd intervention was a "control", Participants sat for 20 minutes and outcome measures were per-
formed pre and post this time period. This was performed on Day 1 by all participants and was not ran-
domised
Outcomes FEV1, FEF25-75, RV, SVC, dry weight of sputum, and SpO2 were recorded before, after, and 45 minutes af-
ter each intervention session.
Distribution of ventilation and gas mixing were also measured by lung clearance examining the phase
111 slope.
Notes 1 participant's data were excluded when it was determined that there was a pulmonary exacerbation.
Published paper
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, no further information was provided.
Allocation concealment
(selection bias)
Unclear risk No information was provided.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Participant and the person providing the therapy were not blinded, no infor-




Low risk One participant's data were excluded when it was determined that there was a
pulmonary exacerbation. All outcome measures were reported under results.
Selective reporting (re-
porting bias)
Low risk Outcome measures are reported in full.
Other bias Low risk 5 day washout period between each intervention thus low risk of carry over ef-







Each treatment given once.
Participants CF confirmed by sweat test; hospitalised with a pulmonary exacerbation.
15 participants 8 males, 7 females, mean (SD) age 17.5 (4.2) years, BMI 18.3 (2).
Interventions 2 Interventions: No washout period between interventions
Darbee 2005 
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PEP using pressures between 10 - 20 cm H2O via facemask for 8 breaths followed by huffing and cough-
ing; this was repeated for 8 - 10 cycles.
HFCWO, pressure 5, frequency 10 Hz for 15 minutes, then 15 Hz for next 15 minutes; 6 cycles of 5 min-
utes with a pause for huffing and coughing in between each cycle.
Outcomes Lung clearance using nitrogen washout measuring Phase III N2 slope, index values. PFT measurements
of FVC and FEV1, and pulse oximetry.
Notes Published paper.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Participants were assigned treatment order by numbering 1 - 15 at study en-
trance. Coin toss was used to allocate whether odd numbered participants re-




High risk All odd numbered participant were pre-allocated order of treatment interven-
tion.
Blinding (performance
bias and detection bias) 
All outcomes








Low risk The outcomes are reported fully reported for all participants pre- and post-
treatment.
Other bias High risk No washout period between interventions, thus potential risk for carryover ef-






Participants 36 participants, confirmed diagnosis of CF.
Age > 18 years, mean (SD) 26 (6.5) years. 14 males, 20 females.
Mild to moderate lung function impairment.
Incusion criteria included in hospital for a pulmonary exacerbation.
Interventions 2 Interventions: One day washout period between interventions. PEP using pressures between 10 - 20
cm H2O, consisted of cycles of 15 breathes through PEP mask interspersed with huffing, number of cy-
cles was individualised.
HFCC also known as HFCWO used Hillrom Vest Model 4, with pressure 6 - 10 and frequency between 15 -
20 Hz. Huffing and coughing was interspersed throughout HFCC.
Fainardi 2011 
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Outcomes PFTs measuring FVC, FEV1 and FEF25-75 % predicted measured pre and post, pulse oxygen saturation
(SpO2%), sputum weight.
Notes 34 participants completed the study, 2 participants withdrew due to discomfort of HFCC device.
Published paper
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Participants were assigned to either intervention by numbering consecutively:
odd numbers got control intervention first. Even numbers got PEP intervention
first. There was no random allocation to intervention.
Allocation concealment
(selection bias)
High risk Thee was no apparent concealment as it was a consecutive numbering se-
quence.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Participant and the person providing the therapy were not blinded - Unclear
risk.




Low risk All outcomes in study design are reported.
Selective reporting (re-
porting bias)
Low risk 2 participants withdrew due to discomfort of HFCC device. All outcomes are re-
ported in full.
Other bias Unclear risk Only one day washout period between interventions.






Each treatment given once.
Participants CF diagnosis, chronic pseudomonas infection, and expectoration of greater than 1.5 g/hr of sputum.
14 participants (10 male); mean age 18 years, range 14 - 30 years; mean FEV1 34, range 15% - 55% pre-
dicted.
Participants were excluded during or immediately after anti-pseudomonas treatment or a change in
routine medication.
Interventions 4 interventions: 1 day washout period between interventions
1. PEP treatment in sitting (PEPs) - pressure 17 cm H2O using an Astra Meditec PEP mask; seated partic-
ipants exhaled 6 - 12 times, followed by forced expirations with the glottis open and coughing as need-
ed, this was repeated for 20 minutes;
2. PEP treatment in PD positions (PEPpd) - participants performed the same breathing regimen for 4 - 5
minutes in each of 7 PD positions, this intervention lasted 35 minutes;
3. PDPV - during the same PD regimen, participants received manual percussion, followed by 3 deep
breaths with vibration, and FET. This intervention lasted 35 minutes;
4. PLBs - seated participants inhaled slowly and exhaled through pursed lips 5 - 8 times, followed by
FET, this intervention lasted 20 minutes.
Falk 1984 
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The 4 interventions were randomised over 2 days: 1 each morning and 1 each afternoon, with an inter-
val of at least 5 hours.
Outcomes FEV1 and FVC were measured before and 50 minutes after each intervention session. Wet weight of ex-
pectorated sputum during and until 50 minutes after each intervention session. Transcutaneous pO2
was measured during the intervention and for 50 minutes after each intervention. Technique efficiency
and acceptability were assessed using a questionnaire completed by the participant, although details
of the questionnaire are not provided.
Notes No withdrawals nor dropouts.
The authors state that 7 participants were studied during admission for their usual anti-pseudomonas
treatment and the other 7 at least 1 month after treatment. This appears inconsistent with the exclu-
sion criteria; see 'Participants'.
Published paper.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, no further information was provided.
Allocation concealment
(selection bias)
Unclear risk No information provided.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Participants and person providing the therapy were not blinded - unclear risk








Low risk Outcome measures were reported in full.
Other bias Unclear risk Only one day washout period between interventions. Groups similar at base-






Each treatment given once.
Participants CF diagnosis.
12 participants.
Interventions 3 interventions: One day washout period between interventions
1. FET;
2. Combined intervention of PEP with FET (PEP + FET). This is a combined intervention;
3. Control (not defined).
Each intervention was applied for 20 minutes on 1 of 3 consecutive days.
Falk 1993 
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Outcomes Retention of radiolabeled secretions in the lung was recorded at 0.5, 1, 2, and 24 hours after the start of
the intervention. (The 24-hour value was used as a measure of the radioaerosol deposition.) Wet weight
of sputum expectorated for the half hour during which the intervention was applied, and for the subse-
quent 1.5 hours was measured. The number of huFs and coughs during the half hour during which the
intervention was applied, and for the subsequent 1.5 hours were counted.
Notes No statement on withdrawals or dropouts.
Published as abstract only, no further information obtained.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, no further information was provided.
Allocation concealment
(selection bias)
Unclear risk No information provided.
Blinding (performance
bias and detection bias) 
All outcomes








Low risk Outcome measures were reported in full.
Other bias Unclear risk Only one day washout period between interventions. Groups similar at base-






Treatment for 2 years.
Participants CF diagnosed by Toronto CF Clinics (criteria not stated); FEV1 > 40% predicted.
66 participants (34 males); mean age 21.6 years, range 11 - 45 years; mean FEV1 70.2% predicted (PEP
group) and 65.3% predicted (PDPV group).
Interventions 2 interventions: 33 participants were randomised to each intervention.
1. PEP treatment - participants exhaled through the Astra Meditec PEP mask;
2. PDPV - not described beyond "conventional postural drainage and percussion".
The daily regimen for use of the devices is not described.
Outcomes FEV1, FVC, QWBS, a cycle ergometer exercise test, and the Brasfield chest radiograph score. All were
recorded at 3-monthly intervals.
The participants also kept adherence and exercise diaries.
Gaskin 1998 
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Notes 5 participants withdrew from the study, but none were lost to follow up. 4 withdrew from the PDPV
group withdrew soon after randomisation and 1 from the PEP group moved away, but returned to the
clinic. No reason is provided for the withdrawals.
Published as an abstract only, further information obtained.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, no further information provided.
Allocation concealment
(selection bias)
Unclear risk No information provided.
Blinding (performance
bias and detection bias) 
All outcomes




Low risk 5 participants withdrew from the study, but none were lost to follow up. 4 from
the PDPV group withdrew soon after randomisation and 1 from the PEP group
moved away, but returned to the clinic. No reason is provided for the with-
drawals.
Data for at least 1 key outcome analysed by 'intention-to-treat'.
Selective reporting (re-
porting bias)
Unclear risk Statistical analysis was only reported for 1 outcome measure (FEV1).






Each treatment given 4 times daily for 1 day.
Participants CF confirmed by positive sweat test, malabsorption, and chronic lung infection.
18 participants (12 male); mean age 22.5 years, range 13 - 37 years; mean FEV1 1.3, range 0.45 - 3.25 L;
and FVC was 2.5, range 1.1 - 5.1 L.
All participants were studied close to the end of an admission to hospital with an exacerbation of their
lung infection.
Interventions 3 interventions: No washout period between interventions
1. PEP treatment in sitting (PEP) - pressure 12 - 17 cm H2O using an Astra Meditec PEP mouthpiece;
seated participants exhaled 6 times through the mouthpiece, followed by relaxed breathing, 1 - 2
forced expirations (huFs) from mid to low lung volume, relaxed breathing, and a huF or cough from
high lung volume if secretions reached the upper airways;
2. PEPpd - the same breathing regimen was performed in (usually) 2 PD positions chosen before the
start of the study as the most appropriate from (undescribed) clinical assessment;
3. BEpd - consisting of 4 deep inspirations with relaxed expiration, breathing control and the FET which
included 1 - 2 forced expirations (huffing) from mid to low lung volume, followed by breathing control
then forced expirations or a cough from high lung volumes.
Hofmeyr 1986 
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In each intervention, the respiratory manoeuvres described above were continued in cycles until the
participant and physiotherapist felt that forced expiration and coughing no longer resulted in expecto-
ration.
4 treatment sessions were performed per day.
Outcomes FEV1 and FVC were measured before and 30 minutes after each intervention session. Wet weight of spu-
tum expectorated during and for 30 minutes after the intervention session was measured. SpO2 was
recorded before, during, and for 30 minutes after each intervention session.
Notes There were no withdrawals or dropouts.
Published paper.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, no further information was provided.
Allocation concealment
(selection bias)
Unclear risk No information provided.
Blinding (performance
bias and detection bias) 
All outcomes




Low risk There were no withdrawals or dropouts. All outcome measures are reported.
Selective reporting (re-
porting bias)
High risk Statistiicial outcome measures are provided for wet weight of sputum expec-
torated during and for 30 minutes and SpO2 but not for FEV1 and FVC.
Other bias High risk No washout period between interventions, thus there is a potential for a carry-







Each treatment given once.
Participants CF diagnosed by CF Clinic at Children's Hospital, Rome.
20 participants (11 males); mean age 15.25, range 6 - 23 years; mean (SD) Schwachman score 80.8 (15.3)
points.
Interventions 2 interventions: One day washout period between interventions
1. PEP treatment - followed the Danish protocol of breathing through a PEP mask against a PEP of 10 -
20 cm H2O pressure, followed by a pause, 2 - 3 huFs and coughing; no further information was provid-
ed;
2. BiPAP - while sitting participants breathed against 11cm H2O inspiratory positive pressure and 9 cm
H2O expiratory positive pressure applied via a mask attached to a Puritan Bennett 335, followed by a
pause, 2 - 3 huFs and coughing.
Kofler 1998 
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Single treatments of 15 minutes were applied on 2 consecutive days. All participants were using PEP
as their airway clearance therapy prior to the study. This was stopped the day before the study com-
menced.
Outcomes FEV1, FVC and FEF25-75 were measured at the beginning, at the end, 15 minutes after and 30 minutes af-
ter each session. Oxygen saturation and heart rate were continuously monitored throughout this time
via pulse-oximetry. Following the 2 sessions, participant preference was recorded.
Notes No statement on withdrawals or dropouts.
All participants were performing PEP prior to the study. PEP was applied "according to the Danish pro-
tocol" (not defined).
Published as an abstract only, no further information obtained.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, no further information was provided.
Allocation concealment
(selection bias)
Unclear risk No information provided.
Blinding (performance
bias and detection bias) 
All outcomes








Unclear risk FEV1, FVC and FEF25-75 were only reported as no significant difference be-
tween groups.
Other bias Unclear risk Only one day washout period between interventions. Groups similar at base-







Participants 15 people with CF, 6 females, 9 males, age 6.9 to 21.5 years.
CF confirmed by sweat test.
Interventions 2 interventions: 8-week washout period between interventions
1. PEPusing Astra Tech system with mouthpiece pressures 10 - 20cm H2O - participant breathed
through the device for 2 minutes followed by huffing; this was repeated 4 times;
2. Oscillating PEP using the flutter - participants were instructed to inhale deeply then exhale quickly
through the device and repeat for 1 minute followed by huffing; this was repeated 4 times.
Lagerkvist 2006 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No mention of how the participants were randomised.
Allocation concealment
(selection bias)
Unclear risk No mention of how the allocation was concealed.
Blinding (performance
bias and detection bias) 
All outcomes




Low risk All outcomes in study design are reported.
Selective reporting (re-
porting bias)
Low risk All outcomes are reported in full.
Other bias Low risk Good washout period, thus low risk of carry over effect. Groups similar at base-






Each treatment given once.
Participants CF with daily sputum production.
9 participants (6 male); mean age 25, range 12 - 36 years; mean FEV1 51, range 20 - 78% predicted; mean
Schwachman score 66, range 39 - 94 points.
Interventions 3 interventions: 1 to 5 day washout period between interventions.
1. PEP treatment - performed in a sitting position using a PEP mask and positive expiratory pressures
15 - 20 cm H2O;
2. PD - participants alternated between deep and relaxed breaths while lying on the leM side, rotated
slightly backward towards supine, 15 degrees head down tilt, (PD position for PD from right middle
lobe) and sat up to cough; no percussion or vibrations were performed;
3. Physical exercise - physical exercise was performed on a cycle ergometer at 80% of the participant's
peak work capacity (as assessed on their most recent annual maximal exercise test).
Each 20-minute intervention session consisted of three 3-minute periods of performing the interven-
tion, each followed by a 3-minute pause, during which a standard number of forced expirations from
mid-lung volume and relaxed breaths were performed.
Outcomes Mucus clearance was measured by delivering a radioaerosol (99mTc-labelled colloidal albumin) to the
airways and measuring the distribution of radiolabeled secretions in the lung fields. Anterior and pos-
terior planar gamma camera images of the thorax were collected for 2 minutes at baseline, after 15
Lannefors 1992 
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minutes rest in sitting, after the 20-minute intervention, and after another 15 minutes rest in sitting.
Clearance was calculated as a reduction in count rate between successive images. Whole lung clear-
ance was calculated. In addition, the planar images were divided into a central 'hilar' region and pe-
ripheral region, and clearance from these regions was calculated.
Notes No withdrawals or dropouts.
Published paper.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, no further information was provided.
Allocation concealment
(selection bias)
Unclear risk No information provided.
Blinding (performance
bias and detection bias) 
All outcomes




Low risk No withdrawals or dropouts.
Selective reporting (re-
porting bias)
High risk Not all outcome measures were reported with statistical analysis.
Other bias Low risk 1 - 5 day washout period between interventions, thus low risk of carry over ef-







Treatment for 2 months.
Participants CF diagnosis.
18 participants, aged 6 - 18 years of age.
Interventions 3 interventions each performed twice a day: One month washout period between interventions
1. PEP treatment using the Astra Meditech mask - participants performed 15 breaths through the mask
with a PEP between 10 - 20 cm H20; this was followed by 2 - 3 huFs from a mid to high lung volume fol-
lowed by a cough and cycle was repeated 6 times;
2. PDP - participants performed PD using 6 positions in the morning and 5 positions in the evening; in
each position their chest wall was percussed for 3 minutes, this was followed by huffing and coughing;
3. AD - performed in a sitting position and participants were instructed to exhale to RV then perform
TV manoeuvres at this level while adjusting the velocity of their expiratory airflow until they felt secre-
tions moving; they then progressed to TV breathing at mid-lung volumes and then to high lung volumes
where they would cough up any secretions. Number of cycles was individualised to each participant,
but each treatment session lasted between 20 - 30 minutes.
Outcomes FEV1, FVC, and FEF25-75 were measured at the start and end of each 2-month treatment period. Sputum
weight weighed after one treatment session per week. Other measures included reported treatment
McIlwaine 1991 
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duration, treatment comfort, requirement for assistance with treatment, flexibility of treatment times,
control in performing own treatment, and how interruptive treatment was to daily living.
Notes Published as an abstract only, further information obtained.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, no further information provided.
Allocation concealment
(selection bias)
Unclear risk No information provided.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Participants and person providing the therapy were not blinded - unclear risk.




Low risk There were no dropouts.
Selective reporting (re-
porting bias)
Unclear risk Results reported for all outcome measures but not in full.
Other bias Low risk one month washout period between each intervention, thus low risk of carry
over effect.
Groups similar at baseline regarding the most important prognostic indicators
Author of the study is one of this review's authors, thus to eliminate bias, the







Treatment for 1 year.
Participants CF confirmed by sweat test.
40 participants (22 male); age range 6 - 17 years; mean age 10.40 years (PEP group) and 9.75 years
(PDPV group); mean FEV1 80.47, range 37 - 115% predicted.
Participants were excluded if their condition was not stable as judged by clinical evaluation, chest ra-
diograph and pulmonary function. Also, no participant entered the study within 1 month of discharge
from hospital or use of IV antibiotics or other intensive therapy for an exacerbation.
Interventions 2 interventions: 20 participants were randomised to each group.
1. PEP treatment - pressure 10 - 20 cm H2O using an Astra Meditec PEP mask; seated participants
breathed 15 times through the mask, followed by 2 - 3 forced expirations, cough and relaxed breathing,
this was repeated 6 times over a 20-minute session;
2. PDP - performed forced expirations and vigorous coughing in 5 - 6 positions, 3 - 5 minutes of percus-
sion, 2 - 4 minutes of expiratory vibrations; these sessions lasted 30 minutes.
Both interventions were performed twice daily.
McIlwaine 1997 
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Outcomes FEV1, FVC, and FEF25-75 were measured at 3-month intervals. Clinical assessments using Shwachman
and Huang scores. Chest radiographs were performed at the start and end of the 1 year period and
measured using the Brasfield scoring system. Compliance was measured via daily record keeping, with
those compliant with less than 85% of the twice-daily sessions over a 1-month period being withdrawn
from the study. Adverse events and participant preference were assessed via questionnaire.




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Described as randomised. Participants were first matched as pairs based on
age, sex and FEV1. Participants within each pair were randomly assigned by
computer to either group.
Allocation concealment
(selection bias)
Unclear risk No information provided.
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Participants and person providing the therapy were not blinded - unclear risk.




Low risk 2 dropouts from each arm, due to non-compliance (< 85% of twice-daily ses-




Unclear risk Not all outcome measures are reported with full statistical analysis.
Other bias Low risk Participants were matched as pairs at baseline, thus groups were similar at
baseline regarding the most important prognostic indicators.
Author of the study is one of this review's author's, thus to eliminate bias, the







Treatment for 1 year.
Participants CF confirmed by sweat test.
40 participants (24 male); age range 7 - 17 years; FEV1 range 47 - 107% predicted; Schwachman score
range 54 - 98 points. Participants were excluded if they had been hospitalised within the past month
for a pulmonary exacerbation, or if they were not stable on clinical evaluation, chest radiograph or pul-
monary function.
Interventions 2 interventions: 20 participants were randomised to each group.
1. PEP treatment - participants inhaled and exhaled through the Astra Meditec PEP mask in sitting;
the resistor which produced 10 to 20 cm H2O pressure during mid-expiration was used. Over approx-
imately 2 minutes, 15 tidal breaths with slightly active expiration were performed. Participants then
McIlwaine 2001 
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removed the mask, performed 2 or 3 forced expirations, and coughed, followed by 1 - 2 minutes of re-
laxed breathing. This sequence was repeated 6 times and these 20-minute sessions were repeated
twice daily;
2. Oscillating PEP - participants exhaled through the flutter device which was angled to maximise the
sensation of vibration in the chest. In sitting, participants inhaled deeply through the nose, followed by
a breath hold for 2 - 3 seconds, and exhaled through the device slightly into the expiratory reserve vol-
ume. After 10 - 15 breaths, participants huFed through the device, increasing the TV and speed of exha-
lation to precipitate coughing and expectoration. This sequence was repeated "until clear" and not for
less than 15 minutes per session, twice daily.
The daily regimen for use of the devices is not described.
Outcomes FEV1, FVC, and FEF25-75 and clinical assessment using Shwachman and Huang scores were measured at
the beginning and at 3-monthly intervals throughout the study.
Number of hospitalizations for pulmonary exacerbations were recorded throughout the study
Compliance with the interventions was recorded daily by the participants. A monthly questionnaire
recorded physical activity, general well-being, cough, sputum production, subjective impression of the
therapy, and adverse events. Chest radiographs were evaluated by a blinded radiologist at the begin-
ning and end of the study.
Notes 3 participants were withdrawn due to non-compliance (< 85% of twice-daily sessions performed over 1
month) in the PEP group. 5 participants dropped out from the flutter group stating that subjectively the
flutter did not appear to clear their secretions.
Published paper.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Unclear risk Not described.
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Participants and person providing the therapy were not blinded - unclear risk.




Low risk 3 participants were withdrawn due to non-compliance (< 85% of twice-daily
sessions performed over 1 month) in the PEP group. 5 participants dropped
out from the flutter group stating that subjectively the flutter did not appear to
clear their secretions, they also had a clinically significant deterioration in pul-
monary function. Intention-to-treat approach used.
Selective reporting (re-
porting bias)
Low risk All outcome measures are reported in full.
Other bias Low risk Both groups were reported to be similar at baseline regarding the most impor-
tant prognostic indicators.
Author of the study is one of the authors on this review, thus to eliminate bias,
the study was assessed by the other two independent authors of this paper
and by the previous authors.
McIlwaine 2001  (Continued)
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Treatment for 1 year.
Participants CF confirmed by sweat test or genotyping.
107 participants from 12 CF centres (57 males); age range 6 - 47 years; FEV1 over 40% predicted. Partic-
ipants were excluded if they had been hospitalised within the past month for a pulmonary exacerba-
tion, or if they were not stable on clinical evaluation, chest radiograph or pulmonary function. On en-
tering the study, participants performed a 2-month washout period before being allocated to an inter-
vention.
Interventions 2 interventions: 51 participants were randomised to PEP and 56 to HFCWO.
1. PEP - using a mask with pressures 10 - 20 cm H20, participants breathed through the device for 15
breaths followed by 2 -3 huFs and a cough; this was repeated for 6 cycles;
2. HFCWO - using the InCourageTM system; 6 sets of 5-minute cycles were performed with frequencies
between 6 - 15 Hz, this was interspersed with huffing and coughing.
Outcomes Number of pulmonary exacerbations and time to first exacerbation.
PFTs measuring FVC, FEV1 and FEF 25-75% in absolute change.
Quality of life using the Cystic Fibrosis Questionnaire and patient satisfaction visual analogue scale.
Notes There were 16 dropouts during the washout period before participants commenced one of the two in-
terventions being studied. These were not included in the results. A further 3 dropped out during the in-
tervention period. These were included in analysis with intention-to-treat analysis.
Published paper.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised was by an independent statistician using a computer-gen-
erated randomisation table. Participants were matched for age, sex and
pseudomonas status. The statistician also attempted to block patients within
each centre to control for any treatment differences between centres.
Allocation concealment
(selection bias)
Low risk The randomisation was performed by an independent statistician who provid-
ed the randomisation to the centre after the participant had enrolled in the
study.
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Participants and person providing the therapy were not blinded - unclear risk.




Low risk All outcomes in study design are reported.Dropouts prior to commencement
of interventions being studies were not included in analysis. 3 dropouts during




Low risk All outcomes in study design are reported. PFTs results were provided by the
author.
Other bias Low risk Author of the study is one of this review's authors, thus to eliminate bias, the
study was assessed by the other two independent authors of this paper.
McIlwaine 2013 
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Each treatment given once.
Participants CF diagnosis and chronic pseudomonas infection.
10 participants (6 male); mean age was 20 years, range 15 - 26 years; mean FEV1 38.5, range 26 - 101%
predicted.
Participants entered the study in the last 2 weeks of regular hospital admission for intravenous an-
ti-pseudomonas treatment.
Interventions 3 interventions: 2 day washout period between interventions
1. PEP treatment - pressure 10 - 20 cm H2O using a mask; seated participants breathed TV breathing
with slightly active expirations through the system for 1 minute, followed by 1 - 2 forced expirations
from mid to low lung volume, relaxed breathing and cough; this breathing regimen was repeated for 20
minutes;
2. BEpd - participants breathed deeply 4 times followed by relaxed breathing for 10 minutes in each
of right and leM side lying with 20 degrees head down tilt; this was again followed by 1 - 2 forced ex-
pirations from mid to low lung volume, relaxed breathing and cough. The same number of huFs and
coughs performed with the first treatment were matched with the subsequent active intervention.
3. Control - 20 minutes of resting in sitting with spontaneous coughing allowed.
Outcomes Mucus clearance was measured directly by delivering a radioaerosol (99mTc-labelled albumin colloid)
to the airways and then measuring the distribution of radiolabeled secretions within the lung fields.
Posterior planar gamma camera images of the thorax were collected as single 5-minute exposures
every 30 minutes for 3 hours. Clearance was calculated as a reduction in count rate between successive
images. Whole lung clearance was calculated. In addition, the planar images were divided into central,
mid and peripheral regions, and upper, mid and basal regions. Clearance from these regions was calcu-
lated. Wet weight of sputum expectorated during the initial 30-minute (intervention) period and for the
remainder of the 3-hour clearance measurement period was measured.
Sputum weight pre and post and 3 hours post and 99mTc-labelled sputum measured post.
Notes No statement on withdrawals or dropouts.
Published paper.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, no further information was provided.
Allocation concealment
(selection bias)
Unclear risk Not discussed.
Blinding (performance
bias and detection bias) 
All outcomes




Unclear risk No statement on withdrawals or dropouts.
Selective reporting (re-
porting bias)
Low risk All outcome measures are fully reported.
Mortensen 1991 
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Other bias Low risk Two day washout period between each intervention, thus low risk of carry over







Treatment for 13 months.
Participants CF diagnosed by St Michael's Hospital CF Clinic, Toronto.
42 participants (24 male).
PEP Group: 21 participants (15 male); mean age 28, SD 8.1 years; mean FEV1 2.5, SD 1.2 litres; mean
FEV1 66, SD 19.9% predicted.
Flutter Group: 21 participants (9 male); mean (SD) age 31 (8.7) years; mean (SD) FEV1 2.2 (0.7) litres;
mean (SD) FEV1 69(18.5) % predicted.
Participants were excluded if they had been hospitalised within the past month for a pulmonary exac-
erbation, had changed their medication within the past month, or did not have a daily cough or daily
sputum.
Interventions 2 interventions: 21 participants were randomised to each group.
1. PEP treatment - pressure 10 - 20 cm H2O using an Astra Meditec PEP mask; seated participants
breathed 10 - 15 times through the mask, followed by huffing, coughing and relaxed breathing, this was
repeated 5 - 6 times, over a 20-minute session, twice daily;
2. Oscillating PEP - participants exhaled through the flutter device (Axcan Scandipharm) which was an-
gled to maximise the sensation of vibration in the chest. In sitting, participants inhaled deeply through
the nose, followed by a breath hold for 2 - 3 seconds, and exhalation through the device. After 5 - 10
breaths, participants increased the TV and speed of exhalation through the device, to precipitate
coughing and expectoration. This sequence was repeated "until clear" or for approximately 20 min-
utes, twice daily.
Outcomes Slope of change in FEV1 , FVC, and FEF25-75 (absolute and % predicted). Number of hospitalisations. Ad-
herence.
Notes 1 participant was withdrawn when he stopped attending the CF clinic.
Published paper.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A random numbers table and block randomisation were used to ensure that
groups would be of equal size.
Allocation concealment
(selection bias)
Low risk Allocation was sealed in opaque envelopes by an independent assistant. The
envelopes were open in sequence after a participant was enrolled.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Participants and person providing the therapy were not blinded - unclear risk.




Low risk 1 participant was withdrawn when he stopped attending the CF clinic.
Newbold 2005 
Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (Review)
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Selective reporting (re-
porting bias)
Low risk Results are reported for all outcome measures.






Each treatment given once.
Participants CF confirmed by repeat sweat tests, and sputum production of > 20 ml per day.
15 participants (9 female, 1 unspecified); mean age 16 years, range 9.8 - 22.4 years; mean Schwachman
score 62.2, range 26 - 90 points.
Participants were excluded if unstable at the time of investigation (criteria unspecified). 6 months be-
fore the study, each participant was trained in the 2 self-administered techniques (PEP and AD).
Interventions 5 interventions: 1 day washout period between each intervention.
1. Hi-PEP intervention - expiratory resistance chosen to increase the FVC to the greatest extent when
performed through the PEP mask; participants inhale and exhale 8 - 10 times followed by a forced expi-
ratory manoeuvre, all through the mask;
2. AD - participants breathed at low lung volumes with progressive increases in the lung volume at
which breathing was performed in response to evidence of secretion transport; coughing and forced
expiratory manoeuvres were avoided;
3. Hi-PEP for the first half of the session, followed by AD;
4. AD for the first half of the session, followed by Hi-PEP;
5. Control - spontaneous coughing only.
Each intervention session was equal to the time taken for the individual participant to clear their lungs
using AD, as judged from pre-study experience.
Outcomes FEV1 , FVC, RV, and TLC were measured at all PFT measurement points. Wet weight of expectorated
sputum during the complete (both halves) intervention period was also measured.
Notes 1 withdrawal due to development of an acute respiratory viral infection during the study.
Published paper.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, no further information provided.
Allocation concealment
(selection bias)
Unclear risk Not discussed.
Blinding (performance
bias and detection bias) 
All outcomes




Low risk 1 withdrawal due to development of an acute respiratory viral infection during
the study.
Pfleger 1992 
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Selective reporting (re-
porting bias)
High risk Not all outcome measure results are reported in full.
Other bias Unclear risk Only one day washout period between each intervention.






Treatment period: 12 months.
Participants 75 participants were enrolled into the study. Age range 17 - 63 years, 47 males, 28 females
CF Diagnosed by sweat test. Inclusion criteria FEV1 over 25% predicted.
Enrolled when stable.
Interventions 5 interventions all performed in a sitting position. Number of treatments per day and length of treat-
ment was individualised to each participant. 15 participants randomised to each group.
1. Active cycle of breathing techniques
2. AD
3. PEP
4. Oscillating PEP using the flutter
5. Oscillating PEP using the RC cornet
Outcomes Primary outcome was FEV1. Other PFT outcomes were FVC, MEF 25 and RV
BMI, modified shuttle test, chronic respiratory questionnaire, short form 36 and number of course of IV
antibiotics were also measured.




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation was computerised and used a random number sequence,
stratified by FEV1 and sputum volume.
Allocation concealment
(selection bias)
Unclear risk Not reported.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Participants and person providing the therapy were not blinded - unclear risk.
Outcome assessors were blinded - low risk
Pryor 2010 
Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (Review)













High risk Number of participants requiring IV antibiotics is listed under outcome mea-
sures but was not reported as could not be analysed due to small numbers and
the scattered nature of the data.
Selective reporting (re-
porting bias)
Unclear risk Only the results of the primary outcome FEV1 were reported in full. All the oth-
er outcome measures were reported only as no significant difference.
Other bias Unclear risk 13 participants withdrew as they did not like the regimen they had been ran-







Treatment length 3 months.
Participants 32 participants with CF.
Age > 18 years of age
FEV1 20% - 69% predicted
Interventions Two interventions both of which were proceeded by inhalation of a bronchodilator and 7% hypertonic
saline. During this inhalation, participants performed autogenic drainage for 15 minutes.
1. PEP mask therapy was performed using a Astra-Tech mask, The participant breathed through the
PEP mask for 10 breaths creating an expiratory pressure of between 10 - 20 cm H2O. This was followed
by huffing. Cycle consisting of inhalation, AD, PEP and was repeated for one hour twice a day.
2. NIV with a Bilevel-PAP device. A minimum inspiratory pressure of 20 cm H2O and an expiratory pres-
sure of 10 cm H2O was given. Participants were instructed to breathe in and out for 2 minutes followed
by huffing and coughing. Cycle consisting of inhalation, AD, NIV and was repeated for one hour twice a
day.
Outcomes Lung function tests measuring FVC, FEV1, in L and % predicted. were performed at baseline and at week
12. LCI performed at baseline and at week 12. Sputum samples were obtained monthly to measure in-
flammatory markers. 6-minute walk test was performed at baseline and week 12. Blood gases, pulse
oximetry and respiratory rate were measured monthly.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants randomly selected an envelope which indicated which interven-
tion they were randomised to.
Allocation concealment
(selection bias)
Low risk Allocation was concealed in an envelope
Blinding (performance
bias and detection bias) 
Unclear risk Participants were not blinded to which intervention they were performing, but
outcome assessors were blinded.
Rodriguez 2016 
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Unclear risk Data results on blood gases, inflammatory markers and FRC were reported as






Each treatment given for 1 month.
Participants CF confirmed by sweat tests.
28 participants (gender unspecified); mean age 14 years, range 8 - 21 years; mean FEV1 68, range 15 -
114% predicted; mean Schwachman score 65, range 33 - 91 points.
Interventions 4 interventions: No washout period between each intervention
1. PEP treatment - pressure 10 - 15 cm H2O; seated participants exhaled 10 - 15 times through an Astra
or Vitapep mask, followed by forced expiration and cough, if required. This cycle was then repeated;
2. PEP & FET intervention - the following was added to the above technique, 1 or 2 forced expirations
with an open glottis from mid-lung volume to low-lung volume followed by a period of relaxed di-
aphragmatic breathing (FET);
3. PDPV & FET intervention - participants received percussion in PD positions, with FET;
4. PEP-PDPV & FET intervention - participants performed PEP (position not defined) for 5 minutes, fol-
lowed by PDPV & FET.
Frequency and duration of treatment sessions was not specified. There was no washout period be-
tween months.
Outcomes FEV1 and FVC were measured at the start and finish of each month. At the end of each month, the wet
weight of expectorated sputum over a 2-hour period which included a treatment with that month's in-
tervention was measured. At the end of the study period, participants nominated which intervention
they would use as ongoing airway clearance physiotherapy.
Notes 2 withdrawals (1 death, 1 non-compliance) and 2 dropouts (1 pneumothorax, 1 subjective lack of ef-
fect).
A fiMh intervention, FET alone, was undertaken by a subset of 5 participants. This treatment was per-




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, no further information provided.
Allocation concealment
(selection bias)
Unclear risk Not discussed.
Blinding (performance
bias and detection bias) 
Unclear risk Not discussed.
Steen 1991 
Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (Review)














Unclear risk 2 withdrawals (1 death, 1 non-compliance) and 2 dropouts (1 pneumothorax, 1
subjective lack of effect).
Selective reporting (re-
porting bias)
High risk Not all outcomes were reported in full.







Treatment period of 12 months.
Participants 30 children with CF, age range 6 - 15 years, 20 females.
Interventions 2 interventions: 15 participants were randomised to each group.
1. PEP (no further data provided);
2. Oscillating PEP provided by the RC cornet (no further data provided).
Outcomes QWBS
FEV1, pulmonary exacerbations, LCI.
Notes Information was provided from 3 abstracts, no further information obtained.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation was stratified by age, sex and FEV1. How randomisation was
generated was not recorded.
Allocation concealment
(selection bias)
Unclear risk Not discussed.
Blinding (performance
bias and detection bias) 
All outcomes




Low risk 2 dropouts are reported, one from each group. One found the cornet ineffec-




Unclear risk Not all outcome measures results were provided in full. QWBS was reported as
no significant changes over the year.
Tannenbaum 2005 
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Each treatment given for 1 month.
Participants CF diagnosed by the Nottingham City Hospital Cystic Fibrosis Clinic.
19 participants (after withdrawals, 9 females and 7 males); mean age 13 years, range 10 - 18 years;
mean Schwachman score 62, range 47 - 85 points.
Interventions 2 interventions:There was no washout period between each treatment period.
1. PEP treatment - pressure 10 - 15 cm H2O; seated participants exhaled 10 times through an Astra
mask, followed by "forced expiratory coughing";
2. PDP - participants received percussion and performed coughing in PD positions.
Treatment was performed for 20 minutes, twice daily.
Outcomes FEV 0.75, FVC, PEFR were recorded before, 20 minutes after, and 90 minutes after a single supervised
treatment at the beginning of the randomisation month. Wet weight of sputum expectorated during
the therapy was also measured. The same measures were repeated over a single treatment at the end
of the randomisation month.
In addition, during each treatment month, diary card records were kept regarding the following symp-
toms: sleep, cough, wheeze, activity, sputum production. (Details of the scoring system for these symp-
toms are not provided.) Although not listed as a formal outcome measures, antibiotic use and partici-
pant preference are also discussed in the results section.
Notes 3 withdrawals due to non-adherence.
Those children who showed airway reversibility with salbutamol were asked to use it before treatment
throughout the whole study.
Published paper.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, no further information provided.
Allocation concealment
(selection bias)
Unclear risk Not discussed.
Blinding (performance
bias and detection bias) 
All outcomes




Unclear risk 3 withdrawals due to non-adherence.
Selective reporting (re-
porting bias)
High risk Not all outcomes were reported in full.
Tyrrell 1986 
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Other bias High risk There was no washout period between each treatment period, thus there is a






Each treatment given for 4 weeks.
Participants CF diagnosed by Camperdown or Westmead Hospitals, and daily sputum production.
13 participants (gender unspecified); age range 7 - 18 years.
No change in treatment in the 2 months prior to commencing the study.
Interventions 2 interventions:There was no washout period between each treatment period.
1. PEP treatment - pressure 10 - 15 cm H2O; participants inhaled and exhaled 10 - 15 times through an
Astra mask (position unspecified), followed by forced expiration and coughing;
2. PDP - participants received manual percussion to all areas in PD positions, followed by forced expira-
tion and coughing.
The PEP intervention was continued for 20 minutes. PDP lasted "at least 20 minutes". Each interven-
tion treatment was administered twice daily for 4 weeks. There was no washout period.
Outcomes FEV1 and FVC were measured before and 1 hour after the first treatment of each randomisation period.
Volume of expectorated sputum was measured over 1 hour which commenced with the first treatment
of the randomisation period.
Notes 2 withdrawals due to infective exacerbations and 1 dropout.
Published paper.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, no further details provided.
Allocation concealment
(selection bias)
Unclear risk Not discussed.
Blinding (performance
bias and detection bias) 
All outcomes




Low risk 2 withdrawals due to infective exacerbations and one dropout.
Selective reporting (re-
porting bias)
High risk Not all outcomes were reported in full.
Other bias High risk Groups similar at baseline regarding the most important prognostic indicators.
There was no washout period between each treatment period, thus there is a
potential for a carryover effect.
van Asperen 1987 
Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (Review)














Each treatment given for 2 weeks.
Participants CF confirmed by sweat tests or DNA mutation analysis.
22 participants (12 male); median age 12 years, range 7 - 17 years; median FEV1 82, range 55% - 129%
predicted.
Participants were excluded if they had been clinically unstable during the 2 weeks prior to entering the
study, according to PEFR and symptoms scores (criteria not specified).
Interventions 2 interventions:There was a one week washout period between each treatment period.
1. PEP treatment - pressure 8 - 12 cm H2O; seated participants breathed through an Astra Meditec PEP
mask 15 times, followed by 3 huFs and coughing, this sequence was repeated 5 times;
2. Oscillating PEP (flutter) - participants inhaled deeply, held their breath for 2 - 3 seconds, then ex-
haled through the VarioRaw flutter device 15 times, following which the participant again huFed 3
times and coughed. This sequence was also repeated 5 times. The flutter was tilted upwards or down-
wards a few degrees from horizontal until the maximum vibration sensation was obtained.
Each intervention was performed twice per day for 2 weeks, preceded by a 1-week washout period.
During the washout weeks, all participants performed "routine physiotherapy" with huF and cough
manoeuvres.
Outcomes FEV1, FVC, and TLC were measured before the initial, 1-week washout period. These measures were re-
peated on the first day of each of the 2 treatment periods, before and 30 minutes after the first session
of therapy. At the end of the 2-week treatment periods, these measures were again taken 30 minutes
after physiotherapy.
Oxygen saturation via pulse oximetry was measured before during and after the first and last treat-
ments of each 2-week period.
Notes No withdrawals or dropouts. One week washout period between treatments.
Published paper.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, no further information provided.
Allocation concealment
(selection bias)
Unclear risk Not discussed.
Blinding (performance
bias and detection bias) 
All outcomes




Low risk No withdrawals or dropouts.
Selective reporting (re-
porting bias)
Low risk All outcomes are reported in full.
Other bias Low risk There was a one week washout period between each treatment period, thus
there is low risk of any carry over effect.
van Winden 1998 
Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis (Review)









Cochrane Database of Systematic Reviews
Groups similar at baseline regarding the most important prognostic indica-






Treatment for 10 days
Participants 23 participants with CF admitted to hospital with an acute exacerbation of CF. 12 randomised to PEP
and 11 to acapella.
Aged between 5 - 18 years of age.
FEV1 range 29 to 114% predicted
Interventions 1. PEP mask 10 breaths followed by one to two huFs and a cough, repeated for 10 sets, performed twice
daily for 10 days.
2. Acapella was performed same as the PEP for consistency. 10 breaths followed by one to two huFs
and a cough repeated for 10 sets, performed twice daily for 10 days.
Outcomes Change in lung function. FEV1, FVC, FEF25-75%and PEFR were measured at baseline and after 10 days.
Exercise performance was measured using the 10 metre shuttle test at baseline and after 10 days.
Total sputum expectorated during each treatment was weighed.
Patient satisfaction was measured using a patient satisfaction survey completed at the end of 10 days.
Notes Published as paper.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random allocation was achieved by placing equal number of papers for each
treatment in double-sealed envelopes
Allocation concealment
(selection bias)
Low risk A research coordinator not involved in the recruitment, assessment or treat-
ment withdrew randomly one of the double sealed envelopes
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Participants and person providing the therapy were not blinded- unclear risk




Unclear risk There was one dropout from the acapella group (reason given) and the study
did not meet the sample size required for the power analysis
Selective reporting (re-
porting bias)
Low risk All outcomes were fully reported
Other bias Unclear risk Demographics at baseline were not matched.
West 2010 
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AD: autogenic drainage
BEpd: breathing exercises in postural drainage positions
BMI: body mass index
CE: cycle ergometry
CF: cystic fibrosis
FEV 0.75: forced expiratory volume in 0.75 sec
FEF25-75: forced expiratory flow 25-75%
FET: forced expiratory technique
FEV1: forced expiratory volume at 1 second
FRC: functional residual capacity
FVC: forced vital capacity
HFCC: high-frequency chest compression
HFCWO: high-frequency chest wall oscillation
Hi-PEP: high-pressure PEP
IV: intravenous
LCI: lung clearance index
PD: postural drainage
PDP: postural drainage with percussion
PDPV: postural drainage with percussion and vibration
PEP: positive expiratory pressure
PEFR: peak expiratory flow rate
PEPpd: PEP in postural drainage
PFT: pulmonary function test
PLBs: pursed lip breathing in sitting
pO2: blood test measuring oxygen in the blood
Ptco2: transcutaneously measured carbon dioxide tension
Pt02: transcutaneous oxygen tension
QWBS: quality of life using the quality of life well-being scale
RCT: randomised controlled trial
RV: residual volume
SD: standard deviation
SpO2: saturation of haemoglobin with oxygen using pulse oximetry
TLC: total lung capacity
TV: tidal volume
nBVS: non-invasive bilevel ventilatory support
SVC: slow vital capacity
W/kg: watt per kilogram
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Aquino 2006 The intervention, to which PEP was compared, was not a physical airway clearance therapy.
Aquino 2012 Neither of the interventions were PEP.
Aubriot 2016 The delivery of an inhaled antibiotic was evaluated using a PEP system compared to a jet nebulizer.
This is not study of the efficacy of PEP compared to another airway clearance technique.
Balestri 2004 Used a different type of PEP system (underwater tubing) which did not meet the PEP criteria for
this review.
Battistini 2001 Used a different type of PEP system (underwater tubing) which did not meet the PEP criteria for
this review.
Bishop 2011 PEP versus other airway clearance was not the randomised comparison made in this study.
Borka 2012 Study was not randomised.
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Study Reason for exclusion
Castle 1994 No outcome data were reported.
Dosman 2003 Used a different type of PEP system (positive end expiratory pressure) which did not meet the PEP
criteria for this review.
Falk 1988 The intervention, to which PEP was compared, was not a physical airway clearance therapy.
Fitzgerald 2001 PEP versus other airway clearance was not the randomised comparison made in this study.
Gotz 1995 No data were reported for the outcomes of interest.
Kraemer 1996 Neither of the interventions were PEP.
Laube 2000 The intervention to which PEP was compared was not a physical airway clearance therapy.
Liedtke 1996 Neither of the interventions were PEP.
Marks 1998 The use of PEP versus the other physical airway clearance therapy (flutter) was not the randomised
comparison made in this study.
McCarren 2006 Study used PEP breathing, but not the PEP technique as defined in this review.
Munro 2007 Study was performed on post-transplant patients.
Oermann 2001 Neither of the interventions being compared was PEP.
Orlik 2000 The use of PEP versus the other physical airway clearance therapies was not the factor which was
random in this study.
Orlik 2015 This was a retrospective study on the use of a PEP system to deliver mucolytics. This is not study of
the efficacy of PEP compared to another airway clearance technique.
Padman 1999 Used a different type of PEP system (Vitalsigns flow independent system) which did not meet the
PEP criteria for this review.
Patel 2013 Neither of the interventions being compared was PEP.
Placidi 2001 Study used PEP breathing, but not the PEP technique as defined in this review.
Reychler 2015 The manoeuvre being compared to PEP was not a recognized airway clearance technique.
Richmond 2016 This was a study examining adherence to PEP therapy. It was not randomised and there was no
control.
Roos 1987 Niether of the interventions were PEP.
Sanchez Riera 1999 PEP technique did not include huffing and was performed in a postural drainage position.
van der Schans 1991 Used a different type of PEP system (Vitalsigns flow independent system) which did not meet the
PEP criteria for this review.
van Hengstum 1987 The study was performed in participants with chronic bronchitis.
Wettstein 2014 The intervention, to which PEP was compared, was not a physical airway clearance therapy.
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Study Reason for exclusion
Wilson 2015 The delivery of hypertonic saline was evaluated using a PEP system compared to an eFlow nebuliz-
er. This is not study of the efficacy of PEP compared to another airway clearance technique.
Znotina 2000 The use of PEP versus the other physical airway clearance therapy (oscillating PEP) was not the fac-
tor which was randomised in this study.
PEP: positive expiratory pressure
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Cross-over RCT.
Participants 12 participants with CF aged 16 to 34 years.
Interventions PEP compared to oscillating PEP, PDPV and ACBT.
Outcomes Mucociliary clearance.




Methods RCT, participants randomised to receive either HFCWO or PEP during the first 3 days of hospitalisa-
tion for an exacerbation.
Participants 23 participants. 12 female, mean age 25 years.
Interventions Use of HFCWO at setting of 20 Hz for 30 minutes compared with 30 minutes of PEP; this occurred
during the first 3 days of treatment.
Outcomes FEV1, FVC and FEF25-75 were assessed pre and 30 minutes post intervention. Sputum volume was
collected after each intervention.





Participants 33 children (19 boys, 14 girls) with CF, mean (SD) age 11 (3.9) years. 23 completed.
Interventions ACBT compared to PEP mask in addition to conventional CF therapy. 4 months treatment A then
changed to other treatment for a further 4 months.
Outcomes FVC, FEV1, MEEF, questionnaire re acceptability of techniques.
Outcomes measured before and after each treatment period.
Kofler 1994 
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Participants 13 participants with CF mean (SD) age 18 (3) years.
Interventions Flutter® compared to EPAP.






Participants Individuals with CF were recruited from the Adult CF Center at the University Hospital Zurich,
Switzerland, between June 2016 and January 2017. Patients aged 18 years and older with a con-
firmed diagnosis of CF able to provide sputum samples were included. Exclusion criteria were as
follows: i) listing for lung transplantation or status post lung transplantation, ii) chronic pulmonary
infection with BBC, iii) unstable clinical condition (i.e., major hemoptysis or pneumothorax with-
in the last 3 months, acute pulmonary exacerbation [13], intravenous antibiotic treatment during
the last 4 weeks, change in pulmonary medication during the study period); iv) cardiac arrhythmias
with exercise ;and v) requirement of additional oxygen with exercise.
Interventions A single bout of continuous cycling exercise at moderate intensity (experiment A, control condi-
tion) vs a combination of interval cycling exercise plus Flutter®
(experiment B).
Outcomes Sputum properties (viscoelasticity, yield stress, solids content, spinnability, and ease of sputum ex-
pectoration), pulmonary diffusing capacity for nitric oxide (DLNO) and carbon monoxide (DLCO)
were assessed at rest, directly and 45 minutes post-exercise (recovery) at 2 consecutive visits. Pri-
mary outcome was change in in sputum viscoelasticity (G’, storage modulus; G”, loss modulus) over






Participants 14 participants with CF, age range 12 - 29 years, mean age 15.9 years, chronic infection with
Pseudomonas aeruginosa.
Interventions PEP compared to conventional physiotherapy, 4 days
Outcomes FVC, FEV1, RV, FRC, TLC, PF, bacteriology (P aeruginosa, S aureus, E coli)
Tonnesen 1982 
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Methods Pilot cross-over RCT.
Participants 12 children, mean (SD) age 12.83 years (1.85 years). Those who had chronic infection and with BCC
and non-tuberculous M Abscessus were excluded.
Interventions ACT prior to CPET vs CPET alone.
Outcomes Spirometry, plethysmography and 2 CPET scans were performed 1 month apart - 1 with ACT imme-






Participants 13 adults (FEV1 ≥ 70% predicted).
Interventions Daily PEP plus exercise or exercise-only for 3 months.






Participants 17 participants with CF and suspected GER, mean age 12.6 years, 4 did not complete study.
Interventions Oesophageal pH monitoring for 48 hours, in this time 2 sessions of PDP and 2 sessions of PEP in an
upright position.
Outcomes Reflux episodes per hour, fractional reflux time, cough.
Notes Abstract only, waiting for further information.
Wong 2000 
ACBT: active cycle of breathing technique
ACT: airway clearance therapy
BBC: Burkholderia cepacia complex
CF: cystic fibrosis
CPET: cardiopulmonary exercise testing
EPAP: expiratory positive airway pressure
E coli: Escherichia coli
FEV1: forced expiratory volume at 1 second
FRC: functional residual capacity
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PAP: positive airway pressure
PEP: positive expiratory pressure
PDP: postural drainage and percussion
PF: pulmonary function
P aeruginosa:Pseudomonas aeruginosa
RCT: randomised controlled trial
RV: residual volume
S aureus: Staphylococcal aureus
TLC: total lung capacity
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   PEP compared with PDPV





Statistical method Effect size
1 Change in FEV1 (% predicted) 4   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 8 days to 1 month 1 10 Mean Difference (IV, Fixed, 95% CI) 0.60 [-6.33, 7.53]
1.2 2 to 3 months 1 20 Mean Difference (IV, Fixed, 95% CI) -0.5 [-3.68, 2.68]
1.3 7 to 12 months 1 36 Mean Difference (IV, Fixed, 95% CI) 8.26 [0.76, 15.76]
1.4 2 years 1 66 Mean Difference (IV, Fixed, 95% CI) -0.65 [-3.25, 1.95]
2 Change in FVC (% predicted) 5   Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Single treatment 1 16 Mean Difference (IV, Fixed, 95% CI) 1.90 [-4.96, 8.76]
2.2 8 days to 1 month 2 26 Mean Difference (IV, Fixed, 95% CI) -4.18 [-12.92, 4.56]
2.3 > 1 to 3 months 1 20 Mean Difference (IV, Fixed, 95% CI) 2.09 [-5.46, 9.64]
2.4 > 6 to 12 months 1 36 Mean Difference (IV, Fixed, 95% CI) 8.74 [1.44, 16.04]
2.5 > 1 to 2 years 1 66 Mean Difference (IV, Fixed, 95% CI) -1.57 [-4.33, 1.19]
3 Change in FEF25-75 (% predicted) 3   Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 8 days to 1 month 1 10 Mean Difference (IV, Fixed, 95% CI) -6.2 [-14.41, 2.01]
3.2 > 1 to 3 months 1 20 Mean Difference (IV, Fixed, 95% CI) -3.08 [-7.87, 1.71]
3.3 > 6 to 12 months 1 36 Mean Difference (IV, Fixed, 95% CI) 3.56 [-6.18, 13.30]
4 TLC 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 > 1 to 3 months 1 20 Mean Difference (IV, Fixed, 95% CI) -3.38 [-13.67, 6.91]
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Statistical method Effect size
5 Radiological imaging: increased
bronchial markings
1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 > 6 to 12 months 1 26 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.69, 1.12]
6 Radiological imaging: change in Bras-
field score
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 > 6 to 12 months 1 36 Mean Difference (IV, Fixed, 95% CI) 0.0 [-1.20, 1.20]
7 Adverse events 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Gastrointestinal reflux 1 26 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.43, 3.63]
7.2 Gastrointestinal reflux leading to
withdrawal from the study
1 26 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.52]
 
 
Analysis 1.1.   Comparison 1 PEP compared with PDPV, Outcome 1 Change in FEV1 (% predicted).
Study or subgroup PEP PDPV Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
1.1.1 8 days to 1 month  
van Asperen 1987 5 1.4 (7.5) 5 0.8 (2.6) 100% 0.6[-6.33,7.53]
Subtotal *** 5   5   100% 0.6[-6.33,7.53]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.17(P=0.87)  
   
1.1.2 2 to 3 months  
Darbee 1990 12 -2.5 (4.6) 8 -2 (2.6) 100% -0.5[-3.68,2.68]
Subtotal *** 12   8   100% -0.5[-3.68,2.68]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.31(P=0.76)  
   
1.1.3 7 to 12 months  
McIlwaine 1997 18 6 (10.6) 18 -2.3 (12.3) 100% 8.26[0.76,15.76]
Subtotal *** 18   18   100% 8.26[0.76,15.76]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.16(P=0.03)  
   
1.1.4 2 years  
Gaskin 1998 33 -2.9 (5.8) 33 -2.3 (4.9) 100% -0.65[-3.25,1.95]
Subtotal *** 33   33   100% -0.65[-3.25,1.95]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.49(P=0.62)  
Favours PDPV 105-10 -5 0 Favours PEP
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Analysis 1.2.   Comparison 1 PEP compared with PDPV, Outcome 2 Change in FVC (% predicted).
Study or subgroup PEP PDPV Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
1.2.1 Single treatment  
Tyrrell 1986 7 4.6 (8.3) 9 2.7 (4.7) 100% 1.9[-4.96,8.76]
Subtotal *** 7   9   100% 1.9[-4.96,8.76]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.54(P=0.59)  
   
1.2.2 8 days to 1 month  
Tyrrell 1986 7 -11.4 (13.4) 9 -2.3 (9.2) 56.44% -9.1[-20.73,2.53]
van Asperen 1987 5 2.8 (14.9) 5 0.6 (2.2) 43.56% 2.2[-11.04,15.44]
Subtotal *** 12   14   100% -4.18[-12.92,4.56]
Heterogeneity: Tau2=0; Chi2=1.58, df=1(P=0.21); I2=36.66%  
Test for overall effect: Z=0.94(P=0.35)  
   
1.2.3 > 1 to 3 months  
Darbee 1990 12 1.1 (10) 8 -1 (7.3) 100% 2.09[-5.46,9.64]
Subtotal *** 12   8   100% 2.09[-5.46,9.64]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.54(P=0.59)  
   
1.2.4 > 6 to 12 months  
McIlwaine 1997 18 6.6 (8.1) 18 -2.2 (13.6) 100% 8.74[1.44,16.04]
Subtotal *** 18   18   100% 8.74[1.44,16.04]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.35(P=0.02)  
   
1.2.5 > 1 to 2 years  
Gaskin 1998 33 -2.5 (6.5) 33 -1 (4.8) 100% -1.57[-4.33,1.19]
Subtotal *** 33   33   100% -1.57[-4.33,1.19]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.12(P=0.26)  
Favours PDPV 2010-20 -10 0 Favours PEP
 
 
Analysis 1.3.   Comparison 1 PEP compared with PDPV, Outcome 3 Change in FEF25-75 (% predicted).
Study or subgroup PEP PDPV Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
1.3.1 8 days to 1 month  
van Asperen 1987 5 -5.2 (9.3) 5 1 (1.4) 100% -6.2[-14.41,2.01]
Subtotal *** 5   5   100% -6.2[-14.41,2.01]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.48(P=0.14)  
   
1.3.2 > 1 to 3 months  
Darbee 1990 12 -2.8 (5.5) 8 0.3 (5.3) 100% -3.08[-7.87,1.71]
Subtotal *** 12   8   100% -3.08[-7.87,1.71]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.26(P=0.21)  
Favours PDPV 105-10 -5 0 Favours PEP
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Study or subgroup PEP PDPV Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
   
1.3.3 > 6 to 12 months  
McIlwaine 1997 18 3.3 (16.1) 18 -0.2 (13.6) 100% 3.56[-6.18,13.3]
Subtotal *** 18   18   100% 3.56[-6.18,13.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.72(P=0.47)  
Favours PDPV 105-10 -5 0 Favours PEP
 
 
Analysis 1.4.   Comparison 1 PEP compared with PDPV, Outcome 4 TLC.
Study or subgroup PEP PDPV Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
1.4.1 > 1 to 3 months  
Darbee 1990 12 2 (9.9) 8 5.4 (12.5) 100% -3.38[-13.67,6.91]
Subtotal *** 12   8   100% -3.38[-13.67,6.91]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.64(P=0.52)  
Favours PDPV 105-10 -5 0 Favours PEP
 
 
Analysis 1.5.   Comparison 1 PEP compared with PDPV, Outcome
5 Radiological imaging: increased bronchial markings.
Study or subgroup PEP PDPV Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.5.1 > 6 to 12 months  
Costantini 2001 13/15 11/11 100% 0.88[0.69,1.12]
Subtotal (95% CI) 15 11 100% 0.88[0.69,1.12]
Total events: 13 (PEP), 11 (PDPV)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.03(P=0.3)  
Favours PEP 20.5 1.50.7 1 Favours PDPV
 
 
Analysis 1.6.   Comparison 1 PEP compared with PDPV, Outcome 6 Radiological imaging: change in Brasfield score.
Study or subgroup PEP PDPV Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
1.6.1 > 6 to 12 months  
McIlwaine 1997 18 0.4 (1.9) 18 0.4 (1.8) 100% 0[-1.2,1.2]
Subtotal *** 18   18   100% 0[-1.2,1.2]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours PDPV 42-4 -2 0 Favours PEP
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Analysis 1.7.   Comparison 1 PEP compared with PDPV, Outcome 7 Adverse events.
Study or subgroup PEP PDPV Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.7.1 Gastrointestinal reflux  
Costantini 2001 5/13 4/13 100% 1.25[0.43,3.63]
Subtotal (95% CI) 13 13 100% 1.25[0.43,3.63]
Total events: 5 (PEP), 4 (PDPV)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.41(P=0.68)  
   
1.7.2 Gastrointestinal reflux leading to withdrawal from the study  
Costantini 2001 0/13 3/13 100% 0.14[0.01,2.52]
Subtotal (95% CI) 13 13 100% 0.14[0.01,2.52]
Total events: 0 (PEP), 3 (PDPV)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.33(P=0.18)  
Favours PEP 1000.01 100.1 1 Favours PDPV
 
 
Comparison 2.   PEP compared with oscillating PEP (Acapella, Flutter and Cornet))





Statistical method Effect size
1 Change in FEV1 (% predicted) 4   Mean Difference (IV, Fixed, 95%
CI)
Subtotals only
1.1 10 days 1 22 Mean Difference (IV, Fixed, 95%
CI)
-9.37 [-24.90, 6.16]
1.2 > 6 to 12 months 1 30 Mean Difference (IV, Fixed, 95%
CI)
9.71 [-2.12, 21.54]
1.3 > 1 to 2 years 2 72 Mean Difference (IV, Fixed, 95%
CI)
-2.34 [-6.86, 2.18]
2 Hospitalisations for respiratory exacer-
bation (number per participant)
1   Mean Difference (IV, Fixed, 95%
CI)
Subtotals only
2.1 > 1 to 2 years 1 42 Mean Difference (IV, Fixed, 95%
CI)
-0.40 [-0.92, 0.12]
3 Change in FVC (% predicted) 3   Mean Difference (IV, Fixed, 95%
CI)
Subtotals only
3.1 10 days 1 22 Mean Difference (IV, Fixed, 95%
CI)
-5.40 [-20.01, 9.21]
3.2 > 6 to 12 months 1 30 Mean Difference (IV, Fixed, 95%
CI)
8.68 [-0.54, 17.90]
3.3 > 1 to 2 years 1 42 Mean Difference (IV, Fixed, 95%
CI)
-1.70 [-6.27, 2.87]
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Statistical method Effect size
4 Change in FEF25-75 (% predicted) 3   Mean Difference (IV, Fixed, 95%
CI)
Subtotals only
4.1 10 days 1 22 Mean Difference (IV, Fixed, 95%
CI)
-15.26 [-40.64, 10.12]
4.2 > 6 to 12 months 1 30 Mean Difference (IV, Fixed, 95%
CI)
5.29 [-7.84, 18.42]
4.3 > 1 to 2 years 1 42 Mean Difference (IV, Fixed, 95%
CI)
-1.1 [-6.50, 4.30]
5 Exercise performance (percentage
change)
1   Mean Difference (IV, Fixed, 95%
CI)
Subtotals only
5.1 10 days 1 22 Mean Difference (IV, Fixed, 95%
CI)
6.32 [-15.46, 28.10]
6 LCI 1   Mean Difference (IV, Fixed, 95%
CI)
Subtotals only
6.1 1 year 1 30 Mean Difference (IV, Fixed, 95%
CI)
0.8 [-1.36, 2.96]
7 User satisfaction (patient satisfaction
survey)
1   Mean Difference (IV, Fixed, 95%
CI)
Subtotals only
7.1 10 days 1 22 Mean Difference (IV, Fixed, 95%
CI)
-0.36 [-0.85, 0.13]
8 Adherence: at least 85% of prescribed
treatments performed
1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 > 6 to 12 months 1 40 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.26, 98.00]
9 Participant preference: self-withdrawal
due to lack of perceived effectiveness
1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 > 6 to 12 months 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 1.54]
 
 
Analysis 2.1.   Comparison 2 PEP compared with oscillating PEP
(Acapella, Flutter and Cornet)), Outcome 1 Change in FEV1 (% predicted).
Study or subgroup PEP Oscillating PEP Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
2.1.1 10 days  
West 2010 12 7.8 (15.8) 10 17.2 (20.5) 100% -9.37[-24.9,6.16]
Subtotal *** 12   10   100% -9.37[-24.9,6.16]
Heterogeneity: Not applicable  
Favours Oscillating PEP 2010-20 -10 0 Favours PEP
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Study or subgroup PEP Oscillating PEP Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Test for overall effect: Z=1.18(P=0.24)  
   
2.1.2 > 6 to 12 months  
McIlwaine 2001 17 -1.2 (9.9) 13 -10.9 (20) 100% 9.71[-2.12,21.54]
Subtotal *** 17   13   100% 9.71[-2.12,21.54]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.61(P=0.11)  
   
2.1.3 > 1 to 2 years  
Newbold 2005 21 -4.2 (8) 21 -2 (8.1) 86.04% -2.2[-7.07,2.67]
Tannenbaum 2005 15 -1.9 (19) 15 1.3 (14.5) 13.96% -3.2[-15.29,8.89]
Subtotal *** 36   36   100% -2.34[-6.86,2.18]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.88); I2=0%  
Test for overall effect: Z=1.02(P=0.31)  
Favours Oscillating PEP 2010-20 -10 0 Favours PEP
 
 
Analysis 2.2.   Comparison 2 PEP compared with oscillating PEP (Acapella, Flutter and
Cornet)), Outcome 2 Hospitalisations for respiratory exacerbation (number per participant).
Study or subgroup PEP Oscillating PEP Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
2.2.1 > 1 to 2 years  
Newbold 2005 21 0.3 (0.7) 21 0.7 (1) 100% -0.4[-0.92,0.12]
Subtotal *** 21   21   100% -0.4[-0.92,0.12]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.5(P=0.13)  
Favours PEP 10.5-1 -0.5 0 Favours oscillating PEP
 
 
Analysis 2.3.   Comparison 2 PEP compared with oscillating PEP
(Acapella, Flutter and Cornet)), Outcome 3 Change in FVC (% predicted).
Study or subgroup PEP Oscillating PEP Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
2.3.1 10 days  
West 2010 12 5 (10) 10 10.4 (21.7) 100% -5.4[-20.01,9.21]
Subtotal *** 12   10   100% -5.4[-20.01,9.21]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.72(P=0.47)  
   
2.3.2 > 6 to 12 months  
McIlwaine 2001 17 0.1 (7.9) 13 -8.6 (15.5) 100% 8.68[-0.54,17.9]
Subtotal *** 17   13   100% 8.68[-0.54,17.9]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.84(P=0.07)  
   
2.3.3 > 1 to 2 years  
Newbold 2005 21 -4.7 (8) 21 -3 (7.1) 100% -1.7[-6.27,2.87]
Favours Oscillating PEP 2010-20 -10 0 Favours PEP
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Study or subgroup PEP Oscillating PEP Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Subtotal *** 21   21   100% -1.7[-6.27,2.87]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.73(P=0.47)  
Favours Oscillating PEP 2010-20 -10 0 Favours PEP
 
 
Analysis 2.4.   Comparison 2 PEP compared with oscillating PEP (Acapella,
Flutter and Cornet)), Outcome 4 Change in FEF25-75 (% predicted).
Study or subgroup PEP Oscillating PEP Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
2.4.1 10 days  
West 2010 12 3.8 (27.5) 10 19.1 (32.4) 100% -15.26[-40.64,10.12]
Subtotal *** 12   10   100% -15.26[-40.64,10.12]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.18(P=0.24)  
   
2.4.2 > 6 to 12 months  
McIlwaine 2001 17 -3.6 (15.5) 13 -8.9 (20) 100% 5.29[-7.84,18.42]
Subtotal *** 17   13   100% 5.29[-7.84,18.42]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.79(P=0.43)  
   
2.4.3 > 1 to 2 years  
Newbold 2005 21 -3.1 (6.2) 21 -2 (11) 100% -1.1[-6.5,4.3]
Subtotal *** 21   21   100% -1.1[-6.5,4.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.4(P=0.69)  
Favours Oscillating PEP 5025-50 -25 0 Favours PEP
 
 
Analysis 2.5.   Comparison 2 PEP compared with oscillating PEP (Acapella,
Flutter and Cornet)), Outcome 5 Exercise performance (percentage change).
Study or subgroup PEP Oscillating PEP Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
2.5.1 10 days  
West 2010 12 23 (22.8) 10 16.7 (28.3) 100% 6.32[-15.46,28.1]
Subtotal *** 12   10   100% 6.32[-15.46,28.1]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.57(P=0.57)  
Favours Oscillating PEP 10050-100 -50 0 Favours PEP
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Analysis 2.6.   Comparison 2 PEP compared with oscillating PEP (Acapella, Flutter and Cornet)), Outcome 6 LCI.
Study or subgroup PEP Oscillating PEP Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
2.6.1 1 year  
Tannenbaum 2005 15 1 (3.5) 15 0.2 (2.5) 100% 0.8[-1.36,2.96]
Subtotal *** 15   15   100% 0.8[-1.36,2.96]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.73(P=0.47)  
Favours Oscillating PEP 52.5-5 -2.5 0 Favours PEP
 
 
Analysis 2.7.   Comparison 2 PEP compared with oscillating PEP (Acapella,
Flutter and Cornet)), Outcome 7 User satisfaction (patient satisfaction survey).
Study or subgroup PEP Oscillating PEP Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
2.7.1 10 days  
West 2010 12 4.1 (0.7) 10 4.4 (0.5) 100% -0.36[-0.85,0.13]
Subtotal *** 12   10   100% -0.36[-0.85,0.13]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.43(P=0.15)  
Favours Oscillating PEP 0.50.25-0.5 -0.25 0 Favours PEP
 
 
Analysis 2.8.   Comparison 2 PEP compared with oscillating PEP (Acapella, Flutter and
Cornet)), Outcome 8 Adherence: at least 85% of prescribed treatments performed.
Study or subgroup PEP Oscillating PEP Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.8.1 > 6 to 12 months  
McIlwaine 2001 2/20 0/20 100% 5[0.26,98]
Subtotal (95% CI) 20 20 100% 5[0.26,98]
Total events: 2 (PEP), 0 (Oscillating PEP)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.06(P=0.29)  
Favours PEP 1000.01 100.1 1 Favours Oscillating PEP
 
 
Analysis 2.9.   Comparison 2 PEP compared with oscillating PEP (Acapella, Flutter and Cornet)),
Outcome 9 Participant preference: self-withdrawal due to lack of perceived e@ectiveness.
Study or subgroup PEP Oscillating PEP Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.9.1 > 6 to 12 months  
McIlwaine 2001 0/20 5/20 100% 0.09[0.01,1.54]
Subtotal (95% CI) 20 20 100% 0.09[0.01,1.54]
Total events: 0 (PEP), 5 (Oscillating PEP)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.66(P=0.1)  
Favours PEP 2000.005 100.1 1 Favours Oscillating PEP
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Comparison 3.   PEP compared with HFCWO





Statistical method Effect size
1 Change in FEV1 (% predicted) 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 1 year 1 88 Mean Difference (IV, Fixed, 95% CI) -3.59 [-9.29, 2.11]
2 Participants experiencing a respira-
tory exacerbation
1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 1 year 1 91 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.55, 0.95]
3 Change in FVC (% predicted) 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 1 year 1 88 Mean Difference (IV, Fixed, 95% CI) -5.00 [-10.30, 0.30]
4 Change in FEF25-75 (% predicted) 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 1 year 1 88 Mean Difference (IV, Fixed, 95% CI) -0.34 [-12.54, 11.86]
 
 
Analysis 3.1.   Comparison 3 PEP compared with HFCWO, Outcome 1 Change in FEV1 (% predicted).
Study or subgroup PEP HFCWO Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
3.1.1 1 year  
McIlwaine 2013 42 5.5 (12.7) 46 9 (14.6) 100% -3.59[-9.29,2.11]
Subtotal *** 42   46   100% -3.59[-9.29,2.11]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.23(P=0.22)  
Favours HFCWO 2010-20 -10 0 Favours PEP
 
 
Analysis 3.2.   Comparison 3 PEP compared with HFCWO,
Outcome 2 Participants experiencing a respiratory exacerbation.
Study or subgroup PEP HFCWO Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
3.2.1 1 year  
McIlwaine 2013 26/43 40/48 100% 0.73[0.55,0.95]
Subtotal (95% CI) 43 48 100% 0.73[0.55,0.95]
Total events: 26 (PEP), 40 (HFCWO)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.3(P=0.02)  
Favours PEP 20.5 1.50.7 1 Favours HFCWO
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Analysis 3.3.   Comparison 3 PEP compared with HFCWO, Outcome 3 Change in FVC (% predicted).
Study or subgroup PEP HFCWO Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
3.3.1 1 year  
McIlwaine 2013 42 6.4 (9.4) 46 11.4 (15.5) 100% -5[-10.3,0.3]
Subtotal *** 42   46   100% -5[-10.3,0.3]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.85(P=0.06)  
Favours HFCWO 105-10 -5 0 Favours PEP
 
 
Analysis 3.4.   Comparison 3 PEP compared with HFCWO, Outcome 4 Change in FEF25-75 (% predicted).
Study or subgroup PEP HFCWO Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
3.4.1 1 year  
McIlwaine 2013 42 6.2 (29.3) 46 6.6 (29.1) 100% -0.34[-12.54,11.86]
Subtotal *** 42   46   100% -0.34[-12.54,11.86]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.05(P=0.96)  
Favours HFCWO 4020-40 -20 0 Favours PEP
 
 







PEP in sitting 14 1421.6 (12.5 - 53.5) g P < 0.01
PEP in PD positions 14 17.4 (5.8 - 50.7) g P < 0.01
Pursed Lip Breathing 14 15.0 (5.4 - 44.9) g P < 0.01
PDPV 14 10.0 (1.9 - 51.1) g P < 0.01
Table 1.   Wet weight of sputum during and 50 minutes aPer treatment (Falk 1984) 
PD: postural drainage
PDPV: postural drainage, percussion and vibration





Mean (range) change P value
PEP in sitting 14 +6.6 (0 - 11) % P < 0.01
Table 2.   FVC change aPer four treatments (Falk 1984) 
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PDPV 14 - 4.7 (0 - 7.9) % P < 0.01
PEP in PD positions NA not stated NA
Pursed Lip Breathing NA not stated NA
Table 2.   FVC change aPer four treatments (Falk 1984)  (Continued)
Note: It is unclear whether these percentages refer to absolute percentage change or change in % predicted
FVC: forced vital capacity
NA: Not applicable
PD: postural drainage
PDPV: postural drainage, percussion and vibration












PEP in sitting 14 14.4 (4.6 - 27.4) % 20 (18-32) min
PEP in pd 14 3.2 (0 - 15.4) % 39 (28-45) min
PLB 14 2.4 (-8.0 - 11.3) % 21 (16-32) min
PDPV 14 4.3 (-9.4 - 12.1) % 37 (33-43) min
P < 0.01
Table 3.   Oxygenation change by 35 minutes aPer treatment (Falk 1984) 
Note: Treatment durations were unequal
PD: postural drainage
PDPV: postural drainage, percussion and ventilation
PEP: positive expiratory pressure







PEP 18 92% (SD not stated)
PDPV 18 96% (SD not stated)
Table 4.   Adherence at one year (McIlwaine 1997) 
PDPV: postural drainage, percussion and ventilation





Table 5.   Adherence at one year (McIlwaine 2001) 
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PEP 95.6% (SD not stated)
Flutter 93.8% (SD not stated)
Table 5.   Adherence at one year (McIlwaine 2001)  (Continued)





Pre Post Pre Post
P value
Forced Expiratory Volume in 1 second (litres) 2.10 (0.6) 2.03 (0.6) 1.60 (0.5) 1.54 (0.36) 0.98
Forced Expiratory Volume in 1 second (% predicted) 55 (15) 54 913) 43 (12) 41 (12) 0.52
Forced Vital Capacity (litres) 3.6 (0.9) 3.61 (0.87) 2.82 (0.77) 2.77 (0.84) 0.54
Forced Vital Capacity (% predicted) 78 (13) 78 (12) 64 (12) 61 (16) 0.25
Lung Clearance Index 9.69 (2.5) 9.76 (2.5) 10.2 (2.37) 9.2 (2.55) 0.01
6 minute walk test (metres) 539 (55) 553 (77) 553 (69) 559 (95) 0.76
Table 6.   Measures of lung function and exercise tolerance before and aPer treatment (Rodriguez 2016)  (Continued)
All reported values are mean and standard deviation
NIV: Non invasive ventilation, PEP; positive expiratory pressure
 
 
Treatment Mean (SD) Chg SpO2 P value
PEP 0.04 (1.28) % P = 0.036
nBVS 1.2 (2.12) % P = 0.036
Table 7.   Oxygenation change during treatment (Kofler 1998) 
PEP: positive expiratory pressure
nBVS: non-invasive bilevel ventilatory support
SD: standard deviation
SpO2: percentage of oxygen saturation in blood
 
 
Treatment Mean (SD) FEV1 P value
Hi-PEP 54 (20) % predicted P < 0.05
AD 56 (19) % predicted NS
Hi-PEP then AD 55 (18) % predicted P < 0.02
AD then Hi-PEP 54 (19) % predicted NS
Table 8.   FEV1 aPer single treatment (Pfleger 1992) 
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AD: autogenic drainage
NS: non significant
PEP: positive expiratory pressure
 
 
Treatment Mean (SD) at 0.5 hr Mean (SD) at 1.0 hr Mean (SD) at 2.0 hr Mean (SD) at 24 hr
PEP + FET 92.4 (5.0) % 90.1 (4.8) % 86.9 (5.1) % 59.2 (8.0)%
FET 92.7 (5.3) % 90.8 (5.4) % 89.9 (6.4) % 61.3 (9.1%)
Table 9.   Percentage of radioaerosol retention (Falk 1993) 
FET: forced expiration technique




Treatment Mean (range) weight
BE in PD positions 79.8 (30.7 - 219.8) g
PEP in PD positions 70.6 (24.7 - 256.8) g
PEP in sitting 66.1 (15.3 - 189.4) g
Table 10.   Wet weight of sputum during and for 30 minutes aPer treatment (Hofmeyer 1986) 
BE: breathing exercises
PD: postural drainage
PEP: positive expiratory pressure
 
 
Treatment Mean (SD) weight
Hi-PEP 50 (29) g
AD 35 (25) g
Hi-PEP then AD 44 (29) g
AD then Hi-PEP 39 (23) g
  NB Data measured from graph
Table 11.   Wet weight of sputum during treatment (Pfleger 1992) 
AD: autogenic drainage




Treatment Mean (SD) FVC P value
Hi-PEP 73 (20) % predicted P < 0.01
Table 12.   FVC aPer single treatment (Pfleger 1992) 
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AD 74 (19) % predicted P < 0.05
Hi-PEP then AD 73 (20) % predicted P < 0.01
AD then Hi-PEP 71 (21) % predicted NS
Table 12.   FVC aPer single treatment (Pfleger 1992)  (Continued)
AD: autogenic drainage
FVC: forced vital capacity
NS: non significant









Comfort Score Flexibility Score In Control of Own Rx Disruption Score
PEP 21 75 73 89 33
AD 25 84 73 87 35
PDPV 27 49 42 62 63
Scales 0 = very uncomfortable
100 = very comfortable
0 = very rigid
100 = very flexible
0 = no control
100 = full control
0 = Rx not interruptive
100 = Rx very interrup-
tive
Table 13.   Measures of technique acceptability (McIlwaine 1991) 
AD: autogenic drainage
PDPV: postural drainage, percussion and vibration





PEP -1.58% predicted per year (SD not stated)
PDPV -1.65% predicted per year (SD not stated)
Table 14.   FEV1 change over two years in participants under 19 years of age (Gaskin 1998) 
PDPV: postural drainage, percussion and ventilation
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W H A T ' S   N E W
 
Date Event Description
25 November 2019 New citation required but conclusions
have not changed
The addition of two new studies (55 participants) to this review
update have not resulted in significant changes to the conclu-
sions.
25 November 2019 New search has been performed Two new studies (55 participants) have been included in the re-
view (Rodriguez 2016; West 2010). Six studies have been added
to 'Excluded studies' (Aubriot 2016; Orlik 2015; Reychler 2015;
Richmond 2016; Wettstein 2014; Wilson 2015). A further three tri-
als have been added to 'Studies awaiting classification' and will
be further assessed at the next update (Radtke 2018; Vendruscu-
lo 2019; Ward 2018).
 
H I S T O R Y
Protocol first published: Issue 3, 2001
Review first published: Issue 1, 2004
 
Date Event Description
20 May 2015 New search has been performed A search of the Group's Cystic Fibrosis Trials register identified
potentially eligible trials. Six newly identified studies met the
inclusion criteria (Darbee 2005; Fainardi 2011; Lagerkvist 2006;
McIlwaine 2013; Pryor 2010; Tannenbaum 2005). A further eight
were excluded after assessment (Aquino 2006; Borka 2012; Bish-
op 2011; McCarren 2006; Munro 2007; Patel 2013; Placidi 2001;
Sanchez Riera 1999). A total of six studies are awaiting assess-
ment (Elkins 2005; Kofler 1994; Parreira 2008; Rodriguez 2013a;
West 2010a; Wong 2000).
Five studies that were included in the previous publication of
this paper have been excluded (Balestri 2004; Battistini 2001;
Padman 1999; Placidi 2001; van der Schans 1991). Two used an
underwater positive expiratory pressure (PEP) technique, two
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Date Event Description
used a flow-independent PEP system and the fiMh one, which
had been published previously only as an abstract, has now been
published as a full paper and revealed that the technique stud-
ied was not the PEP technique.
A new review team has updated the review which was originally
Pubilshed by Mark Elkins, Alice Jones and Cees van der Schans.
20 May 2015 New citation required and conclusions
have changed
The conclusions of this review have been amended due to the in-
clusion of new studies and the exclusion of previously included
studies.
12 November 2008 Amended Converted to new review format.
22 February 2006 New search has been performed Five studies have been added to the list of included studies in
this update (Balestri 2004; Battistini 2001; Darbee 2004; Newbold
2005; Placidi 2001).
Five studies have been added to the list of excluded studies (Cas-
tle 1994; Dosman 2003; Fitzgerald 2001; Oermann 2001; Orlik
2000). 
22 February 2006 Amended Cees van der Schans has stepped down as co-author on this re-
view as from February 2006.
 
C O N T R I B U T I O N S   O F   A U T H O R S
Maggie McIlwaine, Brenda Button and Sarah Nevitt updated the review which was originally drafted by Mark Elkins, Alice Jones and Cees
van der Schans.
Maggie McIlwaine and Brenda Button independently assessed studies for inclusion in the updates of this review from 2014; Kerry Dwan and
Brenda Button independently assessed the studies which were authored by McIlwaine. All review authors contributed to data extraction
and updated the text and analyses in this review. Maggie McIlwaine wrote the text of this version with contributions from Brenda Button;
the original text was written by Mark Elkins, with contributions from Alice Jones.
Maggie McIlwaine acts as guarantor of the review.
D E C L A R A T I O N S   O F   I N T E R E S T
Maggie McIlwaine is the Principal Investigator for four of the included studies. These studies were independently assessed by the other
review authors.
Brenda Button declares no potential conflict of interest.
Sarah Nevitt declares no potential conflict of interest.
S O U R C E S   O F   S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane
Cystic Fibrosis and Genetic Disorders Group.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
The protocol for this review was based on the previous review of 2006. A new team undertook the 2014 review and we amended the primary
outcomes to include direct measures of mucus clearance. The number of respiratory exacerbations was kept as a primary outcome, how-
ever the number of days of intravenous antibiotic use was removed. This was because, between 2006 and 2014, respiratory exacerbations
had further been defined to include both oral and IV antibiotics. Well-being, adverse effects, exercise tolerance and patient preference
were moved to secondary outcomes as none of the studies reviewed had reported any of them as a primary outcome.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Chest Wall Oscillation;  Cystic Fibrosis  [complications]  [*therapy];  Drainage, Postural;  Forced Expiratory Volume;  Mucociliary Clearance;
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